

Effects of pretreatment with clopidogrel and aspirin for
patients undergoing percutaneous coronary intervention

Lancet, The

358, 527-533

DOI: 10.1016/s0140-6736(01)05701-4

Citation Report

#	ARTICLE	IF	CITATIONS
2	HERBERT DINGLE [1972]: Science at the Crossroads. London: Martin Brian and O'Keeffe. Pp. 256. Â£3.00. British Journal for the Philosophy of Science, 1975, 26, 358-362.	2.3	2
3	Platelets in Hematologic and Cardiovascular Disorders. , 2001, , .		4
4	... and in patients undergoing PCI. Inpharma Weekly, 2001, &NA;, 15.	0.0	0
5	Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet, The, 2001, 358, 1533-1538.	13.7	114
6	Clopidogrel. American Journal of Cardiovascular Drugs, 2001, 1, 467-474.	2.2	6
8	Antiplatelet therapy versus other antithrombotic strategies. , 2001, , 367-385.		0
9	Laboratory monitoring of antiplatelet therapy. , 2001, , 386-406.		1
10	Antiplatelet therapies in cardiology. , 2001, , 407-436.		0
11	Plateletâ€“leukocyteâ€“endothelium cross talk. , 2001, , 106-123.		3
12	Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary intervention and the initial treatment of non-ST segment elevation acute coronary syndromes. , 2001, , CD002130.		22
13	Keeping the coronary arteries open: current opportunities. British Journal of Hospital Medicine, 2001, 62, 617-622.	0.2	0
16	Clopidogrel â€“ a myocardial infarction CURE?. Intensive and Critical Care Nursing, 2001, 17, 364-366.	2.9	0
17	Meeting Highlights. Circulation, 2001, 104, .	1.6	5
18	Pharmaceutical thrombosis prevention in cardiovascular disease. Expert Opinion on Investigational Drugs, 2002, 11, 553-563.	4.1	0
19	Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?. British Heart Journal, 2002, 88, 11-14.	2.1	17
20	Low molecular weight heparin: a bridge over troubled water. European Heart Journal, 2002, 23, 1144-1146.	2.2	1
21	ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Nonâ€“ST-Segment Elevation Myocardial Infarctionâ€”2002: Summary Article. Circulation, 2002, 106, 1893-1900.	1.6	863
22	Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2002, 288, 2411.	7.4	2,791

#	ARTICLE	IF	CITATIONS
23	Missed Opportunities to Treat Atherosclerosis in Patients Undergoing Peripheral Vascular Interventions. <i>Circulation</i> , 2002, 106, 1909-1912.	1.6	123
24	Need to Test the Arterial Inflammation Hypothesis. <i>Circulation</i> , 2002, 106, 136-140.	1.6	137
25	Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting. <i>Circulation</i> , 2002, 105, 2347-2354.	1.6	64
26	Twelve Versus Six Months of Clopidogrel to Reduce Major Cardiac Events in Patients Undergoing β -Radiation Therapy for In-Stent Restenosis. <i>Circulation</i> , 2002, 106, 776-778.	1.6	130
28	Percutaneous coronary interventions in patients with renal failure: overcoming in-stent restenosis?. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 701-703.	0.7	0
29	Aspirin for Primary Prevention of Coronary Events. <i>New England Journal of Medicine</i> , 2002, 346, 1468-1474.	27.0	153
30	ÅClopidogrel and acute coronary syndrome. <i>Drug and Therapeutics Bulletin</i> , 2002, 40, 41-42.	0.3	1
31	Clinical Implications of CURE and PCI-CURE in Patients with the Acute Coronary Syndrome without Persistent ST-elevation. <i>Scandinavian Cardiovascular Journal</i> , 2002, 36, 261-271.	1.2	1
32	Review: Which patients with diabetes should receive which antiplatelet agents?. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 157-160.	0.6	1
33	Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study. <i>Circulation</i> , 2002, 106, 2284-2287.	1.6	45
34	Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups. <i>Circulation</i> , 2002, 106, 1622-1626.	1.6	224
35	Recognising and Treating the Diabetic Patient in Cardiovascular Care. <i>European Journal of Cardiovascular Nursing</i> , 2002, 1, 171-181.	0.9	4
36	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2002, 23, 1809-1840.	2.2	764
37	Transfer for primary angioplasty: who and how?. <i>British Heart Journal</i> , 2002, 88, 570-572.	2.1	6
38	New Treatment Guidelines for Unstable Angina/Non-â€”ST-Segment Elevation Myocardial Infarction. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1800-1804.	1.9	1
39	Switching off Embolization From Symptomatic Carotid Plaque Using <i>S</i> -Nitrosoglutathione. <i>Circulation</i> , 2002, 105, 1480-1484.	1.6	47
40	Management strategy of chest pain patients with or without evidence of acute coronary syndrome in the emergency department. <i>European Journal of Emergency Medicine</i> , 2002, 9, 351-357.	1.1	2
41	Combination Antiplatelet Therapy: Implications for Pharmacists. <i>Journal of the American Pharmacists Association</i> , 2002, 42, 880-883.	0.5	1

#	ARTICLE	IF	CITATIONS
42	How to best counteract the enemies? By ensuring adequate oxygen delivery. European Heart Journal Supplements, 2002, 4, G35-G42.	0.1	0
43	Increased Platelet Binding to Circulating Monocytes in Acute Coronary Syndromes. Circulation, 2002, 105, 2166-2171.	1.6	320
44	The vulnerable plaque and acute coronary syndromes. American Journal of Medicine, 2002, 113, 668-680.	1.5	94
45	ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-“ST-segment elevation myocardial infarction” summary article. Journal of the American College of Cardiology, 2002, 40, 1366-1374.	2.8	1,291
46	A Guide to Drug Use During Percutaneous Coronary Intervention. Drugs, 2002, 62, 2589-2601.	10.9	2
47	Nitric oxide donor drugs: current status and future trends. Expert Opinion on Investigational Drugs, 2002, 11, 587-601.	4.1	79
48	Pharmacological Treatment of Elderly Patients with Acute Coronary Syndromes without Persistent ST Segment Elevation. Drugs and Aging, 2002, 19, 633-646.	2.7	11
49	Clopidogrel en el s�ndrome coronario agudo sin elevaci�n del segmento ST. Revista Espanola De Cardiologia, 2002, 55, 452-453.	1.2	0
51	Clopidogrel: a CURE in acute coronary syndromes?. Expert Opinion on Pharmacotherapy, 2002, 3, 351-353.	1.8	0
52	Clopidogrel and percutaneous coronary intervention. Lancet, The, 2002, 359, 169.	13.7	4
53	The RITA 3 trial. Lancet, The, 2002, 360, 1973-1974.	13.7	0
54	Persistence of the prothrombotic state after acute coronary syndromes: Implications for treatment. American Heart Journal, 2002, 143, 205-216.	2.7	15
55	Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. American Heart Journal, 2002, 143, 841-846.	2.7	39
56	Antiplatelet Medications. Journal of Vascular and Interventional Radiology, 2002, 13, P223-P226.	0.5	0
59	Prevention of cardiovascular diseases. Clinics in Geriatric Medicine, 2002, 18, 463-483.	2.6	13
60	Platelet Aggregation Inhibitors for Use in Peripheral Vascular Interventions: What Can We Learn from the Experience in the Coronary Arteries?. Journal of Vascular and Interventional Radiology, 2002, 13, 229-246.	0.5	23
63	Dual antiplatelet therapy for prevention of recurrent ischemic events. American Journal of Health-System Pharmacy, 2002, 59, 1723-1735.	1.0	13
64	Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes. American Journal of Health-System Pharmacy, 2002, 59, S15-S26.	1.0	0

#	ARTICLE	IF	CITATIONS
65	Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. American Journal of Health-System Pharmacy, 2002, 59, S5-S14.	1.0	12
66	Clopidogrel â€“ Confounding or Confirming Our Concept of How to Treat Acute Coronary Syndromes?. Cardiology, 2002, 2, 78-82.	0.3	1
67	Clinical use of novel antithrombotic agents in the management of acute coronary syndromes. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 282-288.	0.3	1
68	Combination Antiplatelet Therapy: Implications for Pharmacists. Pharmacotherapy, 2002, 22, 1211-1215.	2.6	1
69	Current approaches to patients with acute coronary syndromes. Current Problems in Cardiology, 2002, 27, 145-184.	2.4	1
70	Acute coronary syndrome is a common clinical presentation of in-stent restenosis. American Journal of Cardiology, 2002, 89, 491-494.	1.6	65
71	Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. American Journal of Cardiology, 2002, 90, 312-315.	1.6	33
73	Management of Intermittent Claudication: the Importance of Secondary Prevention. European Journal of Vascular and Endovascular Surgery, 2002, 23, 100-107.	1.5	27
74	Platelets: Is aspirin sufficient or must we know how to pronounce abciximab?. Seminars in Vascular Surgery, 2002, 15, 245-255.	2.8	0
75	The role of pharmacotherapy and catheter-based intervention in the management of patients with non-st-segment elevation acute coronary syndromes. Current Cardiology Reports, 2002, 4, 260-271.	2.9	0
76	Early invasive strategies for acute coronary syndromes. Current Cardiology Reports, 2002, 4, 334-340.	2.9	0
80	Measurement of thrombosis and its prevention. British Journal of Clinical Pharmacology, 2002, 54, 96-100.	2.4	11
81	Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-st-elevation myocardial infarction. Clinical Cardiology, 2002, 25, 16-22.	1.8	2
82	Possible mechanisms of aspirin resistance. Journal of Thrombosis and Thrombolysis, 2002, 13, 49-56.	2.1	57
83	Antiplatelet therapies in combination for the treatment of patients with stable and unstable coronary artery disease. Journal of Thrombosis and Thrombolysis, 2002, 13, 177-182.	2.1	1
84	Aspirin resistance and genetic polymorphisms. Journal of Thrombosis and Thrombolysis, 2002, 14, 51-58.	2.1	102
85	Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. Journal of Thrombosis and Thrombolysis, 2002, 14, 145-150.	2.1	42
86	Bench to Bedside: Pathophysiology of Acute Coronary Syndromes and Implications for Therapy. Academic Emergency Medicine, 2002, 9, 1029-1044.	1.8	10

#	ARTICLE	IF	CITATIONS
87	Carotid stenting: Innovation results in a standardized procedure. <i>Seminars in Cerebrovascular Diseases and Stroke</i> , 2002, 2, 302-313.	0.1	0
88	The Role of Clopidogrel in the Management of Patients with Ischemic Heart Disease. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 467-477.	2.6	11
89	2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and nonâ€“ST-segment elevation myocardial infarction: Implications for emergency department practice. <i>Annals of Emergency Medicine</i> , 2003, 41, 355-369.	0.6	44
90	Coronary angioplasty. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 13-24.	0.9	0
91	A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation. <i>Heart and Vessels</i> , 2003, 18, 123-129.	1.2	15
93	Increased platelet aggregation and activation in peripheral arterial disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 25, 16-22.	1.5	106
94	Antiplatelet therapy in peripheral arterial disease. Consensus statement. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 1-16.	1.5	62
95	Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. <i>BMC Cardiovascular Disorders</i> , 2003, 3, 3.	1.7	66
97	Prothrombotic and antithrombotic pathways in acute coronary syndromes. <i>American Journal of Cardiology</i> , 2003, 91, 3-11.	1.6	342
98	Comparison of short- and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. <i>American Journal of Cardiology</i> , 2003, 92, 721-725.	1.6	24
99	Prediction of significant left main coronary artery stenosis by the 12-lead electrocardiogram in patients with rest angina pectoris and the withholding of clopidogrel therapy. <i>American Journal of Cardiology</i> , 2003, 92, 846-848.	1.6	93
100	Modern management of acute myocardial infarction. <i>Current Problems in Cardiology</i> , 2003, 28, 7-127.	2.4	0
101	Late stent thrombosis in the nonbrachytherapy population: A real phenomenon?. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 504-508.	1.7	5
102	Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 21-25.	1.7	96
103	Silicon carbide-coated stents in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 60, 375-381.	1.7	20
104	Prekallikrein (PK) Tokushima: PK deficiency caused by a Gly401â†’Glu mutation. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1314-1316.	3.8	15
105	The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1319-1321.	3.8	7
106	Heterogeneous distribution of factor V Leiden in patients from north India with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1329-1330.	3.8	14

#	ARTICLE	IF	CITATIONS
107	Anticoagulation patterns and clinical decision-making following an intermediate ventilation-perfusion scan in pulmonary thromboembolism. Journal of Thrombosis and Haemostasis, 2003, 1, 1321-1323.	3.8	1
108	Thrombophilia testing. Journal of Thrombosis and Haemostasis, 2003, 1, 1311-1312.	3.8	6
109	Exercise-induced activation of coagulation in thrombophilia. Journal of Thrombosis and Haemostasis, 2003, 1, 1312-1313.	3.8	8
110	Microthrombus formation enhances tumor necrosis factor- α production in the development of ischemia/reperfusion-induced liver injury in rats. Journal of Thrombosis and Haemostasis, 2003, 1, 1316-1317.	3.8	11
111	Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. Journal of Thrombosis and Haemostasis, 2003, 1, 1318-1319.	3.8	21
112	Significant prevalence of the intron 1 factor VIII gene inversion among patients with severe hemophilia A in the Czech Republic. Journal of Thrombosis and Haemostasis, 2003, 1, 1323-1324.	3.8	11
113	Venous thromboembolism in asymptomatic carriers of factor V Leiden mutation from symptomatic families: any role for hormonal replacement treatment?. Journal of Thrombosis and Haemostasis, 2003, 1, 1325-1326.	3.8	0
114	Spontaneous venous thrombosis in inflammatory bowel disease: relevance of factor V Leiden and the prothrombin gene mutation. Journal of Thrombosis and Haemostasis, 2003, 1, 1326-1328.	3.8	9
115	Homocysteine plasma levels after suspension of vitamin treatment. Journal of Thrombosis and Haemostasis, 2003, 1, 1330-1332.	3.8	0
116	Late Thrombosis: A Problem Solved. Journal of Interventional Cardiology, 2003, 16, 9-13.	1.2	1
118	The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia, 2003, 58, 28-35.	3.8	110
119	Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery, 2003, 2, 15-28.	46.4	346
120	Perspectivas terapéuticas de la doble antiagregación plaquetaria. Revista Clinica Espanola, 2003, 203, 388-390.	0.6	0
121	Oral Antiplatelet Therapy for Peripheral Vascular Disease. Journal of Vascular and Interventional Radiology, 2003, 14, P279-P283.	0.5	0
124	Platelet inhibition strategies in percutaneous coronary intervention. Journal of the American College of Cardiology, 2003, 42, 1196-1198.	2.8	11
125	Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. Journal of the American College of Cardiology, 2003, 42, 2007-2013.	2.8	52
126	Antiplatelet prescribing patterns for TIA and ischemic stroke: the Indiana University experience. Journal of the Neurological Sciences, 2003, 207, 5-10.	0.6	8
127	Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Journal of the American College of Cardiology, 2003, 41, S79-S88.	2.8	85

#	ARTICLE	IF	CITATIONS
128	Aspirin resistance: a new independent predictor of vascular events? **Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. Journal of the American College of Cardiology, 2003, 41, 966-968.	2.8	108
129	A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology, 2003, 41, 961-965.	2.8	957
130	“Watchful waiting” after thrombolysis. Journal of the American College of Cardiology, 2003, 42, 17-19.	2.8	14
131	Percutaneous coronary interventions in octogenarians. Journal of the American College of Cardiology, 2003, 42, 428-432.	2.8	48
132	Does glucocorticoid dysregulation contribute to the link between cigarette smoking and insulin resistance? Reply. Journal of the American College of Cardiology, 2003, 42, 771-772.	2.8	0
133	Clopidogrel versus ticlopidine after the placement of coronary artery stents. Journal of the American College of Cardiology, 2003, 42, 772.	2.8	0
134	Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology, 2003, 42, 981-988.	2.8	27
135	Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. Journal of the American College of Cardiology, 2003, 42, 1188-1195.	2.8	111
136	Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thrombosis Research, 2003, 111, 159-164.	1.7	20
137	Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting. Thrombosis Research, 2003, 112, 19-24.	1.7	14
138	What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?. American Heart Journal, 2003, 145, 971-978.	2.7	10
139	Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. American Heart Journal, 2003, 146, 764-774.	2.7	15
140	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2003, 146, 999-1006.	2.7	104
141	Clopidogrel’s role in the management of atherosclerotic disease: a focus on acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2003, 1, 507-522.	1.5	0
143	Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. Thrombosis Research, 2003, 111, 19-27.	1.7	10
144	The role of clopidogrel in the management of acute coronary syndromes. Clinical Therapeutics, 2003, 25, 2155-2181.	2.5	9
145	Comparison of clopidogrel versus ticlopidine for prevention of minor myocardial injury after elective coronary stenting. International Journal of Cardiology, 2003, 87, 143-149.	1.7	11
146	Aspirin “failures,” clopidogrel added to aspirin, and secondary stroke prevention in veterans presenting with TIA or mild-to-moderate ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 37-43.	1.6	0

#	ARTICLE	IF	CITATIONS
147	The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: To what extent should the results be generalizable?. American Heart Journal, 2003, 145, 595-601.	2.7	30
148	Management of patients with unstable angina and non-st-segment elevation myocardial infarction: update ACC/AHA guidelines. American Journal of Emergency Medicine, 2003, 21, 346-351.	1.6	8
150	Clopidogrel and rhabdomyolysis after heart transplantation. Journal of Heart and Lung Transplantation, 2003, 22, 107-108.	0.6	9
151	Clopidogrel is more effective than ticlopidine for preventing minor myocardial injury after elective coronary stenting. Evidence-based Cardiovascular Medicine, 2003, 7, 136-137.	0.0	0
152	Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Journal of Vascular Surgery, 2003, 38, 710-713.	1.1	107
153	Criterios terapéuticos en el síndrome coronario agudo. Revista Clinica Espanola, 2003, 203, 83-85.	0.6	1
155	Aspirin and Clopidogrel in Acute Coronary Syndromes. Archives of Internal Medicine, 2003, 163, 1145.	3.8	79
156	Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent. Circulation, 2003, 108, 1078-1083.	1.6	48
157	Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome. Annals of Pharmacotherapy, 2003, 37, 860-875.	1.9	8
158	Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation. Circulation, 2003, 107, 32-37.	1.6	656
159	Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation, 2003, 107, 2640-2645.	1.6	36
160	Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation. Circulation, 2003, 108, 22III-27.	1.6	40
161	Update on acute coronary syndromes and implications for therapy. Expert Opinion on Investigational Drugs, 2003, 12, 1971-1983.	4.1	3
162	International differences in in-hospital revascularization and outcomes following acute myocardial infarction A multilevel analysis of patients in ASSENT-2. European Heart Journal, 2003, 24, 1640-1650.	2.2	59
163	Antiplatelet Therapy from Clinical Trials to Clinical Practice. Clinical Medicine and Research, 2003, 1, 101-104.	0.8	9
164	Peripheral Arterial Disease. Archives of Internal Medicine, 2003, 163, 2306.	3.8	166
165	Anticoagulants (Thrombin Inhibitors) and Aspirin Synergize With P2Y ₁₂ Receptor Antagonism in Thrombosis. Circulation, 2003, 108, 2697-2703.	1.6	67
166	Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation, 2003, 108, 28III-37.	1.6	52

#	ARTICLE	IF	CITATIONS
167	Coronary revascularization: knife or catheter?. European Heart Journal Supplements, 2003, 5, B43-B48.	0.1	1
171	Coronary Angioplasty versus Fibrinolytic Therapy in Acute Myocardial Infarction. New England Journal of Medicine, 2003, 349, 2167-2169.	27.0	12
173	Oral Anticoagulant Therapy in Patients with Coronary Artery Disease. Seminars in Vascular Medicine, 2003, 03, 323-332.	2.1	7
174	Antiplatelet Therapy for Elective Coronary Stenting: A Moving Target. Seminars in Vascular Medicine, 2003, 03, 415-418.	2.1	9
175	Review Article: Treatment of Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M927-M933.	3.6	5
176	Advances in antiplatelet therapy. Expert Opinion on Emerging Drugs, 2003, 8, 349-363.	2.4	22
177	Highlights of the 2002 Update to the 2000 American College of Cardiology/American Heart Association Acute Coronary Syndrome Guidelines. Cardiology in Review, 2003, 11, 113-121.	1.4	11
178	Benefits of Aggressive Drug Therapy. Journal of Cardiovascular Nursing, 2003, 18, 79-84.	1.1	1
179	In Vivo Comparative Antithrombotic Effects of Ixaglate and Iohexol and Interaction With the Platelet Antiaggregant Clopidogrel. Investigative Radiology, 2003, 38, 34-43.	6.2	13
180	Title is missing!. Coronary Artery Disease, 2003, 14, 373-380.	0.7	1
181	Clopidogrel in the Management of Ischemic Heart Disease. Heart Disease (Hagerstown, Md), 2003, 5, 144-152.	1.3	10
182	Controversies Surrounding the Use of Glycoprotein IIb/IIIa Inhibitors. Critical Pathways in Cardiology, 2003, 2, 231-238.	0.5	0
183	Contemporary use of antiplatelet therapies in percutaneous coronary interventions. Coronary Artery Disease, 2003, 14, 373-380.	0.7	3
184	10 Most Commonly Asked Questions About Which Antiplatelet Agent To Prescribe. Neurologist, 2003, 9, 318-322.	0.7	0
185	Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) Acute Coronary Syndromes Critical Pathway Toolkit. Critical Pathways in Cardiology, 2003, 2, 153-177.	0.5	3
186	Evidence with Antiplatelet Therapy and ADP-Receptor Antagonists. Cerebrovascular Diseases, 2003, 16, 20-26.	1.7	13
187	ADP receptor antagonists as antiplatelet therapeutics. Expert Opinion on Emerging Drugs, 2003, 8, 93-101.	2.4	10
188	Antiplatelet drugs. Medical Journal of Australia, 2003, 178, 568-574.	1.7	54

#	ARTICLE	IF	CITATIONS
189	Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2003, 89, 842-846.	3.4	12
190	The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine. <i>Thrombosis and Haemostasis</i> , 2003, 90, 839-843.	3.4	3
191	Different Locations of Atherosclerosis – Different Risk Factors, Different Therapies?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 262-266.	0.3	2
192	Antiplatelet Therapy for Secondary Prevention of the Complications of Atherothrombotic Disease. <i>The Consultant Pharmacist</i> , 2004, 19, 813-823.	0.4	0
193	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. <i>Thrombosis and Haemostasis</i> , 2004, 92, 668-669.	3.4	9
194	Outcomes of Percutaneous Coronary Interventions Performed at Centers Without and With Onsite Coronary Artery Bypass Graft Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1961.	7.4	109
195	Secondary Prevention of Acute Coronary Syndromes. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, S28-S36.	1.5	3
196	Catheter-based treatment of atherosclerosis. <i>Postgraduate Medicine</i> , 2004, 115, 14-25.	2.0	3
197	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 110, .	1.6	99
198	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2004, , 1107-1128.		0
199	Facts and Principles Learned at the 31st Annual Williamsburg Conference on Heart Disease. <i>Baylor University Medical Center Proceedings</i> , 2004, 17, 106-115.	0.5	0
200	Antiplatelet agents in atherothrombotic diseases. <i>British Journal of Hospital Medicine</i> , 2004, 65, 72-75.	0.2	0
201	Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. <i>European Heart Journal</i> , 2004, 25, 476-483.	2.2	93
202	Controversies of Oral Antiplatelet Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 649-655.	2.7	5
203	Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2004, 25, 190-198.	2.2	79
204	Antiplatelet Drugs in Ischemic Stroke Prevention: From Monotherapy to Combined Treatment. <i>Cerebrovascular Diseases</i> , 2004, 17, 74-80.	1.7	9
205	Antiplatelet Therapy for Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 2004, 350, 2101-2102.	27.0	5
206	Prevention of Cardiovascular Events after Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2004, 350, 2708-2710.	27.0	6

#	ARTICLE	IF	CITATIONS
207	Antiplatelet Therapy for Ischemic Heart Disease. New England Journal of Medicine, 2004, 350, 277-280.	27.0	97
209	The percutaneous assessment of regional and acute coronary hot unstable plaques by thermographic evaluation (PARACHUTE) study: a prospective reproducibility and prognostic clinical study using thermography to predict future ischemic cardiac events. International Journal of Cardiovascular Interventions, 2004, 6, 69-75.	0.5	4
210	A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery: five year clinical follow up. British Heart Journal, 2004, 90, 672-675.	2.1	15
211	Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations. Archives of Internal Medicine, 2004, 164, 2106.	3.8	119
212	Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opinion on Pharmacotherapy, 2004, 5, 493-503.	1.8	18
213	Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 89-96.	7.4	278
214	Multi-vessel coronary disease and percutaneous coronary intervention. Heart, 2004, 90, 341-346.	2.9	10
215	Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy. Circulation, 2004, 110, 1916-1919.	1.6	191
216	Recent Clinical Trial Results with Antiplatelet Therapy: Implications in Stroke Prevention. Cerebrovascular Diseases, 2004, 17, 6-10.	1.7	15
217	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. Circulation, 2004, 110, 588-636.	1.6	3,307
218	Economics of Sirolimus-Eluting Stents. Circulation, 2004, 110, 472-474.	1.6	10
219	Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome. Circulation, 2004, 110, 1202-1208.	1.6	778
220	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 189-197.	2.5	236
221	Painful Horner's syndrome caused by carotid dissection. Postgraduate Medical Journal, 2004, 80, 164-164.	1.8	6
222	Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1. European Heart Journal, 2004, 25, 1197-1207.	2.2	240
223	Aspirin and Clopidogrel. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1980-1987.	2.4	395
224	Antiplatelet therapy in cardiovascular disease. Postgraduate Medical Journal, 2004, 80, 155-164.	1.8	44
226	Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease. JAMA - Journal of the American Medical Association, 2004, 292, 1867.	7.4	158

#	ARTICLE	IF	CITATIONS
227	Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the “Emperor’s New Clothes” revisited. <i>European Heart Journal</i> , 2004, 25, 720-722.	2.2	45
228	Risk reduction with long-term clopidogrel following percutaneous coronary intervention. <i>European Heart Journal</i> , 2004, 25, 2169-2170.	2.2	8
229	Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 335-348.	1.8	1
230	Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. <i>Circulation</i> , 2004, 109, 166-171.	1.6	449
231	Cost-Effectiveness of Clopidogrel. <i>Pharmacoeconomics</i> , 2004, 22, 1-3.	3.3	2
233	Effects of a Novel Platelet Nitric Oxide Donor (LA816), Aspirin, Clopidogrel, and Combined Therapy in Inhibiting Flow- and Lesion-Dependent Thrombosis in the Porcine Ex Vivo Model. <i>Circulation</i> , 2004, 110, 1686-1693.	1.6	43
234	Antiplatelet agents. <i>The Hematology Journal</i> , 2004, 5, S170-S174.	1.4	9
235	Acute coronary syndromes and diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2004, 1, 23-32.	2.0	20
236	Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. <i>Journal of Pharmacy Practice</i> , 2004, 17, 347-369.	1.0	1
237	Clopidogrel in the management of cerebrovascular events. <i>International Journal of Clinical Practice</i> , 2004, 58, 402-410.	1.7	3
238	Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2138-2145.	3.8	199
239	Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: A Cost-Utility Analysis in Spain. <i>Value in Health</i> , 2004, 7, 52-60.	0.3	34
240	Role of Clopidogrel in Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: From Literature and Guidelines to Practice. <i>Pharmacotherapy</i> , 2004, 24, 1037-1049.	2.6	2
241	Practical approach to incorporating new studies and guidelines for antiplatelet therapy in the management of patients with non-ST-segment elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , 2004, 93, 69-72.	1.6	1
242	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 93, 679-684.	1.6	117
243	Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. <i>American Journal of Cardiology</i> , 2004, 93, 830-835.	1.6	116
244	Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). <i>American Journal of Cardiology</i> , 2004, 94, 118-120.	1.6	66
245	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. <i>American Journal of Cardiology</i> , 2004, 94, 623-625.	1.6	33

#	ARTICLE	IF	CITATIONS
246	Quelle méthode d'angiographie pour prédire le risque coronaire en 2003? Annales De Cardiologie Et D'Angéiologie, 2004, 53, 79-90.	0.6	0
248	Modulating Thrombotic Potential in Catheter-Based Percutaneous Coronary and Peripheral Vascular Interventions. Journal of Thrombosis and Thrombolysis, 2004, 17, 11-20.	2.1	1
249	Facilitating Optimal Care of Acute Coronary, Cerebrovascular and Peripheral Vascular Syndromes in the Emergency Department: The Role of Oral Antiplatelet Therapy. Journal of Thrombosis and Thrombolysis, 2004, 17, 29-34.	2.1	3
250	Patient-Specific Antiplatelet Therapy. Journal of Thrombosis and Thrombolysis, 2004, 17, 63-77.	2.1	2
251	Percutaneous Coronary Intervention in Diabetics. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 277-285.	5.7	6
254	Does Clopidogrel Increase the Degree of Platelet Inhibition When a Platelet Glycoprotein IIb/IIIa Inhibitor Has Been Given? Insights From an Optical Platelet Aggregometry Study. Journal of Thrombosis and Thrombolysis, 2004, 18, 25-30.	2.1	2
255	Diabetes and Percutaneous Coronary Revascularization in the Drug-Eluting Stent Era. Herz, 2004, 29, 542-50.	1.1	1
257	Acute coronary syndromes in women: Is treatment different? should it be?. Current Cardiology Reports, 2004, 6, 243-252.	2.9	26
258	Clopidogrel: How good is it and how does it work?. Current Cardiology Reports, 2004, 6, 264-268.	2.9	14
259	Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. Current Cardiology Reports, 2004, 6, 279-286.	2.9	1
260	Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiology and Drug Safety, 2004, 13, 841-853.	1.9	296
261	Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial). Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 11.	1.5	7
262	Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: Need to assess aspirin resistance?. Catheterization and Cardiovascular Interventions, 2004, 62, 39-42.	1.7	6
263	Angiographic predictors of left ventricular ejection fraction after successful angioplasty in acute myocardial infarction: An angiographic risk score for use in the catheterization laboratory. Catheterization and Cardiovascular Interventions, 2004, 61, 338-343.	1.7	3
264	Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes. Annals of Emergency Medicine, 2004, 43, 666-668.	0.6	0
265	Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes. Current Medical Research and Opinion, 2004, 20, 1839-1843.	1.9	6
266	Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation. Expert Opinion on Investigational Drugs, 2004, 13, 457-460.	4.1	17
267	Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases. International Journal of Cardiovascular Interventions, 2004, 6, 160-164.	0.5	0

#	ARTICLE	IF	CITATIONS
268	Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI. Scandinavian Cardiovascular Journal, 2004, 38, 9-15.	1.2	1
269	El sistema hemostático en los síndromes coronarios agudos: implicaciones fisiopatológicas y terapéuticas. Revista Clínica Española, 2004, 204, 221-227.	0.6	2
270	Stent liberador de rapamicina en el tratamiento de lesiones coronarias con alto riesgo de reestenosis. Seguimiento clínico a 6 meses de los primeros 100 pacientes. Revista Española De Cardiología, 2004, 57, 116-122.	1.2	19
271	Antiplaquettaires et anesthésie. Praticien En Anesthesie Reanimation, 2004, 8, 29-34.	0.0	0
272	Sirolimus-Eluting Stents to Treat Lesions With a High Risk of Restenosis. Six-Month Clinical Follow-Up in the First 100 Patients. Revista Española De Cardiología (English Ed), 2004, 57, 116-122.	0.6	1
273	Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology, 2004, 43, 585-591.	2.8	267
274	Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. Journal of the American College of Cardiology, 2004, 43, 979-984.	2.8	130
275	Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000. Journal of the American College of Cardiology, 2004, 43, 1755-1762.	2.8	82
276	Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. Journal of the American College of Cardiology, 2004, 43, 1122-1126.	2.8	467
277	For how long should treatment with clopidogrel be continued after coronary stent implantation?. Journal of the American College of Cardiology, 2004, 43, 1331.	2.8	1
279	Therapeutic failure or resistance to aspirin. Journal of the American College of Cardiology, 2004, 43, 1332.	2.8	3
281	Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. Journal of the American College of Cardiology, 2004, 44, 20-24.	2.8	51
282	A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 799-803.	2.8	43
283	Diminishing returns and too many choices: the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2004, 44, 25-27.	2.8	4
284	Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade. Journal of the American College of Cardiology, 2004, 44, 1194-1199.	2.8	17
285	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2004, 44, E1-E211.	2.8	1,028
286	Foundation and sites of action of antithrombotic agents. Best Practice and Research in Clinical Haematology, 2004, 17, 3-22.	1.7	8
287	Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Practice and Research in Clinical Haematology, 2004, 17, 55-64.	1.7	41

#	ARTICLE	IF	CITATIONS
288	Platelet glycoprotein IIb/IIIa inhibitors. Best Practice and Research in Clinical Haematology, 2004, 17, 65-76.	1.7	19
289	Quelle m�thode d'angiographie pour pr�dire le risque coronaire en 2003�? Aspects r�glementaires et pratiques de l'utilisation de la coronarographie, de l'IRM et de l'angioscanner. Annales De Cardiologie Et D'Angeiologie, 2004, 53, 79-90.	0.6	2
290	A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: why it may be a better carotid artery intervention. Journal of Vascular Surgery, 2004, 39, 994-1002.	1.1	59
291	Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) Trial. American Heart Journal, 2004, 147, 475.	2.7	25
292	A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation. American Heart Journal, 2004, 147, 676.	2.7	17
293	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2004, 148, 263-268.	2.7	193
294	Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?. American Heart Journal, 2004, 148, 371-377.	2.7	7
295	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal, 2004, 148, 764-775.	2.7	231
296	Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. American Journal of Medicine, 2004, 116, 253-262.	1.5	100
297	Integrating antithrombin and antiplatelet therapies with early invasive management for non�ST-segment elevation acute coronary syndromes. American Journal of Medicine, 2004, 116, 119-129.	1.5	4
299	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction�Executive Summary. Journal of the American College of Cardiology, 2004, 44, 671-719.	2.8	1,084
300	Advances in Stent-Assisted Management of Intracranial Occlusive Disease and Cerebral Aneurysms. Techniques in Vascular and Interventional Radiology, 2004, 7, 202-209.	1.0	5
301	The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patients with symptomatic advanced systemic arterial diseases. Atherosclerosis, 2004, 176, 125-132.	0.8	7
302	Nuevas estrategias antitromb�ticas en la trombosis arterial. Medicine, 2004, 9, 1414-1422.	0.0	0
303	The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. Coronary Artery Disease, 2004, 15, 347-352.	0.7	12
304	Risk Stratification and the Management of Non�ST-Segment Elevation Acute Coronary Syndromes. Critical Pathways in Cardiology, 2004, 3, 83-86.	0.5	2
305	Diabetes Mellitus: An Imperative for Prevention and Intense Management. Journal of Clinical Pharmacology, 2004, 44, 394-396.	2.0	1
306	Reply: Long-term clopidogrel following PCI: marginal antithrombotic effects are offset by increased bleeding risks. European Heart Journal, 2004, 25, 2170-2171.	2.2	2

#	ARTICLE	IF	CITATIONS
307	The Value of Clopidogrel in Addition to Standard Therapy in Reducing Atherothrombotic Events. <i>Pharmacoeconomics</i> , 2004, 22, 29-41.	3.3	8
308	Antithrombotic Therapy During Percutaneous Coronary Intervention. <i>Chest</i> , 2004, 126, 576S-599S.	0.8	220
309	PLA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 89-93.	1.0	88
310	Monitoring and maintenance of arteriovenous fistulae and graft function in haemodialysis patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 655-660.	2.0	6
311	Glycoprotein IIb/IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: From Pharmacology to Individual Patient's Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 477-484.	1.9	5
312	Atherothrombosis: Epidemiology, Pathophysiology, and Prevention. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, S5-S13.	1.5	56
313	Antiplatelet agents and anticoagulants for hypertension. , 2004, , CD003186.		21
314	Effects of Antiplatelet Agents on Subacute Thrombosis and Restenosis After Successful Coronary Stenting-A Randomized Comparison of Ticlopidine and Cilostazol-. <i>Circulation Journal</i> , 2004, 68, 610-614.	1.6	37
315	A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. <i>Archives of Internal Medicine</i> , 2004, 164, 1490.	3.8	54
316	Antithrombotic Therapy for Acute Coronary Syndromes. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, S14-S27.	1.5	4
317	Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockadeA REPLACE-2 substudy. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1194-1199.	2.8	33
318	Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients. <i>Cardiology</i> , 2005, 5, 187-192.	0.3	0
319	Acute Coronary Syndromes and Diabetes: How Much Can We Intervene?. , 2005, , 31-40.		0
320	What Is the Optimal Timing of Clopidogrel in Acute Coronary Syndromes?. <i>Critical Pathways in Cardiology</i> , 2005, 4, 46-50.	0.5	7
321	The Plastic Surgeon's Guide to Drugs Affecting Hemostasis. <i>Annals of Plastic Surgery</i> , 2005, 54, 570-576.	0.9	12
322	Complete myocardial revascularization: between myth and reality. <i>European Heart Journal</i> , 2005, 26, 1824-1830.	2.2	50
324	Part 5: Acute coronary syndromes. <i>Resuscitation</i> , 2005, 67, 249-269.	3.0	36
325	European Resuscitation Council Guidelines for Resuscitation 2005. <i>Resuscitation</i> , 2005, 67, S87-S96.	3.0	41

#	ARTICLE	IF	CITATIONS
326	Are We Putting the Cart Ahead of the Horse: Who Determines the Standard of Care for the Management of Patients in the Emergency Department?. Annals of Emergency Medicine, 2005, 46, 198-200.	0.6	2
327	Prediction of coronary artery disease severity in patients referred for coronary angiography. Clinical Cardiology, 2005, 28, 288-292.	1.8	0
328	Small Molecule Anticoagulant/Antithrombotic Agents. Annual Reports in Medicinal Chemistry, 2005, , 85-101.	0.9	8
329	Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Journal of Thrombosis and Haemostasis, 2005, 3, 85-92.	3.8	367
330	Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1577-1589.	3.8	74
331	Preventable stroke and stroke prevention. Journal of Thrombosis and Haemostasis, 2005, 3, 1638-1645.	3.8	47
332	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. Journal of Thrombosis and Haemostasis, 2005, 3, 2649-2655.	3.8	50
333	Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. British Journal of Pharmacology, 2005, 146, 419-424.	5.4	49
334	Antithrombotic therapy in hypertension: a Cochrane Systematic review. Journal of Human Hypertension, 2005, 19, 185-196.	2.2	25
335	Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy. International Journal of Clinical Practice, 2005, 59, 1070-1081.	1.7	2
336	Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. American Journal of Cardiology, 2005, 95, 509-510.	1.6	114
337	Treating Patients With Acute Coronary Syndromes With Aggressive Antiplatelet Therapy (from the Tj ETQq1 1 0.784314 rgBT /Overl	1.6	17
338	Actualizaci3n en cardiolog3a intervencionista 2004. Revista Espanola De Cardiologia Suplementos, 2005, 5, 104A-117A.	0.2	0
339	The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. , 2005, 108, 180-192.		96
340	A new mechanical connector for distal coronary artery anastomoses in coronary artery bypass grafting: A randomized, controlled study. Journal of Thoracic and Cardiovascular Surgery, 2005, 129, 146-150.	0.8	19
341	Antiplatelet Drug Resistance: Not Ready for Prime Time. Pharmacotherapy, 2005, 25, 1621-1628.	2.6	9
342	Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials. Catheterization and Cardiovascular Interventions, 2005, 64, 61-66.	1.7	1
343	Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. Catheterization and Cardiovascular Interventions, 2005, 65, 520-524.	1.7	29

#	ARTICLE	IF	CITATIONS
344	Clopidogrel (Plavix) desensitization: A case series. Catheterization and Cardiovascular Interventions, 2005, 65, 525-527.	1.7	39
345	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheterization and Cardiovascular Interventions, 2005, 66, 149-157.	1.7	14
346	Platelet Inhibition in Percutaneous Coronary Interventions. Herz, 2005, 30, 189-196.	1.1	0
347	The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. European Journal of Health Economics, 2005, 6, 354-362.	2.8	21
348	Lower extremity arterial occlusive disease: Role of percutaneous revascularization. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 99-107.	0.9	0
349	Novel serologic markers of cardiovascular risk. Current Atherosclerosis Reports, 2005, 7, 148-154.	4.8	12
350	Effects of SolCD39, a Novel Inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model. Journal of Thrombosis and Thrombolysis, 2005, 19, 115-122.	2.1	27
351	The Variability of Platelet Response to Aspirin and Clopidogrel: Revisiting the Caprie, Cure, Credo, and Match Trials. Baylor University Medical Center Proceedings, 2005, 18, 331-336.	0.5	9
353	The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thrombosis and Haemostasis, 2005, 94, 438-43.	3.4	33
354	The role of clopidogrel in the emergency department. Canadian Journal of Emergency Medicine, 2005, 7, 22-27.	1.1	2
355	Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thrombosis and Haemostasis, 2005, 94, 568-577.	3.4	115
357	Intracranial Stenting. , 2005, 17, 70-84.		1
359	Adding aspirin to clopidogrel after TIA and ischemic stroke. Neurology, 2005, 64, 1117-1121.	1.1	21
360	Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein Ib. Platelets, 2005, 16, 453-461.	2.3	5
361	Inappropriate pacemaker therapy in congestive heart failure. Heart, 2005, 91, 1140-1140.	2.9	0
362	Cardiac sarcoidosis with delayed enhanced MRI. Heart, 2005, 91, 1185-1185.	2.9	6
363	Peri-procedural myocardial injury: 2005 update. European Heart Journal, 2005, 26, 2493-2519.	2.2	286
364	Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 2908.	7.4	717

#	ARTICLE	IF	CITATIONS
365	Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. <i>Heart</i> , 2005, 91, 1135-1140.	2.9	6
366	To Cath or Not to Cath. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2935.	7.4	28
367	Part 8: Stabilization of the Patient With Acute Coronary Syndromes. <i>Circulation</i> , 2005, 112, IV-89-IV-110.	1.6	9
368	Surgery Is Preferred for the Diabetic With Multivessel Disease. <i>Circulation</i> , 2005, 112, 1500-1515.	1.6	31
369	Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. <i>New England Journal of Medicine</i> , 2005, 352, 238-244.	27.0	567
370	Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. <i>Circulation</i> , 2005, 111, 940-953.	1.6	214
372	Use of Antiplatelet Inhibitors in Peripheral Vascular Interventions. <i>Seminars in Interventional Radiology</i> , 2005, 22, 80-87.	0.8	2
374	Clopidogrel: cardiologistsâ€™ panacea or neurologistsâ€™ headache?. <i>Future Cardiology</i> , 2005, 1, 579-590.	1.2	1
375	Treatment of unprotected left main coronary artery stenosis with a drug eluting stent in a heart transplant patient with allograft vasculopathy. <i>Heart</i> , 2005, 91, e11-e11.	2.9	6
376	Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. <i>European Heart Journal</i> , 2005, 26, 1180-1187.	2.2	183
377	Clopidogrel and Ticlopidine: P2Y ₁₂ Adenosine Diphosphate-Receptor Antagonists for the Prevention of Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 174-183.	2.7	302
378	Platelet VASP phosphorylation assessment in clopidogrel-treated patients: Lack of agreement between Western blot and flow cytometry. <i>Platelets</i> , 2005, 16, 474-481.	2.3	12
379	The role of antiplatelet therapy in the management of acute coronary syndromes. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 541-556.	2.4	6
380	Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 635-646.	1.5	1
381	Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 113-125.	1.7	0
382	Clopidogrel in Acute Coronary Heart Disease. <i>The American Heart Hospital Journal</i> , 2005, 3, 234-242.	0.2	2
383	Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. <i>Heart</i> , 2005, 91, 1181-1185.	2.9	50
384	Dual Antiplatelet Therapy for Coronary Stenting. <i>Circulation</i> , 2005, 111, 1097-1099.	1.6	7

#	ARTICLE	IF	CITATIONS
403	Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. European Heart Journal, 2005, 26, 567-575.	2.2	34
404	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. European Heart Journal, 2005, 26, 1379-1384.	2.2	44
405	A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. European Heart Journal, 2005, 27, 1401-1407.	2.2	38
406	Platelets and new antiplatelet drugs. Therapy: Open Access in Clinical Medicine, 2005, 2, 465-502.	0.2	8
407	Preventing in-hospital cardiac and renal complications in high-risk PCI patients. Country Review Ukraine, 2005, 7, G13-G24.	0.8	2
409	Case 6. 2005 Thoracotomy After Myocardial Infarction and Intracoronary Stenting: A Balance Between Myocardial Recovery and Procedural Risk. Journal of Cardiothoracic and Vascular Anesthesia, 2005, 19, 794-800.	1.3	0
412	Antiplatelet Therapy in Neuroendovascular Therapeutics. Neurosurgery Clinics of North America, 2005, 16, 517-540.	1.7	42
413	Antiplatelet Agents: Current Drugs and Future Trends. Hematology/Oncology Clinics of North America, 2005, 19, 87-117.	2.2	10
414	Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients. Cardiology Clinics, 2005, 23, 185-191.	2.2	2
415	Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. Journal of Vascular Surgery, 2005, 42, 252-258.	1.1	13
416	The drug-based pipeline against restenosis. Expert Opinion on Emerging Drugs, 2005, 10, 67-86.	2.4	2
417	Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?. Scandinavian Cardiovascular Journal, 2005, 39, 135-136.	1.2	2
418	Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel. Circulation, 2005, 112, 2946-2950.	1.6	605
419	Evolving role of clopidogrel in acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2005, 3, 977-980.	1.5	0
420	Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2005, 5, 307-318.	2.2	14
421	Anaesthetic considerations in a parturient with critical coronary artery disease and a drug-eluting stent presenting for caesarean section. International Journal of Obstetric Anesthesia, 2005, 14, 167-171.	0.4	34
422	Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. International Journal of Cardiology, 2005, 103, 293-297.	1.7	15
423	The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clinical Therapeutics, 2005, 27, 100-110.	2.5	33

#	ARTICLE	IF	CITATIONS
424	Commentary 2. Evidence-based Cardiovascular Medicine, 2005, 9, 282-283.	0.0	0
425	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. <i>Thrombosis Research</i> , 2005, 115, 101-108.	1.7	154
426	Potential of platelet aggregation by heparin in human whole blood is attenuated by P2Y ₁₂ and P2Y ₁ antagonists but not aspirin. <i>Thrombosis Research</i> , 2005, 115, 301-307.	1.7	21
427	Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. <i>Thrombosis Research</i> , 2005, 116, 55-66.	1.7	21
428	Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. <i>Thrombosis Research</i> , 2005, 116, 293-300.	1.7	7
429	In-Hospital Patients Exposed to Clopidogrel Before Coronary Artery Bypass Graft Surgery: A Word of Caution. <i>Annals of Thoracic Surgery</i> , 2005, 79, 1210-1216.	1.3	110
430	Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2005, 80, 768-779.	1.3	60
431	Aprotinin Reduces Bleeding and Blood Product Use in Patients Treated With Clopidogrel Before Coronary Artery Bypass Grafting. <i>Annals of Thoracic Surgery</i> , 2005, 80, 922-927.	1.3	39
432	Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf therapy. <i>American Heart Journal</i> , 2005, 149, 138-144.	2.7	27
433	The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design. <i>American Heart Journal</i> , 2005, 149, 13-19.	2.7	80
434	Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors. <i>American Heart Journal</i> , 2005, 149, S43-S53.	2.7	40
435	Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling. <i>American Heart Journal</i> , 2005, 149, 947-949.	2.7	1
436	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>American Heart Journal</i> , 2005, 150, 1177-1184.	2.7	67
437	Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. <i>American Heart Journal</i> , 2005, 149, 1135.e11-1135.e18.	2.7	12
438	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2005, 150, 401.e1-401.e7.	2.7	29
439	A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. <i>American Heart Journal</i> , 2005, 150, 220.e1-220.e5.	2.7	18
440	Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non- α -ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. <i>American Heart Journal</i> , 2005, 150, 401.e9-401.e14.	2.7	21
441	Cilostazol improves long-term outcomes after coronary stent implantation. <i>American Heart Journal</i> , 2005, 150, 568.e1-568.e5.	2.7	17

#	ARTICLE	IF	CITATIONS
445	Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. <i>Drugs</i> , 2005, 65, 725-732.	10.9	38
446	Diabetes and Percutaneous Interventional Therapy. , 2005, , 519-541.		0
447	Advances in Adjunctive Pharmacological Therapy for Percutaneous Coronary Interventions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005, 58, 729-743.	0.6	0
448	Aspirin Resistance and Atherothrombotic Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 986-993.	2.8	179
449	Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2005, 45, 369-376.	2.8	41
450	Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. <i>Journal of the American College of Cardiology</i> , 2005, 45, 363-368.	2.8	201
451	Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 838-845.	2.8	103
452	Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2005, 45, 2088-2092.	2.8	611
453	Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2005, 46, 761-769.	2.8	115
454	Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1473-1478.	2.8	46
456	Economic Effects of Extended Clopidogrel Therapyâ€”A Word of Caution. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1376.	2.8	0
458	Platelet Reactivity in Patients and Recurrent Events Post-Stenting. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1820-1826.	2.8	628
459	Cardiovascular Drug Therapy in Elderly Patients. <i>Drugs and Aging</i> , 2005, 22, 913-941.	2.7	35
461	Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. <i>The Cochrane Library</i> , 2005, , CD005313.	2.8	37
462	Tirofiban in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 193-206.	1.5	11
464	Regulatory issues facing the development of drug-eluting stents: a US FDA perspective. <i>Expert Review of Medical Devices</i> , 2006, 3, 297-300.	2.8	7
465	Chronic Antithrombotic Therapy in Postâ€”Myocardial Infarction Patients. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 167-182.	2.6	0
466	Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement. <i>Circulation</i> , 2006, 113, 2803-2809.	1.6	789

#	ARTICLE	IF	CITATIONS
467	Pathogenesis and Early Management of Non-“ST-segment Elevation Acute Coronary Syndromes. Cardiology Clinics, 2006, 24, 19-35.	2.2	5
468	Clopidogrel use in coronary artery disease. Expert Review of Cardiovascular Therapy, 2006, 4, 7-15.	1.5	6
469	Clopidogrel. Pharmacoeconomics, 2006, 24, 709-726.	3.3	16
470	The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. American Journal of Cardiovascular Drugs, 2006, 6, 149-157.	2.2	16
471	Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2006, 6, 313-325.	2.2	1
472	Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ: British Medical Journal, 2006, 333, 726.	2.3	324
473	Clopidogrel in the treatment of ischaemic heart disease. Expert Opinion on Pharmacotherapy, 2006, 7, 1109-1120.	1.8	3
474	Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology, 2006, 22, 13C-20C.	1.7	0
475	Controversia terapéutica: clopidogrel y estatinas. Clínica E Investigación En Arteriosclerosis, 2006, 18, 34-48.	0.8	0
476	Prasugrel. Expert Opinion on Investigational Drugs, 2006, 15, 1627-1633.	4.1	21
477	Consequences of coronary artery stenting for non-cardiac surgery. Transfusion Alternatives in Transfusion Medicine, 2006, 8, 151-155.	0.2	1
478	Percutaneous coronary intervention. Medicine, 2006, 34, 197-202.	0.4	1
479	Present and Future Anticoagulants. Advances in Anesthesia, 2006, 24, 29-66.	0.9	4
480	Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clinic Proceedings, 2006, 81, 641-652.	3.0	49
482	Antithrombotic Therapy for Percutaneous Coronary Intervention. Cardiology Clinics, 2006, 24, 175-199.	2.2	3
483	Antiplatelet Agents and Arterial Thrombosis. Clinics in Geriatric Medicine, 2006, 22, 57-74.	2.6	5
484	Conduite à tenir devant un patient porteur d’une endoprothèse coronaire devant être anesthésié et opéré. Praticien En Anesthésie Réanimation, 2006, 10, 202-212.	0.0	0
485	Ischemic Heart Disease in Women: Clinical Presentation, Non-Invasive Testing, and Management of Acute Coronary Syndromes. Revista Espanola De Cardiologia (English Ed), 2006, 59, 371-381.	0.6	1

#	ARTICLE	IF	CITATIONS
486	Effect of Sex on Revascularization Strategy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 487-501.	0.6	1
490	Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Chest</i> , 2006, 130, 1823-1827.	0.8	81
491	Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2006, 47, 939-943.	2.8	177
492	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article. <i>Journal of the American College of Cardiology</i> , 2006, 47, 216-235.	2.8	372
493	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2006, 47, e1-e121.	2.8	435
494	A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 931-938.	2.8	509
495	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-“ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1339-1345.	2.8	329
496	Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1742-1750.	2.8	558
497	Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 116-118.	0.0	1
499	Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2006, 119, 1056-1061.	1.5	452
500	Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. <i>American Heart Journal</i> , 2006, 151, 219-227.	2.7	67
501	Highlights from the 55th Annual Scientific Sessions of the American College of Cardiology: March 11 to 14, 2006, Atlanta, Georgia. <i>American Heart Journal</i> , 2006, 151, 1156-1172.	2.7	2
502	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). <i>American Heart Journal</i> , 2006, 152, 627-635.	2.7	290
503	Adding tirofiban to standard pretreatment does not alter outcomes for people with non ST-elevation ACS undergoing early invasive therapy. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 38-40.	0.0	1
505	Simultaneous multivessel acute drug-eluting stent thrombosis. <i>International Journal of Cardiology</i> , 2006, 113, E11-E15.	1.7	12
506	Pre-treatment with clopidogrel and postprocedure troponin elevation after elective percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2006, 95, 337-340.	3.4	8
507	A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. <i>Chinese Medical Journal</i> , 2006, 119, 360-366.	2.3	27
509	Guidelines for the management of acute coronary syndromes 2006. <i>Medical Journal of Australia</i> , 2006, 184, S1-S32.	1.7	121

#	ARTICLE	IF	CITATIONS
510	Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chinese Medical Journal, 2006, 119, 32-36.	2.3	45
511	Myocardial Infarction as a Presentation of Clinical In-Stent Restenosis. Circulation Journal, 2006, 70, 1026-1029.	1.6	72
512	Antithrombotic therapy in secondary stroke prevention. Aging Health, 2006, 2, 787-797.	0.3	0
513	The superior doctor. BMJ: British Medical Journal, 2006, 333, 728.	2.3	1
514	Do patients undergoing percutaneous coronary intervention benefit from clopidogrel pretreatment?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 12-13.	3.3	0
515	The Effects of Clopidogrel and Calcium Dobesilate on Intimal Hyperplasia Following Vascular Injury. Acta Chirurgica Belgica, 2006, 106, 206-210.	0.4	9
516	Histopathology of Carotid Atherosclerotic Disease. Neurosurgery, 2006, 59, S3-219-S3-227.	1.1	157
517	Clopidogrel in non-ST-segment elevation acute coronary syndromes. Country Review Ukraine, 2006, 8, G25-G30.	0.8	7
518	Clinical evaluation of clopidogrel across the whole spectrum of indications: primary and secondary prevention of coronary artery disease. Country Review Ukraine, 2006, 8, G10-G14.	0.8	2
519	Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention. Country Review Ukraine, 2006, 8, G20-G24.	0.8	1
520	A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coronary Artery Disease, 2006, 17, 261-269.	0.7	53
521	Clopidogrel (Plavix) Revisited. Obstetrics and Gynecology, 2006, 108, 200-202.	2.4	0
522	Survey of Clopidogrel Use in a Teaching Hospital. Journal of Pharmacy Practice and Research, 2006, 36, 40-43.	0.8	0
523	Current Concepts in the Management of Intracranial Atherosclerotic Disease. Neurosurgery, 2006, 59, S210-S218.	1.1	21
524	Variability of Response to Clopidogrel. Cardiology in Review, 2006, 14, 136-142.	1.4	27
525	Optimal revascularization strategies for multivessel coronary artery disease. Current Opinion in Cardiology, 2006, 21, 595-601.	1.8	7
526	ANTIPLATELET THERAPY IN PERIPHERAL OCCLUSIVE ARTERIAL DISEASE. ANZ Journal of Surgery, 2006, 76, 364-372.	0.7	0
527	Temporal trends in major angioplasty complications: technical issues and the case for on-site coronary surgery. Internal Medicine Journal, 2006, 36, 458-461.	0.8	2

#	ARTICLE	IF	CITATIONS
528	High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2006, 4, 542-549.	3.8	349
529	High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis?. Journal of Thrombosis and Haemostasis, 2006, 4, 536-538.	3.8	2
530	P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. Journal of Thrombosis and Haemostasis, 2006, 4, 638-647.	3.8	106
531	Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. Journal of Thrombosis and Haemostasis, 2006, 4, 2508-2509.	3.8	217
532	Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. Journal of Thrombosis and Haemostasis, 2006, 4, 2504-2508.	3.8	8
533	The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. Journal of Thrombosis and Haemostasis, 2006, 4, 2308-2316.	3.8	23
534	Platelet hyperactivity and risk of recurrent thrombosis. Journal of Thrombosis and Haemostasis, 2006, 4, 2544-2546.	3.8	19
535	Life after CHARISMA. International Journal of Stroke, 2006, 1, 167-168.	5.9	1
536	Duration of Clopidogrel Therapy with Drug-Eluting Stents. Journal of Interventional Cardiology, 2006, 19, S40-S46.	1.2	7
537	Aspirin and Clopidogrel Resistance: Consideration and Management. Journal of Interventional Cardiology, 2006, 19, 439-448.	1.2	51
538	Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. Annals of Emergency Medicine, 2006, 48, 270-301.	0.6	49
539	Possible mechanisms of drug-induced aspirin and clopidogrel resistance. Journal of Thrombosis and Thrombolysis, 2006, 22, 139-150.	2.1	22
540	The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. Journal of Thrombosis and Thrombolysis, 2006, 22, 103-110.	2.1	63
541	Women and men with unstable angina and/or non-ST-elevation myocardial infarction. Wiener Klinische Wochenschrift, 2006, 118, 52-57.	1.9	3
542	Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift, 2006, 156, 472-480.	1.1	8
546	Use of antiplatelet drugs in secondary prevention in patients with atherothrombotic disease. Comprehensive Therapy, 2006, 32, 182-188.	0.2	1
547	Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?. Current Cardiology Reports, 2006, 8, 267-271.	2.9	10
548	Clopidogrel Loading Dose (300 Versus 600 mg) Strategies for Patients With Stable Angina Pectoris Subjected to Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 97, 984-989.	1.6	39

#	ARTICLE	IF	CITATIONS
549	Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. American Journal of Cardiology, 2006, 98, 447-452.	1.6	10
550	Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. American Journal of Cardiology, 2006, 98, 681-684.	1.6	130
551	Effectiveness and Safety of Glycoprotein IIb/IIIa Inhibitors and Clopidogrel Alone and in Combination in Non-ST-Segment Elevation Myocardial Infarction (from the National Registry of Myocardial) Tj ETQq0 0 0 rgBT1,6 Overlock 110 Tf 50 6	1.6	10
552	Effect of Clopidogrel Plus Aspirin on ST Segments in Patients With ST-Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2006, 98, 1435-1438.	1.6	0
553	Clopidogrel Response Variability, Resistance, or Both?. American Journal of Cardiology, 2006, 98, S18-S24.	1.6	38
554	Evolving Management of ST-Segment Elevation Myocardial Infarction: Update on Recent Data. American Journal of Cardiology, 2006, 98, S10-S21.	1.6	13
556	Modern Management of Acute Myocardial Infarction. Current Problems in Cardiology, 2006, 31, 769-817.	2.4	16
557	Estrategia invasiva en el SCASEST. Tratamiento antitrombótico. Revista Espanola De Cardiologia Suplementos, 2006, 6, 29H-38H.	0.2	1
558	Antiangregación oral e intervencionismo coronario percutáneo. Revista Espanola De Cardiologia Suplementos, 2006, 6, 49H-56H.	0.2	0
559	Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals. Pharmacotherapy, 2006, 26, 1537-1556.	2.6	16
560	Clopidogrel-Induced Hepatotoxicity and Fever. Pharmacotherapy, 2006, 26, 1023-1026.	2.6	18
561	ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary) Tj ETQq1 1 0.7843145 BT /Ove	1.7	145
562	Successful thrombus extraction with the Rescue, a thrombus management system during acute percutaneous coronary intervention improves flow but does not necessarily restore optimal myocardial tissue perfusion. Catheterization and Cardiovascular Interventions, 2006, 67, 879-886.	1.7	4
563	Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 68, 56-61.	1.7	68
564	Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) a single-center study comparing Cypher, sirolimus-eluting with Taxus, paclitaxel-eluting stents. Catheterization and Cardiovascular Interventions, 2006, 68, 663-668.	1.7	10
565	The role of covered stents: More than an occasional cameo?. Catheterization and Cardiovascular Interventions, 2006, 68, 21-26.	1.7	8
566	Abnormal haemoglobin levels in acute coronary syndromes. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 851-862.	0.5	24
567	Bleeding and management of bleeding. Country Review Ukraine, 2006, 8, G38-G45.	0.8	60

#	ARTICLE	IF	CITATIONS
569	Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2006, 7, 1669-1673.	1.8	0
570	Antiplatelet therapy: current strategies and future trends. Future Cardiology, 2006, 2, 343-366.	1.2	31
571	Primary stent therapy for symptomatic intracranial atherosclerotic stenosis: 1-year follow-up angiographic and midterm clinical outcomes. Journal of Neurosurgery, 2006, 105, 235-241.	1.6	29
572	The Charisma of Subgroups and the Subgroups of CHARISMA. New England Journal of Medicine, 2006, 354, 1744-1746.	27.0	57
573	Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 2006, 27, 2420-2425.	2.2	453
574	Thienopyridines in Percutaneous Coronary Interventions: Standard Procedures and High Risk Subsets. Current Pharmaceutical Design, 2006, 12, 1281-1286.	1.9	0
575	Thienopyridines and Statins: Assessing a Potential Drug-Drug Interaction. Current Pharmaceutical Design, 2006, 12, 1271-1280.	1.9	27
576	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. Circulation, 2006, 114, 2871-2891.	1.6	109
577	Pharmacological Characterization of 2NTX-99 [4-Methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a Potential Antiatherothrombotic Agent with Antithromboxane and Nitric Oxide Donor Activity in Platelet and Vascular Preparations. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 830-837.	2.5	9
578	Is Clopidogrel Cardiovascular Medicine's Double-Edged Sword?. Circulation, 2006, 113, 1638-1640.	1.6	21
579	Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart, 2006, 92, 49-51.	2.9	18
580	Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function. Circulation, 2006, 114, 2449-2457.	1.6	139
581	Clopidogrel Resistance: Myth or Reality?. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 47-53.	2.0	30
582	Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Cmaj, 2006, 174, 1715-1722.	2.0	177
583	Direct Comparison of the A to Z and PROVE IT Trials. Circulation, 2006, 113, 1382-1384.	1.6	9
584	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article. Circulation, 2006, 113, 156-175.	1.6	987
585	Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice. Circulation, 2006, 113, 1434-1441.	1.6	316
586	Clopidogrel resistance / Clopidogrel-Resistenz. Das Medizinische Laboratorium, 2006, 30, 310-316.	0.0	2

#	ARTICLE	IF	CITATIONS
587	Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction. Evidence-Based Medicine, 2006, 11, 82-83.	0.6	1
588	Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment¹The ISAR-REACT 2 Randomized Trial². JAMA - Journal of the American Medical Association, 2006, 295, 1531.	7.4	682
589	A contraindication for internal mammary to coronary bypass. Heart, 2006, 92, 51-51.	2.9	0
590	Invasive Assessment of the Coronary Microcirculation. Circulation, 2006, 113, 2054-2061.	1.6	336
591	ACC/AHA/SCAI Practice Guidelines, February 21, 2006. Circulation, 2006, 113, e166-286.	1.6	525
592	Antiplatelet Therapy after Percutaneous Coronary Intervention. Cerebrovascular Diseases, 2006, 21, 25-34.	1.7	14
593	Antiplatelet therapy and the vascular tree. Heart, 2006, 92, 3-4.	2.9	24
594	The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opinion on Drug Safety, 2006, 5, 815-826.	2.4	17
595	Inflammation in Atherosclerosis. Circulation, 2006, 113, e728-32.	1.6	52
596	The cost-effectiveness of clopidogrel: a review by indication. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 123-130.	1.4	0
597	Does clopidogrel pretreatment counteract the benefits of off-pump CABG surgery?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 530-531.	3.3	2
598	Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal, 2006, 27, 647-654.	2.2	286
599	Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1648-1652.	2.4	140
600	Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor. Clinical Chemistry, 2006, 52, 383-388.	3.2	67
601	Handbook Of Complex Percutaneous Carotid Intervention. , 2007, , .		4
603	Clopidogrel: a pharmacoeconomic review. Journal of Medical Economics, 2007, 10, 553-571.	2.1	0
604	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Circulation, 2007, 116, e148-304.	1.6	1,247
605	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. Expert Review of Cardiovascular Therapy, 2007, 5, 939-953.	1.5	1

#	ARTICLE	IF	CITATIONS
606	Drug-Eluting Stents: Can We Move Beyond Stent Thrombosis?. The American Heart Hospital Journal, 2007, 5, 155-158.	0.2	2
607	Platelets and Vascular Risk: An Option for Treatment. Current Pharmaceutical Design, 2007, 13, 1669-1683.	1.9	22
608	The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. European Heart Journal, 2007, 29, 1259-1266.	2.2	71
609	Late Coronary Stent Thrombosis. Circulation, 2007, 116, 1952-1965.	1.6	218
610	Variability in response to clopidogrel: where is the threshold for 'low response'?. European Heart Journal, 2007, 28, 515-516.	2.2	0
611	Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. European Heart Journal, 2007, 28, 1025-1032.	2.2	45
612	A comparison between coronary artery bypass grafting surgery and drug eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >=75 years). European Heart Journal, 2007, 28, 2714-2719.	2.2	82
613	Pharmacological antithrombotic adjuncts to percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2007, 8, 759-776.	1.8	1
614	Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight). Country Review Ukraine, 2007, 9, A25-A31.	0.8	0
615	Efficacy and Safety of Clopidogrel 600 mg Administered Pre-Hospitally to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (CIPAMI): Study Rationale and Design. Cardiology, 2007, 108, 265-272.	1.4	25
616	Combination Antiplatelet Therapy with Aspirin and Clopidogrel: The Role of Antecedent and Concomitant Doses of Aspirin. Cardiology, 2007, 107, 307-312.	1.4	4
617	Does prolonged clopidogrel therapy improve outcome in patients with drug-eluting or bare-metal stents?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 302-303.	3.3	1
618	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. Journal of Human Hypertension, 2007, 21, 183-211.	2.2	113
619	Clopidogrel use with stenting. Expert Opinion on Pharmacotherapy, 2007, 8, 1399-1402.	1.8	1
620	Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. Future Cardiology, 2007, 3, 365-375.	1.2	3
621	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal, 2007, 28, 2200-2207.	2.2	68
622	Drug-Eluting Stents: The Next Chapter of the Coronary Stent Saga. The American Heart Hospital Journal, 2007, 5, 173-176.	0.2	0
623	Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. British Journal of Anaesthesia, 2007, 98, 19-22.	3.4	104

#	ARTICLE	IF	CITATIONS
624	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2007, 116, 803-877.	1.6	177
625	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1769.	7.4	1
626	Acute Coronary Care in the Elderly, Part I. <i>Circulation</i> , 2007, 115, 2549-2569.	1.6	693
627	Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 400-406.	2.4	62
628	Clopidogrel: an updated and comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 621-631.	3.3	16
629	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. <i>Circulation</i> , 2007, 116, 745-754.	1.6	430
630	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1769.	7.4	2
631	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1769.	7.4	5
632	Brain Injury Secondary to Carotid Intervention. <i>Journal of Endovascular Therapy</i> , 2007, 14, 219-231.	1.5	14
633	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation-“Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1769.	7.4	6
634	Usefulness of Antiplatelet Drugs in Ischaemic Stroke Prevention -“Update on New Trials. <i>Cerebrovascular Diseases</i> , 2007, 24, 112-115.	1.7	0
635	Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. <i>Circulation</i> , 2007, 115, 2196-2207.	1.6	191
636	Drug-Eluting Stent Update 2007. <i>Circulation</i> , 2007, 116, 961-968.	1.6	58
637	Recombinant Factor VIIa Reduces Bleeding Risk in Patients on Platelet Aggregation Inhibitors Immediately prior to Renal Transplantation -“A Retrospective Analysis. <i>Urologia Internationalis</i> , 2007, 78, 135-139.	1.3	5
638	Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. <i>Future Cardiology</i> , 2007, 3, 345-364.	1.2	6
639	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. , 2007, , CD005158.		15
641	10 Most Commonly Asked Questions About Carotid Artery Stent Placement. <i>Neurologist</i> , 2007, 13, 318-322.	0.7	2
642	The role of clopidogrel in the management of ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2007, 22, 273-279.	1.8	13

#	ARTICLE	IF	CITATIONS
643	Clopidogrel Desensitization Protocol for the Treatment of Thienopyridine Hypersensitivity. Critical Pathways in Cardiology, 2007, 6, 26-29.	0.5	13
644	The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Current Opinion in Cardiology, 2007, 22, 565-571.	1.8	31
645	Therapeutic Benefit of Low-Dose Clopidogrel in Patients Undergoing Carotid Surgery Is Linked to Variability in the Platelet Adenosine Diphosphate Response and Patients' Weight. Stroke, 2007, 38, 2464-2469.	2.0	13
646	Objective Assessment of Keloid Scars with Three-Dimensional Imaging: Quantifying Response to Intralesional Steroid Therapy. Plastic and Reconstructive Surgery, 2007, 119, 556-561.	1.4	57
647	Antiplatelet therapy in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 124-131.	2.3	43
648	Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. Journal of Cardiovascular Medicine, 2007, 8, 221-229.	1.5	10
649	Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. Journal of Cardiovascular Medicine, 2007, 8, 625-628.	1.5	2
650	Antiplatelet therapy in acute coronary syndromes. Clinical Medicine, 2007, 7, 388-391.	1.9	0
651	Variability in response to clopidogrel: where is the threshold for 'low response'? reply. European Heart Journal, 2007, 28, 516-516.	2.2	1
652	Acute cardiovascular medicine. Clinical Medicine, 2007, 7, 257-261.	1.9	0
653	Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 518-524.	3.6	4
654	Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. Journal of Cardiovascular Pharmacology, 2007, 50, 555-562.	1.9	159
655	Dual antiplatelet therapy in high-risk patients. Country Review Ukraine, 2007, 9, D3-D9.	0.8	8
656	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERify Thrombosis risk ASsessment (VERITAS) study. Thrombosis Research, 2007, 119, 277-284.	1.7	198
657	Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thrombosis Research, 2007, 119, 285-291.	1.7	27
658	Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thrombosis Research, 2007, 119, 563-570.	1.7	46
659	Clopidogrel resistance?. Thrombosis Research, 2007, 120, 311-321.	1.7	151
660	The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thrombosis Research, 2007, 120, 353-359.	1.7	25

#	ARTICLE	IF	CITATIONS
661	Measuring antiplatelet drug effects in the laboratory. <i>Thrombosis Research</i> , 2007, 120, 323-336.	1.7	171
662	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2007, 120, 893-899.	1.7	77
663	Antiplatelet agents make a comeback in ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2007, 154, 603-606.	2.7	0
664	A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. <i>American Heart Journal</i> , 2007, 153, 66.e9-66.e16.	2.7	483
665	Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. <i>American Heart Journal</i> , 2007, 153, 289-295.	2.7	50
666	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2007, 154, 221-231.	2.7	390
667	Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. <i>American Heart Journal</i> , 2007, 154, 344.e1-344.e5.	2.7	10
668	The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting. <i>American Heart Journal</i> , 2007, 154, 676-681.	2.7	23
669	Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. <i>American Heart Journal</i> , 2007, 154, 846-851.	2.7	45
670	Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 183-188.	0.8	16
671	Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials. <i>Clinical Therapeutics</i> , 2007, 29, 1184-1202.	2.5	20
673	Coronary angiography in the elderly with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2007, 116, 249-256.	1.7	8
674	A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?. <i>International Journal of Cardiology</i> , 2007, 116, 93-97.	1.7	7
675	Percutaneous Coronary Interventions and Antiplatelet Therapy in the Perioperative Period. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 436-442.	1.3	8
676	Pro: Continuation of Aspirin/Clopidogrel for Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 602-605.	1.3	1
677	Con: Continuation of Aspirin/Clopidogrel for Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 606-609.	1.3	2
678	The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. <i>Canadian Journal of Cardiology</i> , 2007, 23, 201-206.	1.7	31
679	Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: A long-term analysis based on the CURE trial. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1037-1042.	1.7	18

#	ARTICLE	IF	CITATIONS
680	Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute. Canadian Journal of Cardiology, 2007, 23, 80B-83B.	1.7	2
681	Variability in Individual Responsiveness to Clopidogrel. Journal of the American College of Cardiology, 2007, 49, 1505-1516.	2.8	886
682	Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician. Mayo Clinic Proceedings, 2007, 82, 583-593.	3.0	20
683	Novel thromboresistant materials. Journal of Vascular Surgery, 2007, 45, A104-A115.	1.1	135
684	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. European Heart Journal, 2007, 28, 1717-1722.	2.2	121
685	Medical Treatment of Stable Angina. , 2007, , 911-936.		0
686	Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. British Journal of Anaesthesia, 2007, 99, 316-328.	3.4	286
687	Platelet Inhibitors and Monitoring Platelet Function: Implications for Bleeding. Hematology/Oncology Clinics of North America, 2007, 21, 51-63.	2.2	5
688	Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Current Medical Research and Opinion, 2007, 23, 1453-1462.	1.9	16
689	Rapid Desensitization Protocols for Patients with Cardiovascular Disease and Aspirin Hypersensitivity in an Era of Dual Antiplatelet Therapy. Annals of Pharmacotherapy, 2007, 41, 61-67.	1.9	27
690	Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention. Pharmacoeconomics, 2007, 25, 769-782.	3.3	20
691	Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. Pharmacoeconomics, 2007, 25, 1063-1082.	3.3	21
692	Appropriate pharmacology should be initiated before, during and following percutaneous coronary intervention in patients with left ventricular dysfunction or heart failure. Drugs and Therapy Perspectives, 2007, 23, 16-20.	0.6	0
693	Clopidogrel: a guide to its use in the prevention of thrombosis. Drugs and Therapy Perspectives, 2007, 23, 1-4.	0.6	0
694	The Role of Clopidogrel in Revascularized and Nonrevascularized Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2007, 7, 159-168.	2.2	4
695	ADP Receptor Antagonism. American Journal of Cardiovascular Drugs, 2007, 7, 423-432.	2.2	52
696	Clopidogrel poor responders: An objective definition based on Bayesian classification. Platelets, 2007, 18, 428-435.	2.3	25
697	Clopidogrel resistance â€” The cardiologist's perspective. Platelets, 2007, 18, 175-181.	2.3	12

#	ARTICLE	IF	CITATIONS
698	Clopidogrel anti-platelet effect: An evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100®). Platelets, 2007, 18, 491-496.	2.3	50
699	Clinical Aspects of Platelet Inhibitors and Thrombus Formation. Circulation Research, 2007, 100, 1261-1275.	4.5	327
700	Acute Coronary Syndromes in the Elderly. Clinics in Geriatric Medicine, 2007, 23, 425-440.	2.6	13
701	Management of non-“ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America, 2007, 91, 683-700.	2.5	3
702	Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. Critical Care Clinics, 2007, 23, 709-735.	2.6	10
705	Clopidogrel. Drugs, 2007, 67, 613-646.	10.9	67
706	Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Review of Cardiovascular Therapy, 2007, 5, 45-55.	1.5	76
707	Contemporary Treatment of In-Stent Restenosis and the Incidence of Recurrent In-Stent Restenosis in the Era of Drug-Eluting Stents. Heart Lung and Circulation, 2007, 16, 269-273.	0.4	4
708	Clopidogrel Resistance. Heart Lung and Circulation, 2007, 16, S17-S28.	0.4	24
709	Coronary Heart Disease in Patients With Diabetes. Journal of the American College of Cardiology, 2007, 49, 643-656.	2.8	127
710	Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 2007, 49, 2312-2317.	2.8	607
711	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, e1-e157.	2.8	1,587
712	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction-“Executive Summary. Journal of the American College of Cardiology, 2007, 50, 652-726.	2.8	252
713	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
714	Coronary Heart Disease and Diabetes. , 0, , 37-67.		0
715	AZD6140. Expert Opinion on Investigational Drugs, 2007, 16, 225-229.	4.1	50
716	Diabetes and Acute Coronary Syndromes. , 0, , 69-92.		0
717	RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology, 2007, 3, 52-59.	0.8	3

#	ARTICLE	IF	CITATIONS
718	Treatment with Drug-Eluting Stents. , 2007, , 135-156.		0
719	Pharmacologic Options for Treatment of Ischemic Disease. , 2007, , 77-120.		4
721	Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2007, , 51-81.		0
722	Clinical Tests of Platelet Function. , 2007, , 445-474.		14
723	Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. JAMA - Journal of the American Medical Association, 2007, 297, 1769.	7.4	0
724	Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance. Thrombosis and Haemostasis, 2007, 97, 385-393.	3.4	95
725	Pharmacoeconomic Analysis of Clopidogrel in Secondary Prevention of Coronary Artery Disease. Journal of Managed Care Pharmacy, 2007, 13, 326-336.	2.2	14
726	Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circulation Journal, 2007, 37, 135.	1.9	7
727	Pacientes com angina instável tratados por meio de intervenções coronarianas percutâneas no novo milênio: o que os caracteriza?. Arquivos Brasileiros De Cardiologia, 2007, 88, 26-30.	0.8	1
728	Non ST-Elevation Acute Coronary Syndromes. , 2007, , 221-245.		0
729	ADP Receptor Antagonists. , 2007, , 1127-1144.		13
730	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Thrombosis and Haemostasis, 2007, 98, 852-857.	3.4	67
731	Prevention of sudden cardiac death. , 0, , 449-462.		0
735	Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial. Catheterization and Cardiovascular Interventions, 2007, 70, 44-51.	1.7	10
736	Oral antiplatelet therapy for percutaneous coronary revascularization. Catheterization and Cardiovascular Interventions, 2007, 69, 637-642.	1.7	5
737	Antiplatelet and antithrombotic approaches in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2007, 70, 388-406.	1.7	16
738	Platelet-neutrophil-interactions: Linking hemostasis and inflammation. Blood Reviews, 2007, 21, 99-111.	5.7	544
739	Dual antiplatelet therapy and drug eluting stents: a marriage of convenience. Thrombosis Journal, 2007, 5, 15.	2.1	4

#	ARTICLE	IF	CITATIONS
740	Utilisation review of clopidogrel: are they used under the FDA-approved indications?. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 1031-1037.	1.9	2
741	Myocardial infarction: contemporary management strategies. <i>Journal of Internal Medicine</i> , 2007, 262, 59-77.	6.0	15
742	Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , 2007, 37, 157-164.	3.4	15
743	Optimizing Platelet P2Y12 Inhibition for Patients Undergoing PCI. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 188-203.	4.1	29
744	Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 357-374.	4.1	227
745	Quality Indicators for the Care of Ischemic Heart Disease in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S366-72.	2.6	14
746	Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 884-886.	3.8	23
747	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 255-263.	3.8	73
748	Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1630-1636.	3.8	268
749	The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 54-61.	3.8	200
750	Clinical use of clopidogrel in acute coronary syndrome. <i>International Journal of Clinical Practice</i> , 2007, 61, 473-481.	1.7	7
751	Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. <i>International Journal of Clinical Practice</i> , 2008, 62, 287-299.	1.7	15
752	FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations. <i>Journal of Interventional Cardiology</i> , 2007, 20, 425-446.	1.2	23
753	Non-ST segment elevation acute coronary syndromes: Treatment guidelines for the nurse practitioner. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 19, 277-289.	1.4	2
754	Contemporary Issues in Clopidogrel Therapy: New Evidence Shaping Clinical Practice. <i>Pharmacotherapy</i> , 2007, 27, 553-563.	2.6	10
755	Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long-Term Warfarin Therapy. <i>Pharmacotherapy</i> , 2007, 27, 691-696.	2.6	82
756	Antiplatelet Therapy in Patients with Unstable Angina and Non-ST-Segment-Elevation Myocardial Infarction: Findings from the CRUSADE National Quality Improvement Initiative. <i>Pharmacotherapy</i> , 2007, 27, 1145-1162.	2.6	27
757	Perioperative use of anti-platelet drugs. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2007, 21, 241-256.	4.0	61

#	ARTICLE	IF	CITATIONS
758	Glycoprotein IIb/IIIa inhibitors: questioning indications and treatment algorithms. Cardiovascular Revascularization Medicine, 2007, 8, 281-288.	0.8	1
759	New Antiplatelet Strategies in Atherothrombosis and Their Indications. European Journal of Vascular and Endovascular Surgery, 2007, 34, 10-17.	1.5	28
760	Long-Term Versus Short-Term Clopidogrel Therapy in Patients Undergoing Coronary Stenting (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 349-352.	1.6	29
761	Comparison of Coronary Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 779-784.	1.6	80
762	Analysis of 36 Reported Cases of Late Thrombosis in Drug-Eluting Stents Placed in Coronary Arteries. American Journal of Cardiology, 2007, 99, 1039-1043.	1.6	60
763	Measuring Aspirin Resistance, Clopidogrel Responsiveness, and Postprocedural Markers of Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 99, 1518-1522.	1.6	48
764	Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1637-1642.	1.6	45
765	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. American Journal of Cardiology, 2007, 99, S1-S35.	1.6	20
766	Comparison of Platelet Function and Morphology in Patients Undergoing Percutaneous Coronary Intervention Receiving Bivalirudin Versus Unfractionated Heparin Versus Clopidogrel Pretreatment and Bivalirudin. American Journal of Cardiology, 2007, 100, 417-424.	1.6	58
767	Interventions for preventing high cholesterol levels in patients undergoing Percutaneous Coronary Intervention—Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sa. American Journal of Cardiology, 2007, 100, 1199-1206.	1.6	110
770	Stents coronaires et anti-agrégants plaquettaires. Annales De Cardiologie Et D'Angéiologie, 2007, 56, S53-S62.	0.6	0
774	Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. Clinical Cardiology, 2007, 30, II4-II15.	1.8	3
775	Contemporary use of clopidogrel in patients with coronary artery disease. Current Cardiology Reports, 2007, 9, 257-263.	2.9	5
776	New antiplatelet therapies for acute coronary syndromes. Current Cardiology Reports, 2007, 9, 303-311.	2.9	4
780	Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2007, 21, 375-388.	2.6	14
782	Clopidogrel and risk for acute coronary events. Current Atherosclerosis Reports, 2007, 9, 401-408.	4.8	5
783	Optimal management of platelet function after coronary stenting. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 37-45.	0.9	8
784	Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders. JACC: Cardiovascular Interventions, 2008, 1, 649-653.	2.9	140

#	ARTICLE	IF	CITATIONS
785	Platelet Hyperaggregability: Impaired Responsiveness to Nitric Oxide (â€œPlatelet NO Resistanceâ€) as a Therapeutic Target. Cardiovascular Drugs and Therapy, 2008, 22, 193-203.	2.6	31
787	Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. Journal of Thrombosis and Thrombolysis, 2008, 25, 239-246.	2.1	5
788	P2 receptors in cardiovascular regulation and disease. Purinergic Signalling, 2008, 4, 1-20.	2.2	309
790	Acute Coronary Syndromes. Herz, 2008, 33, 25-37.	1.1	11
796	Clopidogrel and coronary stents: Risks and benefits. Current Atherosclerosis Reports, 2008, 10, 303-308.	4.8	0
797	Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Current Atherosclerosis Reports, 2008, 10, 367-368.	4.8	0
798	Antiplatelet therapy in acute coronary syndromes. Current Cardiology Reports, 2008, 10, 327-333.	2.9	5
799	Antiplatelet therapy in the era of late stent thrombosis. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 12-17.	0.9	4
802	Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. Journal of Gastroenterology, 2008, 43, 679-686.	5.1	27
803	Secondary prevention of ischemic stroke: Challenging patient scenarios. Journal of Hospital Medicine, 2008, 3, S20-S28.	1.4	0
804	2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2008, 71, E1-40.	1.7	26
805	Usage patterns and 2â€year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry. Catheterization and Cardiovascular Interventions, 2008, 72, 433-445.	1.7	39
806	The Role of Aspirin Resistance in the Treatment of Acute Coronary Syndromes. Clinical Cardiology, 2008, 31, 11-17.	1.8	4
807	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. Clinical Cardiology, 2008, 31, I2-I9.	1.8	9
808	Indications for Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Evidence-Based Recommendations for Use. Annals of Pharmacotherapy, 2008, 42, 550-557.	1.9	57
809	Managing antiplatelet therapy in the ACS patient: Straight from the emergency department to you. Journal of Hospital Medicine, 2008, 3, S15-S19.	1.4	0
810	Aggressive management of ischemic stroke: The case for the hospitalist. Journal of Hospital Medicine, 2008, 3, S9-S14.	1.4	1
811	Stroke and atherothrombosis: An Update on the Role of Antiplatelet Therapy. International Journal of Stroke, 2008, 3, 175-181.	5.9	10

#	ARTICLE	IF	CITATIONS
812	Vulnerable Plaque: Scope of the Problem. Journal of Interventional Cardiology, 2008, 21, 443-451.	1.2	5
813	Antiplatelet Therapy: Antiischemic Benefits versus Bleeding Risk. Journal of Interventional Cardiology, 2008, 21, S3-9.	1.2	5
814	Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis. Value in Health, 2008, 11, 853-861.	0.3	9
815	Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. Journal of Thrombosis and Haemostasis, 2008, 6, 2027-2034.	3.8	40
816	THE ROLE OF STENTS IN THE CURRENT ERA: LONG-TERM ANTIPLATELET THERAPY AND LATE-STENT THROMBOSIS. ANZ Journal of Surgery, 2008, 78, 2-5.	0.7	0
817	Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. Journal of Internal Medicine, 2008, 264, 472-480.	6.0	82
818	Initiation and persistence with clopidogrel treatment after acute myocardial infarction â€“ a nationwide study. British Journal of Clinical Pharmacology, 2008, 66, 875-884.	2.4	28
819	Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 439-449.	1.5	42
820	Effects of a Waiting Period After Clopidogrel Treatment Before Performing Coronary Artery Bypass Grafting. Pharmacotherapy, 2008, 28, 151-155.	2.6	7
821	Clopidogrel Desensitization: Case Report and Review of Published Protocols. Pharmacotherapy, 2008, 28, 259-270.	2.6	27
822	Prognostic Value of Early Exercise Testing After Coronary Stent Implantation. American Journal of Cardiology, 2008, 101, 807-811.	1.6	6
823	Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. American Journal of Cardiology, 2008, 101, 960-966.	1.6	116
824	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. American Journal of Cardiology, 2008, 101, 1088-1093.	1.6	194
825	Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing) Tj ETQq1 1 0.784314 rgBT /Overlook compensation for U.S. Patent Application P-17232, â€œMethod for Treating Vascular Diseases With Prasugrel.â€ assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogr. American Journal of Cardiology, 2008, 101, 1364-1366.	1.6	14
826	The Editor's Roundtable: Management and Treatment of Non-ST-Segment Elevation in Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 1580-1598.	1.6	2
827	Relation of Low Response to Clopidogrel Assessed With Point-of-Care Assay to Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Stenting for Stable Angina Pectoris. American Journal of Cardiology, 2008, 101, 1700-1703.	1.6	64
828	Comparison of the Impact of Short (<1 Year) and Long-Term (â‰¥1 Year) Clopidogrel Use Following Percutaneous Coronary Intervention on Mortality. American Journal of Cardiology, 2008, 102, 1159-1162.	1.6	32
829	Impact of a 600-mg Loading Dose of Clopidogrel on 30-Day Outcome in Unselected Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2008, 102, 1318-1322.	1.6	17

#	ARTICLE	IF	CITATIONS
830	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 747 Td (1477-1481.	1.6	23
831	Antiplatelet therapy and coronary stents in perioperative medicine â€“ the two sides of the coin. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2008, 22, 81-94.	4.0	16
832	ACC/AHA Nonâ€“ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. Progress in Cardiovascular Nursing, 2008, 23, 53-56.	0.4	0
833	Contemporary Approach to the Diagnosis and Management of Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases, 2008, 50, 311-351.	3.1	16
834	Benefits and limitations of current antiplatelet therapies. American Journal of Health-System Pharmacy, 2008, 65, S5-S10.	1.0	6
835	The Perioperative Management of Antithrombotic Therapy. Chest, 2008, 133, 299S-339S.	0.8	763
836	Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. Journal of Vascular Surgery, 2008, 47, 774-781.e1.	1.1	142
838	Safety of Clopidogrel and Aspirin for??Stroke Prevention. Drug Safety, 2008, 31, 449-458.	3.2	4
839	Platelet Activation, and Antiplatelet Targets and Agents. Drugs, 2008, 68, 1647-1664.	10.9	16
841	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 51, 172-209.	2.8	590
843	The Role of Aspirin in Cardiovascular Prevention. Journal of the American College of Cardiology, 2008, 51, 1829-1843.	2.8	248
844	Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens. Journal of the American College of Cardiology, 2008, 51, 1066-1072.	2.8	65
845	Clopidogrel Resistance. Journal of the American College of Cardiology, 2008, 51, 1935-1937.	2.8	15
846	Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions. Journal of the American College of Cardiology, 2008, 51, 2220-2227.	2.8	110
847	Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 52, 743-749.	2.8	302
848	Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. Journal of the American College of Cardiology, 2008, 52, 734-739.	2.8	189
849	Optimizing Clopidogrel Therapy Before Stent Implantation: Should Clinical Setting Be Taken Into Account?. Journal of the American College of Cardiology, 2008, 52, 1349.	2.8	1
850	Bleeding Events with Antithrombotic Therapy in Patients with Unstable Angina or non-ST-segment Elevation Myocardial Infarction; Insights from a Large Clinical Practice Registry (GRACE). Heart Lung and Circulation, 2008, 17, 5-8.	0.4	6

#	ARTICLE	IF	CITATIONS
851	Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes. Archives of Cardiovascular Diseases, 2008, 101, 743-751.	1.6	8
852	Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention. Mayo Clinic Proceedings, 2008, 83, 995-1001.	3.0	7
853	Intensity of Antiplatelet Therapy in Patients with Acute Coronary Syndromes and Percutaneous Coronary Intervention: the Promise of Prasugrel?. Cardiology Clinics, 2008, 26, 629-637.	2.2	6
854	Chronic Antithrombotic Therapy in Post-Myocardial Infarction Patients. Cardiology Clinics, 2008, 26, 277-288.	2.2	5
855	Diagnosis and Treatment of Non-ST-Segment Elevation Myocardial Infarction. , 2008, , 60-72.		0
856	Prolonged combination anti-platelet therapy following per-cutaneous coronary intervention (PCI) is impractical in the elderly. International Journal of Cardiology, 2008, 125, 268-269.	1.7	0
857	Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. International Journal of Cardiology, 2008, 129, 379-387.	1.7	70
858	Antiplatelet Therapy in Acute Coronary Syndromes: The Emergency Physician's Perspective. Journal of Emergency Medicine, 2008, 35, 5-13.	0.7	11
859	Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. American Heart Journal, 2008, 155, 133-139.	2.7	11
860	Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. American Heart Journal, 2008, 155, 382-387.	2.7	17
861	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. American Heart Journal, 2008, 155, 687-693.	2.7	175
862	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal, 2008, 155, 910-917.	2.7	38
863	The economic consequences of non-evidence-based clopidogrel use. American Heart Journal, 2008, 155, 904-909.	2.7	25
864	High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. American Heart Journal, 2008, 155, 954-958.	2.7	33
865	Transient ST-elevation myocardial infarction: Clinical course with intense medical therapy and early invasive approach, and comparison with persistent ST-elevation myocardial infarction. American Heart Journal, 2008, 155, 848-854.	2.7	31
866	Antiplatelet drug nonresponsiveness. American Heart Journal, 2008, 155, 591-599.	2.7	52
867	Correlates of late and very late thrombosis of drug eluting stents. American Heart Journal, 2008, 156, 141-147.	2.7	31
868	Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. American Heart Journal, 2008, 156, 513-519.	2.7	36

#	ARTICLE	IF	CITATIONS
869	Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction. American Heart Journal, 2008, 156, 1S-2S.	2.7	2
870	Current antiplatelet therapies: Benefits and limitations. American Heart Journal, 2008, 156, 3S-9S.	2.7	48
871	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. American Heart Journal, 2008, 156, 855-863.e2.	2.7	243
872	Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. American Heart Journal, 2008, 156, 1080-1088.e1.	2.7	140
873	ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. American Journal of Emergency Medicine, 2008, 26, 212-220.	1.6	9
874	Antiplatelet Therapy for Postdischarge Medical Management of Acute Coronary Syndrome. American Journal of Medicine, 2008, 121, 171-178.	1.5	3
875	Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention. Thrombosis Research, 2008, 122, 285-288.	1.7	2
876	Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thrombosis Research, 2008, 122, 336-345.	1.7	48
877	Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thrombosis Research, 2008, 122, 776-781.	1.7	153
878	Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation. Thrombosis Research, 2008, 123, 79-84.	1.7	5
879	Clopidogrel Treatment Before Coronary Artery Bypass Graft Surgery Increases Postoperative Morbidity and Blood Product Requirements. Journal of Cardiothoracic and Vascular Anesthesia, 2008, 22, 60-66.	1.3	46
880	Monitoring oral antiplatelet therapy: is it justified?. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 485-496.	2.1	13
881	A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Atherosclerosis, 2008, 196, 689-695.	0.8	75
883	Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet, The, 2008, 371, 1353-1363.	13.7	420
884	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Circulation, 2008, 117, 261-295.	1.6	715
885	Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance. Journal of the American College of Cardiology, 2008, 51, 1404-1411.	2.8	531
886	Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. Critical Care Clinics, 2008, 24, 201-229.	2.6	10
887	Antiplatelet Agents and Arterial Thrombosis. Cardiology Clinics, 2008, 26, 189-201.	2.2	9

#	ARTICLE	IF	CITATIONS
889	Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2008, 8, 91-112.	2.2	21
890	Pharmacologic Inhibition of Platelet Function. American Journal of Cardiovascular Drugs, 2008, 8, 283-295.	2.2	2
891	Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 261-267.	0.5	10
893	Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opinion on Pharmacotherapy, 2008, 9, 377-386.	1.8	7
894	Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Current Medical Research and Opinion, 2008, 24, 2089-2101.	1.9	20
895	Guideline on antiplatelet and anticoagulation management in cardiac surgery. European Journal of Cardio-thoracic Surgery, 2008, 34, 73-92.	1.4	280
896	The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. Platelets, 2008, 19, 479-488.	2.3	106
897	Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience. American Journal of Neuroradiology, 2008, 29, 1389-1394.	2.4	126
898	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 766-780.	3.3	80
899	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal, 2008, 30, 900-907.	2.2	115
900	Safety of drug-eluting stents. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 316-328.	3.3	18
901	2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies. Annals of Pharmacotherapy, 2008, 42, 989-1001.	1.9	14
902	Dual antiplatelet therapy with clopidogrel and aspirin. American Journal of Health-System Pharmacy, 2008, 65, 1134-1143.	1.0	9
903	Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus. Circulation, 2008, 118, 2277-2285.	1.6	121
904	Which patients receiving warfarin can be treated safely with a drug-eluting stent?. Heart, 2008, 94, 275-277.	2.9	1
905	Primary Percutaneous Coronary Intervention. Fundamental and Clinical Cardiology, 2008, , 91-117.	0.0	0
906	Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. European Heart Journal, 2008, 29, 1729-1738.	2.2	32
907	Updating the Chest Pain Algorithm. Critical Pathways in Cardiology, 2008, 7, 211-222.	0.5	6

#	ARTICLE	IF	CITATIONS
908	Antiplatelet therapy in acute coronary syndromes. Country Review Ukraine, 2008, 10, A4-A12.	0.8	2
909	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. European Heart Journal, 2008, 29, 455-461.	2.2	55
910	Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. European Heart Journal, 2008, 29, 1495-1503.	2.2	132
911	Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?. European Heart Journal, 2008, 29, 1475-1477.	2.2	2
912	Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment. European Heart Journal, 2008, 29, 1699-1700.	2.2	3
913	Antiplatelet Therapy for Vascular Interventions. Perspectives in Vascular Surgery and Endovascular Therapy, 2008, 20, 28-35.	0.6	8
914	Facilitated PCI: Rationale, Current Evidence, Open Questions, and Future Directions. Journal of Cardiovascular Pharmacology, 2008, 51, 3-10.	1.9	15
915	Thrombosis after stent implantation: how much of a problem is there?. Future Cardiology, 2008, 4, 261-267.	1.2	9
916	Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function. Cardiology, 2008, 111, 247-253.	1.4	10
917	Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes and Vascular Disease Research, 2008, 5, 138-144.	2.0	109
918	Cost-Effectiveness of Clopidogrel: Seeing through the Smoke. Medical Decision Making, 2008, 28, 803-809.	2.4	3
919	Therapeutic Controversies: Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?. Annals of Pharmacotherapy, 2008, 42, 790-805.	1.9	42
920	P2Y ₁₂ Antagonism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s33-8.	2.4	91
921	Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. American Journal of Health-System Pharmacy, 2008, 65, S22-S28.	1.0	5
922	Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. Acute Cardiac Care, 2008, 10, 43-48.	0.2	9
923	Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal, 2008, 30, 192-201.	2.2	290
924	Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart, 2008, 94, 743-747.	2.9	55
925	The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opinion on Drug Safety, 2008, 7, 809-819.	2.4	25

#	ARTICLE	IF	CITATIONS
926	Acute Thrombosis of a Mesenteric Artery Drug-Eluting Stent Following Clopidogrel Cessation. Vascular and Endovascular Surgery, 2008, 41, 564-567.	0.7	0
927	Cardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel. New England Journal of Medicine, 2008, 359, 1802-1810.	27.0	74
930	Periprocedural Drug Therapy in Carotid Artery Stenting: The Need for More Evidence. Vascular, 2008, 16, 303-309.	0.9	15
931	Heart disease and erythropoietin. Future Cardiology, 2008, 4, 57-64.	1.2	4
932	Impact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Circulation, 2008, 118, 1828-1836.	1.6	70
933	Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 425-433.	0.5	14
934	Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up—a large series of all-comers. Annals of Medicine, 2008, 40, 296-302.	3.8	2
935	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. Circulation: Cardiovascular Interventions, 2008, 1, 217-225.	3.9	15
936	Studies of Drug-Eluting Stents. Circulation, 2008, 117, 2047-2050.	1.6	15
937	Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example. Journal of Cardiovascular Pharmacology and Therapeutics, 2008, 13, 107-119.	2.0	4
938	Early intervention in acute coronary syndrome: is bivalirudin monotherapy an effective antithrombotic strategy?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 308-309.	3.3	0
939	Restrictive access to clopidogrel and mortality following coronary stent implantation. Cmaj, 2008, 178, 413-420.	2.0	22
940	Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction. New England Journal of Medicine, 2008, 359, 1330-1342.	27.0	482
941	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. New England Journal of Medicine, 2008, 359, 688-696.	27.0	323
942	Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2008, 299, 532.	7.4	330
943	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. Expert Opinion on Pharmacotherapy, 2008, 9, 2893-2900.	1.8	43
944	Atherothrombotic Disease and the Role of Antiplatelet Therapy in Women. Journal of Women's Health, 2008, 17, 35-46.	3.3	6
945	Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. European Heart Journal Supplements, 2008, 10, I25-I29.	0.1	5

#	ARTICLE	IF	CITATIONS
946	Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. European Heart Journal Supplements, 2008, 10, I8-I13.	0.1	0
947	When and how to discontinue antiplatelet therapy. Country Review Ukraine, 2008, 10, A35-A41.	0.8	16
948	Clopidogrel Use in Coronary Heart Disease and Percutaneous Coronary Intervention. Journal of Investigative Medicine, 2008, 56, 689-700.	1.6	3
949	Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel. Circulation Journal, 2008, 72, 1165-1169.	1.6	82
950	The Primary and Secondary Prevention of Coronary Artery Disease. Chest, 2008, 133, 776S-814S.	0.8	234
951	Antithrombotic Therapy for Non-“ST-Segment Elevation Acute Coronary Syndromes. Chest, 2008, 133, 670S-707S.	0.8	145
952	The direct thrombin inhibitor hirudin. Thrombosis and Haemostasis, 2008, 99, 819-829.	3.4	207
953	Antiplatelet Therapy in ST-Elevation Myocardial Infarction. , 0, , 164-177.		0
954	Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits. , 0, , 231-250.		0
955	Management of Antiplatelet Therapy for Non-Cardiac Surgery. , 0, , 251-264.		0
956	Antiplatelet Therapy and Coronary Stents. , 0, , 265-279.		0
957	Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesthesia and Analgesia, 2008, 107, 552-569.	2.2	62
958	Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness. Blood Coagulation and Fibrinolysis, 2008, 19, 421-428.	1.0	9
959	The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?. Current Cardiology Reviews, 2008, 4, 84-91.	1.5	1
960	Antiplatelet therapy in percutaneous coronary intervention. Country Review Ukraine, 2008, 10, A13-A20.	0.8	8
961	Unmet needs in antiplatelet therapy. Country Review Ukraine, 2008, 10, D3-D11.	0.8	7
962	Commentary on "Antiplatelet Therapy for Vascular Interventions". Perspectives in Vascular Surgery and Endovascular Therapy, 2008, 20, 36-37.	0.6	0
963	Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome. Current Vascular Pharmacology, 2008, 6, 313-328.	1.7	30

#	ARTICLE	IF	CITATIONS
964	Shoulder Pain. Journal of Clinical Rheumatology, 2008, 14, 253-254.	0.9	53
965	New Classes of Anticoagulation and Antiplatelet Agents. Journal of Computer Assisted Tomography, 2008, 32, 475-479.	0.9	0
966	CURRENT CONCEPTS IN THE MANAGEMENT OF INTRACRANIAL ATHEROSCLEROTIC DISEASE. Neurosurgery, 2008, 62, S210-S218.	1.1	2
967	The Effects of Clopidogrel on Elderly Traumatic Brain Injured Patients. Journal of Trauma, 2008, 65, 1303-1308.	2.3	99
968	Prasugrel. Cardiology in Review, 2008, 16, 314-318.	1.4	16
969	Laryngeal Involvement in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2008, 14, 254.	0.9	1
970	Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiology, 2008, 4, 33-55.	1.2	17
971	Effects of Coronary Prestenting Platelet Inhibition on Coronary Poststenting Inflammation. Journal of Cardiovascular Pharmacology, 2008, 51, 286-292.	1.9	6
972	Anaesthesia in patients with drug-eluting stents. Current Opinion in Anaesthesiology, 2008, 21, 55-59.	2.0	11
973	Effects of Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention After Pretreatment With Clopidogrel. Critical Pathways in Cardiology, 2008, 7, 5-10.	0.5	11
974	Acute Ischemic Coronary Artery Disease and Ischemic Stroke: Similarities and Differences. American Journal of Therapeutics, 2008, 15, 137-149.	0.9	22
975	Acute Arthritis Associated With Loading Dose of Clopidogrel. Journal of Clinical Rheumatology, 2008, 14, 254-255.	0.9	16
977	Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chinese Medical Journal, 2008, 121, 522-527.	2.3	21
978	ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS. Rational Pharmacotherapy in Cardiology, 2008, 4, 91-100.	0.8	1
979	Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. Vascular Health and Risk Management, 2008, Volume 4, 493-505.	2.3	12
980	Percutaneous coronary intervention for acute myocardial infarction. , 2008, , 243-254.		0
981	Acute Coronary Syndromes and Acute Myocardial Infarction. , 2008, , 589-646.		0
982	Clopidogrel and the prevention of cardiovascular events. British Journal of Cardiac Nursing, 2008, 3, 15-21.	0.1	0

#	ARTICLE	IF	CITATIONS
984	S�ndromes coronarianas agudas: tratamento e estratifica��o de risco. Revista Brasileira De Terapia Intensiva, 2008, 20, 197-204.	0.3	4
985	Analysis of platelet ��2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thrombosis and Haemostasis, 2008, 100, 829-838.	3.4	31
986	Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. Vascular Health and Risk Management, 2009, 5, 275.	2.3	4
987	Perioperative Clopidogrel is Seven Days Enough?. American Surgeon, 2009, 75, 909-913.	0.8	7
988	Treatment disparities and effect on late mortality in patients with diabetes presenting with acute myocardial infarction: observations from the ACACIA registry. Medical Journal of Australia, 2009, 191, 539-543.	1.7	18
989	Prasugrel for the treatment of patients with acute coronary syndrome. Vascular Health and Risk Management, 2009, 5, 321.	2.3	1
991	Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. Clinical Medicine Therapeutics, 2009, 1, CMT.S1170.	0.1	1
992	The influence of clinical characteristics, laboratory and inflammatory markers on ��high on-treatment platelet reactivity��� as measured with different platelet function tests. Thrombosis and Haemostasis, 2009, 102, 719-727.	3.4	88
993	Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. Vascular Health and Risk Management, 2009, 5, 677.	2.3	0
994	Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular Health and Risk Management, 2009, 5, 873.	2.3	37
995	Efficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation. Korean Circulation Journal, 2009, 39, 190.	1.9	9
996	Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thrombosis and Haemostasis, 2009, 102, 772-778.	3.4	43
997	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis, 2009, 101, 333-339.	3.4	114
998	Platelet P2Y12 receptor inhibition by thienopyridines: status and future. Expert Opinion on Investigational Drugs, 2009, 18, 1317-1332.	4.1	20
999	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Current Medical Research and Opinion, 2009, 25, 2631-2641.	1.9	22
1000	Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay. Circulation, 2009, 119, 237-242.	1.6	502
1001	Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Current Medical Research and Opinion, 2009, 25, 2327-2334.	1.9	11
1002	Clopidogrel Inhibits CYP2C19��Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms. Journal of Clinical Pharmacology, 2009, 49, 574-581.	2.0	39

#	ARTICLE	IF	CITATIONS
1003	Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome. Journal of Medical Economics, 2009, 12, 325-330.	2.1	2
1004	Percutaneous Coronary Intervention in Perspective. Circulation: Cardiovascular Interventions, 2009, 2, 574-579.	3.9	3
1005	Variability in aggregometry response before and after initiation of clopidogrel therapy. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 673-679.	1.2	5
1006	Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine, 2009, 361, 2330-2341.	27.0	560
1007	Personalized medicine and antiplatelet therapy: ready for prime time?. European Heart Journal, 2009, 30, 1943-1963.	2.2	37
1008	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine, 2009, 361, 2318-2329.	27.0	533
1009	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal, 2009, 30, 2226-2232.	2.2	95
1010	Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future Cardiology, 2009, 5, 237-246.	1.2	1
1011	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. American Journal of Gastroenterology, 2009, 104, 2903-2917.	0.4	35
1012	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. Expert Review of Cardiovascular Therapy, 2009, 7, 1525-1532.	1.5	1
1013	Visualization of Activated Platelets by Targeted Magnetic Resonance Imaging Utilizing Conformation-Specific Antibodies against Glycoprotein IIb/IIIa. Journal of Vascular Research, 2009, 46, 6-14.	1.4	66
1014	The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective. Clinical Risk, 2009, 15, 106-108.	0.1	0
1015	Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. Circulation, 2009, 120, 2322-2329.	1.6	210
1016	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) Tj ETQq1 1 0.784314 rgt / Overlo	1.6	1,073
1017	Common Variation in the Platelet Receptor <i>P2RY12</i> Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions. Circulation: Cardiovascular Genetics, 2009, 2, 515-521.	5.1	52
1018	Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation. Circulation, 2009, 119, 987-995.	1.6	345
1019	Update on dual antiplatelet therapy for percutaneous coronary intervention. Heart, 2009, 95, 861-865.	2.9	3
1020	New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. European Heart Journal, 2009, 30, 1695-1702.	2.2	18

#	ARTICLE	IF	CITATIONS
1021	Platelet interactions as therapeutic targets for prevention of atherothrombosis. <i>Future Cardiology</i> , 2009, 5, 285-296.	1.2	3
1022	Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery. <i>Archives of Internal Medicine</i> , 2009, 169, 788.	3.8	61
1023	Antiplatelet Agents in the Perioperative Period. <i>Archives of Surgery</i> , 2009, 144, 69.	2.2	80
1024	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2009, 121, 59-72.	2.0	5
1025	Clinical Reinfarction according to Infarct Location and Reperfusion Modality in Patients with ST Elevation Myocardial Infarction. <i>Cardiology</i> , 2009, 113, 72-80.	1.4	5
1026	Use of stress testing prior to percutaneous coronary intervention in patients with stable coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1061-1066.	1.5	1
1029	Update on Antiplatelet Therapy in Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 13-17.	2.2	1
1030	Update on oral antiplatelet therapy: principles, problems and promises. <i>Future Cardiology</i> , 2009, 5, 247-258.	1.2	29
1032	Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. <i>Heart</i> , 2009, 95, 1483-1488.	2.9	65
1033	Effects of clopidogrel on aspirin specific pathways of platelet inhibition. <i>Platelets</i> , 2009, 20, 386-390.	2.3	34
1035	Prasugrel: A New Thienopyridine Inhibitor. <i>Journal of Pharmacy Practice</i> , 2009, 22, 158-165.	1.0	2
1036	Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 171-176.	1.7	7
1037	Clopidogrel versus prasugrel in rabbits. <i>Thrombosis and Haemostasis</i> , 2009, 101, 108-115.	3.4	28
1038	P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. <i>European Heart Journal</i> , 2009, 30, 1964-1977.	2.2	353
1040	Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography® Platelet Mapping™. <i>British Journal of Anaesthesia</i> , 2009, 102, 492-498.	3.4	100
1041	Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. <i>Journal of Medical Economics</i> , 2009, 12, 141-153.	2.1	2
1042	The Role of Aspirin in Cardiovascular Disease Prevention in Women. <i>American Journal of Lifestyle Medicine</i> , 2009, 3, 123-134.	1.9	3
1043	Avoiding and Managing Bleeding Complications in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Angiology</i> , 2009, 60, 148-158.	1.8	2

#	ARTICLE	IF	CITATIONS
1044	Dual Antiplatelet Drug Resistance Is a Risk Factor for Cardiovascular Events after Percutaneous Coronary Intervention. <i>Clinical Chemistry</i> , 2009, 55, 1171-1176.	3.2	21
1045	Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. <i>Heart</i> , 2009, 95, 1579-1586.	2.9	31
1046	Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. <i>Heart</i> , 2009, 95, 1214-1219.	2.9	17
1047	Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 6-13.	3.9	105
1048	Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 330-338.	3.9	49
1049	Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. , 2009, 123, 178-186.		75
1050	Antiplatelet agents used for early intervention in acute coronary syndrome: Myocardial salvage versus bleeding complications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 807-810.e7.	0.8	13
1051	Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 1377-1384.	0.8	59
1052	Clopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 608-612.	2.6	24
1053	Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease. <i>Pharmacotherapy</i> , 2009, 29, 812-821.	2.6	15
1054	Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor. <i>Pharmacotherapy</i> , 2009, 29, 1089-1102.	2.6	78
1055	Current Controversies in the Pharmacogenomics of Clopidogrel. <i>Progress in Cardiovascular Nursing</i> , 2009, 24, 105-109.	0.4	1
1056	Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 103, 5-10.	1.6	271
1057	Introduction. <i>American Journal of Cardiology</i> , 2009, 103, 1A-3A.	1.6	1
1058	Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 103, 11A-19A.	1.6	24
1059	Combination Antiplatelet Therapy for Secondary Stroke Prevention: Enhanced Efficacy or Double Trouble?. <i>American Journal of Cardiology</i> , 2009, 103, 1107-1112.	1.6	45
1060	Effect of Blood Hematocrit and Erythrocyte Deformability on Adenosine 5'-Diphosphate Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2009, 104, 764-768.	1.6	24
1061	Oral Antiplatelet Therapy in Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction, ST-Segment Elevation Myocardial Infarction, and Percutaneous Coronary Intervention: Is it Time for a Guideline Update?. <i>American Journal of Cardiology</i> , 2009, 104, 4C-8C.	1.6	0

#	ARTICLE	IF	CITATIONS
1062	Antiplatelet Therapy in Older Adults with Non-“ST-Segment Elevation Acute Coronary Syndrome: Considering Risks and Benefits. American Journal of Cardiology, 2009, 104, 16C-21C.	1.6	17
1063	Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2009, 10, 36-44.	0.8	29
1064	Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome. Cardiovascular Revascularization Medicine, 2009, 10, 94-102.	0.8	5
1065	The Prevalence of Intolerance for Low-Dose Acetylsalicylic acid in the Secondary Prevention of Atherothrombosis. European Journal of Vascular and Endovascular Surgery, 2009, 37, 597-603.	1.5	22
1066	Prognostic Value of Kidney Function in Patients With ST-Elevation and Non-“ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. American Journal of Kidney Diseases, 2009, 54, 830-839.	1.9	25
1067	Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheterization and Cardiovascular Interventions, 2009, 73, 771-779.	1.7	8
1068	Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. Catheterization and Cardiovascular Interventions, 2009, 73, 866-870.	1.7	6
1069	Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?. Catheterization and Cardiovascular Interventions, 2009, 74, S7-S11.	1.7	6
1070	Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheterization and Cardiovascular Interventions, 2009, 74, 579-597.	1.7	26
1071	Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting. Catheterization and Cardiovascular Interventions, 2009, 74, 1010-1016.	1.7	7
1072	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) Tj ETQq0 0 0 fBT /Overföck 10 Tf	1.7	56
1074	Section Original article. Zeitschrift Fur Gesundheitswissenschaften, 2009, 17, 425-432.	1.6	4
1075	Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clinical Research in Cardiology, 2009, 98, 691-699.	3.3	7
1076	Oral Antiplatelet Therapy for Acute and Chronic Management of NSTEMI ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy, 2009, 23, 489-499.	2.6	6
1077	Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes. Journal of Thrombosis and Thrombolysis, 2009, 27, 36-43.	2.1	5
1078	Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. Journal of Thrombosis and Thrombolysis, 2009, 27, 300-306.	2.1	5
1079	Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. Journal of Thrombosis and Thrombolysis, 2009, 28, 151-155.	2.1	14
1080	Neuentwicklungen in der Thrombozytenaggregationshemmung - sinnvolle Alternativen für ASS/Clopidogrel-Non-Responder?. Clinical Research in Cardiology Supplements, 2009, 4, 184-191.	2.0	0

#	ARTICLE	IF	CITATIONS
1081	Antithrombotische Therapie bei Patienten mit Indikation zur oralen Antikoagulation und koronarer Stentimplantation. Clinical Research in Cardiology Supplements, 2009, 4, 150-153.	2.0	0
1082	Aspirin resistance: An update. Current Atherosclerosis Reports, 2009, 11, 105-110.	4.8	6
1083	Thienopyridine therapy and risk for cardiovascular events in secondary prevention. Current Atherosclerosis Reports, 2009, 11, 364-370.	4.8	4
1084	Contemporary issues on clopidogrel therapy. Internal and Emergency Medicine, 2009, 4, 201-211.	2.0	1
1085	Contemporary issues on clopidogrel therapy: a critical appraisal. Internal and Emergency Medicine, 2009, 4, 195-198.	2.0	2
1086	Prasugrel: Clinical development and therapeutic application. Advances in Therapy, 2009, 26, 999-1011.	2.9	10
1087	New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. Advances in Therapy, 2009, 26, 1058-1071.	2.9	8
1089	Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. Thrombosis Journal, 2009, 7, 4.	2.1	45
1090	Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor- κ B and activator protein 1 activation in pigs. European Journal of Clinical Investigation, 2009, 39, 174-182.	3.4	10
1091	The Impact of Diabetes Mellitus on Two-Year Mortality Following Contemporary Percutaneous Coronary Intervention: Implications for Revascularization Practice. Journal of Interventional Cardiology, 2009, 22, 420-426.	1.2	2
1092	Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal of Interventional Cardiology, 2009, 22, 378-384.	1.2	4
1093	Crushed Clopidogrel Administered via Nasogastric Tube Has Faster and Greater Absorption than Oral Whole Tablets. Journal of Interventional Cardiology, 2009, 22, 385-389.	1.2	39
1094	Development and Validation of a Risk Scoring Model to Predict Net Adverse Cardiovascular Outcomes after Primary Percutaneous Coronary Intervention in Patients Pretreated with 600 mg Clopidogrel: Rationale and Design of the RISK-PCI Study. Journal of Interventional Cardiology, 2009, 22, 320-328.	1.2	13
1095	Identification of patients at risk of ischemic events for long-term secondary prevention. Journal of the American Academy of Nurse Practitioners, 2009, 21, 677-689.	1.4	5
1096	Management of patients with unstable angina/ non-ST-elevation myocardial infarction: a critical review of the 2007 ACC/AHA guidelines. International Journal of Clinical Practice, 2009, 63, 642-655.	1.7	7
1097	New antiplatelet drugs: beyond aspirin and clopidogrel. International Journal of Clinical Practice, 2009, 63, 776-789.	1.7	18
1098	Managing The Risk Of Perioperative Thromboembolism. ANZ Journal of Surgery, 2009, 79, 544-547.	0.7	3
1099	Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. Value in Health, 2009, 12, 872-879.	0.3	29

#	ARTICLE	IF	CITATIONS
1100	Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 1-9.	1.9	11
1101	Identifying the “Optimal” Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1279-1285.	2.9	34
1102	In search of a better platelet ADP-receptor blocker. <i>Netherlands Heart Journal</i> , 2009, 17, 188-189.	0.8	1
1103	Acute Coronary Syndrome in the Elderly. <i>Clinical Cardiology</i> , 2009, 32, 608-613.	1.8	18
1104	Acute Coronary Syndromes: Selective vs Early Invasive Strategies. <i>Clinical Cardiology</i> , 2009, 32, 621-626.	1.8	1
1105	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. <i>Thrombosis Research</i> , 2009, 123, 597-603.	1.7	72
1106	Effect of increased aspirin dose after Stenting in association with CLOpidogrel: The FIASCO randomized study. <i>Thrombosis Research</i> , 2009, 124, 33-36.	1.7	2
1107	Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. <i>Thrombosis Research</i> , 2009, 124, 46-51.	1.7	38
1108	Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. <i>Thrombosis Research</i> , 2009, 124, 6-13.	1.7	48
1109	Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2009, 124, 678-682.	1.7	3
1110	Evidence guided antiplatelet treatment: Time to move from bench to bedside. <i>Thrombosis Research</i> , 2009, 124, 649-650.	1.7	1
1111	Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-TACOIN survey. <i>International Journal of Cardiology</i> , 2009, 133, 32-40.	1.7	7
1112	Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. <i>International Journal of Cardiology</i> , 2009, 133, 341-345.	1.7	78
1113	Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: When does the risk outweigh the benefit?. <i>International Journal of Cardiology</i> , 2009, 133, 8-17.	1.7	7
1114	Evidence-based prescribing and adherence to antiplatelet therapy—How much difference do they make to patients with atherothrombosis?. <i>International Journal of Cardiology</i> , 2009, 134, 150-159.	1.7	11
1115	Glycoprotein IIb-IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. <i>Journal of Emergency Medicine</i> , 2009, 36, 162-170.	0.7	1
1116	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , 2009, 157, 369-374.	2.7	69
1117	Facts and controversies of aspirin and clopidogrel therapy. <i>American Heart Journal</i> , 2009, 157, 412-422.	2.7	20

#	ARTICLE	IF	CITATIONS
1118	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. American Heart Journal, 2009, 157, 620-624.e2.	2.7	91
1119	Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. American Heart Journal, 2009, 157, 642-650.e1.	2.7	28
1120	Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: Study design and rationale of a Korean multicenter prospective randomized trial. American Heart Journal, 2009, 157, 811-817.e1.	2.7	34
1121	Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. American Heart Journal, 2009, 157, 889-893.	2.7	78
1122	The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. American Heart Journal, 2009, 157, 899-907.	2.7	35
1123	Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina"Comparison of the effects of drug-eluting versus bare-metal stents. American Heart Journal, 2009, 158, 271-276.	2.7	41
1124	Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)"Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy. American Heart Journal, 2009, 158, e21-e26.	2.7	32
1125	Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naïve patients with stable or unstable angina: A comparison of two strategies. American Heart Journal, 2009, 158, 585-591.	2.7	13
1126	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non"ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. American Heart Journal, 2009, 158, 917-924.	2.7	18
1127	Does timing matter? Upstream or downstream administration of antiplatelet therapy. American Journal of Emergency Medicine, 2009, 27, 348-361.	1.6	1
1128	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. Archives of Cardiovascular Diseases, 2009, 102, 829-845.	1.6	21
1129	Advanced Age, Antithrombotic Strategy, and Bleeding in Non"ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 1021-1030.	2.8	125
1130	Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity. Journal of the American College of Cardiology, 2009, 53, 1101-1109.	2.8	431
1131	Outcomes Following Pre-Operative Clopidogrel Administration in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2009, 53, 1965-1972.	2.8	140
1132	Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology, 2009, 54, 95-109.	2.8	140
1133	Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 969-984.	2.8	53
1134	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology, 2009, 54, 1041-1057.	2.8	92
1135	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology, 2009, 54, 2261-2276.	2.8	44

#	ARTICLE	IF	CITATIONS
1136	Diabetes and acute coronary syndromes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 305-316.	4.7	16
1137	Differentiating ischemic stroke subtypes: Risk factors and secondary prevention. Journal of the Neurological Sciences, 2009, 279, 1-8.	0.6	45
1138	Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. Journal of Vascular Surgery, 2009, 50, 861-869.	1.1	10
1139	Current evidence and clinical implications of aspirin resistance. Journal of Vascular Surgery, 2009, 50, 1500-1510.	1.1	44
1140	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	27.0	6,019
1141	Post-Treatment Platelet Reactivity Predicts Long-Term Adverse Events Better Than the Response to Clopidogrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2009, 62, 126-135.	0.6	4
1142	In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. The Global Registry of Acute Coronary Events. Revista Espanola De Cardiologia (English Ed), 2009, 62, 501-509.	0.6	1
1143	Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. Journal of Translational Medicine, 2009, 7, 42.	4.4	10
1144	Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings, 2009, 84, 917-938.	3.0	310
1145	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology, 2009, 6, 273-282.	13.7	90
1146	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2009, 7, 361-369.	1.5	12
1147	Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. Current Medical Research and Opinion, 2009, 25, 2317-2325.	1.9	9
1148	An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events. Journal of the American Board of Family Medicine, 2009, 22, 51-56.	1.5	18
1149	Management of Acute Coronary Syndromes in Mexico. American Journal of Cardiovascular Drugs, 2009, 9, 143-148.	2.2	4
1150	Oral Antiplatelet Therapy in the Secondary Prevention of Atherothrombotic Events. American Journal of Cardiovascular Drugs, 2009, 9, 197-209.	2.2	8
1151	Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome. Pharmacoeconomics, 2009, 27, 585-595.	3.3	12
1152	Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2009, 9, 213-229.	2.2	34
1153	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 423-433.	1.4	4

#	ARTICLE	IF	CITATIONS
1154	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Canadian Journal of Cardiology, 2009, 25, 683-689.	1.7	78
1155	Ischaemia versus bleeding: the art of clinical decision-making. Lancet, The, 2009, 373, 695-696.	13.7	14
1156	Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, The, 2009, 373, 723-731.	13.7	981
1157	The ischaemia/bleeding balance in PCI. Lancet, The, 2009, 373, 872-873.	13.7	1
1158	Secondary cardiovascular risk prevention—we can do better. Lancet, The, 2009, 373, 873-875.	13.7	8
1159	Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet, The, 2009, 374, 1967-1974.	13.7	507
1162	2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused) Tj ETQq0 0 0 fgbT /Overhock 10 Tf	2.8	1378
1163	Prasugrel: A Novel Platelet ADP P2Y ₁₂ Receptor Antagonist. Cardiovascular Therapeutics, 2009, 27, 194-198.	2.5	6
1164	Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics, 2009, 27, 199-215.	2.5	10
1165	Cangrelor: a review on its mechanism of action and clinical development. Expert Review of Cardiovascular Therapy, 2009, 7, 1195-1201.	1.5	81
1166	Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Current Medical Research and Opinion, 2009, 25, 1477-1490.	1.9	9
1167	Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy. Gastroenterology Clinics of North America, 2009, 38, 289-303.	2.2	22
1169	Coronary bypass surgery in patients treated with clopidogrel. Is it safe?. Current Opinion in Cardiology, 2009, 24, 539-543.	1.8	3
1170	Antiplatelet Intervention in Acute Coronary Syndrome. American Journal of Therapeutics, 2009, 16, e29-e40.	0.9	20
1171	New P2Y ₁₂ antagonists. Current Opinion in Hematology, 2009, 16, 371-377.	2.5	28
1172	Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?. Journal of Cardiovascular Medicine, 2009, 10, S17-S26.	1.5	5
1173	FACTORS ASSOCIATED WITH ASPIRIN RESISTANCE IN PATIENTS PREMEDITATED WITH ASPIRIN AND CLOPIDOGREL FOR ENDOVASCULAR NEUROSURGERY. Neurosurgery, 2009, 64, 890-896.	1.1	27
1174	Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients. Journal of Pharmacy Practice and Research, 2009, 39, 265-268.	0.8	0

#	ARTICLE	IF	CITATIONS
1175	Strategies to minimize bleeding complications of percutaneous coronary intervention. Current Opinion in Cardiology, 2009, 24, 273-278.	1.8	9
1176	Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600â€‰mg) versus low loading dose (300â€‰mg). Coronary Artery Disease, 2009, 20, 150-154.	0.7	17
1177	Clopidogrel in the Management of Acute Coronary Syndromes. Critical Pathways in Cardiology, 2009, 8, 49-54.	0.5	1
1178	Post-Hospitalization Care of Patients with Acute Coronary Syndrome. , 2009, , 173-208.		0
1179	Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interventional Cardiology, 2009, 1, 51-62.	0.0	12
1180	Clopidogrel Resistance in Japanese Patients Scheduled forPercutaneous Coronary Intervention. Circulation Journal, 2009, 73, 336-342.	1.6	54
1181	Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan. Circulation Journal, 2009, 73, 1498-1503.	1.6	85
1182	Unstable Angina and Non-ST-Elevation Myocardial Infarction. , 2009, , 37-78.		0
1183	New anticoagulants for atrial fibrillation. Journal of Cardiovascular Medicine, 2009, 10, 446-453.	1.5	4
1184	Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current Opinion in Cardiology, 2010, 25, 305-311.	1.8	6
1185	Impact of age on outcomes of percutaneous coronary intervention in acute coronary syndromes patients. Interventional Cardiology, 2010, 2, 319-325.	0.0	5
1186	Cilostazol in the Management of Atherosclerosis. Current Vascular Pharmacology, 2010, 8, 363-372.	1.7	23
1187	Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring. European Journal of Anaesthesiology, 2010, 27, 138-145.	1.7	6
1188	Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease. Current Vascular Pharmacology, 2010, 8, 93-101.	1.7	6
1189	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Yearbook of Critical Care Medicine, 2010, 2010, 75-77.	0.2	0
1190	Dosing Strategies for Antiplatelet Therapy in Percutaneous Coronary Intervention. Hospital Practice (1995), 2010, 38, 50-58.	1.0	2
1191	Q: What is a heart catheterization?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2010, 23, 55.	0.3	0
1192	Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics, 2010, 17, e24-e40.	0.9	8

#	ARTICLE	IF	CITATIONS
1193	Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 91-97.	1.9	48
1194	Preventing Serious Sequelae After an Acute Coronary Syndrome: The Consequences of Thrombosis Versus Bleeding With Antiplatelet Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 55, 585-594.	1.9	7
1195	Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 18-25.	1.5	81
1196	Early Antiplatelet Therapy in Coronary Artery Bypass Grafting a Calculated Benefit. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2010, 5, 317-325.	0.9	3
1197	Very Late Bare Metal Stent Thrombosis Presenting with Acute Myocardial Infarction: 14 Years after Coronary Stenting. <i>Internal Medicine</i> , 2010, 49, 1549-1552.	0.7	2
1198	Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. <i>Thrombosis and Haemostasis</i> , 2010, 103, 71-82.	3.4	116
1199	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. , 2010, , CD002130.		17
1200	Basic Principles of Platelet Biology and Clinical Implications. <i>Circulation Journal</i> , 2010, 74, 597-607.	1.6	239
1201	Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. <i>Interventional Cardiology</i> , 2010, 2, 705-718.	0.0	2
1202	Aspirin for Acute Coronary Syndromes: Have We Learned the Correct Dose Yet?. <i>Current Cardiology Reports</i> , 2010, 12, 344-347.	2.9	3
1203	Periprocedural Myocardial Infarction: Review and Classification. <i>Clinical Cardiology</i> , 2010, 33, 476-483.	1.8	32
1204	Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y ₁₂ receptor antagonist. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 151-158.	1.5	76
1206	The State of Periprocedural Antiplatelet Therapy After Recent Trials. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 571-583.	2.9	45
1207	Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. <i>Clinical Research in Cardiology</i> , 2010, 99, 743-752.	3.3	46
1209	Revaluation of clopidogrel: let the data speak for themselves. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2010, 30, 299-306.	1.0	1
1210	Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 84-99.	0.9	2
1212	Acute Coronary Syndrome in the Patient with Diabetes: Is the Management Different?. <i>Current Cardiology Reports</i> , 2010, 12, 321-329.	2.9	10
1213	Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 61-70.	2.6	8

#	ARTICLE	IF	CITATIONS
1214	Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 207-216.	2.6	2
1215	Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 316-321.	2.1	12
1216	Secondary prevention strategies for coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 8-24.	2.1	24
1217	Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 200-209.	2.1	5
1218	Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 486-495.	2.1	32
1219	Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 240-249.	2.1	1
1220	The epidemiology and management of elderly patients with myocardial infarction or heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 407-413.	3.9	9
1221	Prevención secundaria en enfermedad cardiovascular. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2010, 17, 5-41.	0.0	0
1222	Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. <i>Journal of Cardiology</i> , 2010, 55, 34-40.	1.9	3
1223	Management of ST-elevation myocardial infarction. <i>Medicine</i> , 2010, 38, 431-437.	0.4	0
1224	Understanding Clopidogrel's Interaction with CYP2C19 Inhibitors. <i>Journal for Nurse Practitioners</i> , 2010, 6, 715-720.	0.8	1
1225	Current strategies in antiplatelet therapy – Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. , 2010, 127, 95-107.		18
1226	Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 211-217.	4.9	3
1227	Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 6.	1.7	8
1228	Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2010, 105, 174-178.	1.6	11
1229	Relation of Endothelial Function to Residual Platelet Reactivity After Clopidogrel in Patients With Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 333-338.	1.6	35
1230	Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2010, 105, 323-332.	1.6	24
1231	Disparities in Management Patterns and Outcomes of Patients With Non-ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. <i>American Journal of Cardiology</i> , 2010, 105, 1083-1089.	1.6	27

#	ARTICLE	IF	CITATIONS
1232	Antiplatelet Agents in Acute Coronary Syndromes. <i>Current Problems in Cardiology</i> , 2010, 35, 123-170.	2.4	16
1233	Early and late outcomes of clopidogrel and Coumadin combination for patients on oral anticoagulants undergoing coronary stenting. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 159-162.	0.8	6
1237	Oral antiplatelet therapy in PCI patients. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, S7-14.	1.7	1
1238	Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 513-524.	1.7	5
1239	European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. <i>Resuscitation</i> , 2010, 81, 1353-1363.	3.0	58
1240	European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. <i>Resuscitation</i> , 2010, 81, 1219-1276.	3.0	1,215
1241	Part 9: Acute coronary syndromes. <i>Resuscitation</i> , 2010, 81, e175-e212.	3.0	43
1242	Pulmonary hemorrhage in a middle-aged woman as a complication of treatments for acute myocardial infarction. <i>Journal of Cardiology Cases</i> , 2010, 1, e37-e41.	0.5	3
1243	High Residual Platelet Reactivity After Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 35-40.	2.9	65
1244	Perioperative Management of Patients With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 131-142.	2.9	74
1245	Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 318-323.	2.9	54
1246	Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 731-741.	2.9	78
1247	Update: Use of Platelet Glycoprotein IIb/IIIa Inhibitors in Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. <i>Annals of Emergency Medicine</i> , 2010, 56, e1-e2.	0.6	12
1248	Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 613-615.	3.8	73
1249	Prasugrel vs. clopidogrel for cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1678-1684.	3.8	92
1250	Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2326-2328.	3.8	8
1251	Antiplatelet therapies for the treatment of cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 154-169.	46.4	329
1252	BRIEF COMMUNICATION: Rapid and sequential desensitization to both aspirin and clopidogrel. <i>Internal Medicine Journal</i> , 2010, 40, 596-599.	0.8	6

#	ARTICLE	IF	CITATIONS
1253	Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics and Personalized Medicine, 2010, 3, 33.	0.7	17
1254	Antiplatelet Therapy. , 2010, , 452-469.		0
1255	Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction. , 2010, , 110-144.		0
1256	Diagnosis and Management of Coronary Artery Disease. , 2010, , 286-294.		0
1257	Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests. Annals of Laboratory Medicine, 2010, 30, 460-468.	2.5	15
1258	Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Drug Design, Development and Therapy, 2010, 4, 203.	4.3	7
1259	Differences in Efficacy and Safety of Pharmaceutical Treatments between Men and Women: An Umbrella Review. PLoS ONE, 2010, 5, e11895.	2.5	19
1260	Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2010, 17, 1122-1131.	2.0	15
1261	Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. Thrombosis and Haemostasis, 2010, 103, 774-779.	3.4	9
1262	High-dose clopidogrel, prasugrel or ticagrelor: trying to unravel a skein into a ball. Drugs and Therapy Studies, 2010, 1, 13.	0.6	0
1263	Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. Patient Related Outcome Measures, 2010, 2, 7.	1.2	6
1264	THE MODERN ASPECTS OF CLOPIDOGREL USE. Rational Pharmacotherapy in Cardiology, 2010, 6, 185-191.	0.8	0
1265	Ausência de interação clopidogrel-estatina em pacientes submetidos a implante de "stent" coronário. Arquivos Brasileiros De Cardiologia, 2010, 95, 321-327.	0.8	4
1266	Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vascular Health and Risk Management, 2010, 6, 855.	2.3	11
1267	Emerging antiplatelet agents, differential pharmacology, and clinical utility. Journal of Blood Medicine, 2010, 1, 79.	1.7	6
1268	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. Journal of Blood Medicine, 2010, 1, 61.	1.7	2
1269	The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thrombosis and Haemostasis, 2010, 103, 920-925.	3.4	80
1270	Impact of race and gender on antithrombotic therapy. Thrombosis and Haemostasis, 2010, 104, 471-484.	3.4	68

#	ARTICLE	IF	CITATIONS
1271	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug, Healthcare and Patient Safety, 2010, 2, 233.	2.5	9
1272	Medical Management of Unstable Angina and Non-“ST Segment Elevation Myocardial Infarction. , 2010, , 183-195.		0
1273	Recurrent Ischemia after Reperfusion Therapy for Acute Myocardial Infarction. , 2010, , 203-211.		0
1274	Clopidogrel and the Reduced-Function CYP2C19 Genetic Variant. JAMA - Journal of the American Medical Association, 2010, 304, 1839.	7.4	32
1275	Combination Antithrombotic Therapies. Circulation, 2010, 121, 569-583.	1.6	112
1276	Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Review of Cardiovascular Therapy, 2010, 8, 1215-1229.	1.5	2
1277	Part 9: Acute Coronary Syndromes. Circulation, 2010, 122, S422-65.	1.6	93
1279	Primary Angioplasty Versus Fibrinolysis in Acute Myocardial Infarction. Circulation, 2010, 121, 1484-1491.	1.6	83
1280	An Algorithm for Use of Prasugrel (Effient) in Patients Undergoing Cardiac Catheterization and Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2010, 9, 192-198.	0.5	10
1281	Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Drug-eluting Stents. Critical Pathways in Cardiology, 2010, 9, 203-206.	0.5	8
1282	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal, 2010, 31, 3046-3053.	2.2	138
1283	Prasugrel. Critical Pathways in Cardiology, 2010, 9, 199-202.	0.5	3
1284	Vascular surgery: operating on patients on clopidogrel or warfarin. Clinical Risk, 2010, 16, 135-140.	0.1	0
1285	Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years. Circulation: Cardiovascular Interventions, 2010, 3, 140-147.	3.9	69
1286	Dual Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke: A Ghost from the Past or a New Frontier?. Stroke Research and Treatment, 2010, 2010, 1-8.	0.8	6
1287	Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y ₁₂ -Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y ₁₂ Inhibition to Prevent Subsequent Neointima. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2385-2391.	2.4	50
1288	Pharmacogenetics guided anticoagulation. Clinical Chemistry and Laboratory Medicine, 2010, 48, S119-27.	2.3	0
1289	Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA - Journal of the American Medical Association, 2010, 303, 754.	7.4	744

#	ARTICLE	IF	CITATIONS
1290	Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 393-407.	3.3	20
1291	Development and performance of the zotarolimus-eluting Endeavor® coronary stent. Expert Review of Medical Devices, 2010, 7, 449-459.	2.8	8
1292	Platelet function tests for the monitoring of P2Y12 inhibitors. Expert Opinion on Medical Diagnostics, 2010, 4, 251-265.	1.6	2
1293	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk. American Journal of Health-System Pharmacy, 2010, 67, S7-S17.	1.0	4
1294	Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation. Circulation: Cardiovascular Interventions, 2010, 3, 230-235.	3.9	41
1295	Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Review of Clinical Pharmacology, 2010, 3, 553-561.	3.1	14
1296	Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opinion on Pharmacotherapy, 2010, 11, 2391-2403.	1.8	13
1297	Engineering and Characterization of a Chimeric Anti-platelet Glycoprotein Ib/IIb Monoclonal Antibody and Preparation of Its Fab Fragment. Hybridoma, 2010, 29, 125-132.	0.4	7
1298	Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 450-459.	3.9	18
1299	Role of Ticagrelor in Clopidogrel Nonresponders: Resistance Is Futile?. Circulation, 2010, 121, 1169-1171.	1.6	21
1300	Protein kinase C delta: a master regulator of apoptosis in neointimal thickening?. Cardiovascular Research, 2010, 85, 407-408.	3.8	2
1301	Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diabetes and Vascular Disease Research, 2010, 7, 274-288.	2.0	8
1302	Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention. Critical Care Nurse, 2010, 30, 45-54.	1.0	5
1305	How Does One Diagnose and Manage Acute Myocardial Ischemia in the Intensive Care Unit?. , 2010, , 303-310.		0
1306	Very Late (10-Year-Old) Bare Metal Stent Thrombosis. Cardiology, 2010, 115, 127-129.	1.4	2
1307	Prevalence of Embolic Signals in Acute Coronary Syndromes. Stroke, 2010, 41, 261-266.	2.0	6
1308	Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology, 2010, 27, 999-1015.	1.7	447
1311	Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine, 2010, 4, 421-434.	1.4	4

#	ARTICLE	IF	CITATIONS
1312	Clinical Impact of Enhanced Inhibition of P2Y ₁₂ -Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Hospital Practice (1995), 2010, 38, 38-43.	1.0	3
1313	Three-vessel coronary disease in diabetics: personalized versus evidence-based revascularization strategy. Future Cardiology, 2010, 6, 797-809.	1.2	2
1314	Is it naive to load only clopidogrel-naïve patients prior to PCI?. European Heart Journal, 2010, 31, 1298-1300.	2.2	0
1315	Recent advances in cardiology. Future Cardiology, 2010, 6, 11-17.	1.2	5
1316	National Estimates of Emergency Department Visits for Hemorrhage-Related Adverse Events From Clopidogrel Plus Aspirin and From Warfarin. Archives of Internal Medicine, 2010, 170, 1926-33.	3.8	92
1317	Efficacy and Safety of Ticagrelor: A Reversible P2Y ₁₂ Receptor Antagonist. Annals of Pharmacotherapy, 2010, 44, 524-537.	1.9	41
1318	Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. Current Medical Research and Opinion, 2010, 26, 641-651.	1.9	8
1319	Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Review of Cardiovascular Therapy, 2010, 8, 449-470.	1.5	24
1320	Emerging Oral Antiplatelet Therapies for Acute Coronary Syndromes. Hospital Practice (1995), 2010, 38, 29-37.	1.0	2
1321	Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiology, 2010, 6, 445-453.	1.2	51
1322	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 930-942.	27.0	681
1323	Prasugrel. Italian Journal of Medicine, 2010, 4, 43-50.	0.3	1
1324	Prasugrel® en pratique dans l'urgence, pour quels patients ?. JEUR/Journal Européen Des Urgences, 2010, 23, S48-S51.	0.0	0
1327	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine, 2010, 363, 1704-1714.	27.0	497
1328	Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y ₁₂ Receptor Antagonist. Journal of Clinical Pharmacology, 2010, 50, 27-35.	2.0	128
1329	Slow Response to Clopidogrel Predicts Low Response. Journal of the American College of Cardiology, 2010, 55, 815-822.	2.8	28
1330	In-Laboratory High-Dose Clopidogrel Loading. Journal of the American College of Cardiology, 2010, 56, 558-560.	2.8	1
1331	Level of Adenosine Diphosphate Receptor P2Y ₁₂ Blockade During Percutaneous Coronary Intervention Predicts the Extent of Endothelial Injury, Assessed by Circulating Endothelial Cell Measurement. Journal of the American College of Cardiology, 2010, 56, 1024-1031.	2.8	27

#	ARTICLE	IF	CITATIONS
1332	Clopidogrel and Endothelial Injury After Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2010, 56, 1032-1033.	2.8	4
1333	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 56, 1447-1455.	2.8	118
1334	Antithrombotic Therapy in the Elderly. Journal of the American College of Cardiology, 2010, 56, 1683-1692.	2.8	121
1335	Coronary Stents. Journal of the American College of Cardiology, 2010, 56, S1-S42.	2.8	447
1336	Observational study of adherence to European clinical practice guidelines for the management of acute coronary syndrome in revascularized versus non-revascularized patients â€” the CONNECT Study. Archives of Cardiovascular Diseases, 2010, 103, 437-446.	1.6	12
1337	Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion. Journal of Vascular Surgery, 2010, 52, 243-247.	1.1	52
1338	Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine, 2010, 363, 1909-1917.	27.0	1,019
1339	Platelet Adenosine Diphosphate P2Y12 Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions. Revista Espanola De Cardiologia (English Ed), 2010, 63, 60-76.	0.6	36
1340	Resistance to aspirin: Prevalence, mechanisms of action and association with thromboembolic events. A narrative review. Farmacia Hospitalaria (English Edition), 2010, 34, 32-43.	0.0	2
1341	Urological Surgery and Antiplatelet Drugs After Cardiac and Cerebrovascular Accidents. Journal of Urology, 2010, 183, 2128-2136.	0.4	69
1342	Antiplatelet therapy and vascular disease: an update. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 249-275.	2.1	16
1343	Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. Circulation, 2010, 122, 2131-2141.	1.6	474
1344	Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation. International Journal of Cardiology, 2010, 140, 66-72.	1.7	22
1345	Oral triple antiplatelet therapy after percutaneous coronary intervention: Subject with ongoing arguments?. International Journal of Cardiology, 2010, 144, 112-113.	1.7	0
1346	A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thrombosis Research, 2010, 125, 309-314.	1.7	44
1347	Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thrombosis Research, 2010, 125, e167-e170.	1.7	20
1348	Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. Thrombosis Research, 2010, 125, 110-111.	1.7	47
1349	Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thrombosis Research, 2010, 125, e190-e196.	1.7	28

#	ARTICLE	IF	CITATIONS
1350	The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: A comparison with the flowcytometric VASP assay and optical aggregometry. <i>Thrombosis Research</i> , 2010, 126, 44-49.	1.7	23
1351	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). <i>Thrombosis Research</i> , 2010, 126, e397-e399.	1.7	3
1352	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. <i>Thrombosis Research</i> , 2010, 126, e400-e402.	1.7	24
1353	Clopidogrel use and clinical events after drug-eluting stent implantation: Findings from the HealthCore Integrated Research Database. <i>American Heart Journal</i> , 2010, 159, 462-470.e1.	2.7	21
1354	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). <i>American Heart Journal</i> , 2010, 160, 65-72.	2.7	72
1355	Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary Intervention. <i>American Heart Journal</i> , 2010, 160, 202-207.	2.7	23
1356	Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. <i>American Heart Journal</i> , 2010, 160, 543-551.	2.7	188
1357	Rapid adoption of drug-eluting stents: Clinical practices and outcomes from the early drug-eluting stent era. <i>American Heart Journal</i> , 2010, 160, 767-774.e1.	2.7	15
1358	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, 804-811.	2.7	66
1359	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. <i>American Heart Journal</i> , 2010, 160, 1025-1041.e1.	2.7	158
1360	Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. <i>American Heart Journal</i> , 2010, 160, 1056-1064.e2.	2.7	19
1361	Individualised Assessment of Response to Clopidogrel in Patients Presenting with Acute Coronary Syndromes: A Role for Short Thrombelastography?. <i>Cardiovascular Therapeutics</i> , 2010, 28, 139-146.	2.5	22
1362	Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 17-26.	3.9	95
1363	Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. <i>Atherosclerosis</i> , 2010, 212, 367-376.	0.8	57
1365	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. <i>Lancet, The</i> , 2010, 375, 283-293.	13.7	624
1366	Ticagrelor in ACS: redefining a new standard of care?. <i>Lancet, The</i> , 2010, 375, 263-265.	13.7	16
1367	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	13.7	725
1369	Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. <i>Annual Review of Medicine</i> , 2010, 61, 215-231.	12.2	6

#	ARTICLE	IF	CITATIONS
1370	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1
1371	Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Platelets, 2010, 21, 563-570.	2.3	18
1372	A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. Annals of Medicine, 2010, 42, 115-126.	3.8	46
1373	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 121-130.	2.2	3
1374	High Maintenance Dosage of Clopidogrel is Associated with a Reduced Risk of Stent Thrombosis in Clopidogrel-Resistant Patients. American Journal of Cardiovascular Drugs, 2010, 10, 29-35.	2.2	18
1375	Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. American Journal of Cardiovascular Drugs, 2010, 10, 115-124.	2.2	4
1376	Platelet P2Y12 Receptor Inhibition. American Journal of Cardiovascular Drugs, 2010, 10, 217-226.	2.2	24
1377	Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?. Heart, 2010, 96, 736-740.	2.9	60
1378	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert Opinion on Investigational Drugs, 2011, 20, 119-133.	4.1	14
1379	Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics Journal, 2011, 11, 199-206.	2.0	152
1380	Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Current Medical Research and Opinion, 2011, 27, 633-641.	1.9	33
1381	AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation, 2011, 124, 2458-2473.	1.6	1,369
1382	Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel. Platelets, 2011, 22, 75-76.	2.3	13
1383	Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets, 2011, 22, 98-102.	2.3	23
1384	Clinical Update on Nursing Home Medicine: 2011. Journal of the American Medical Directors Association, 2011, 12, 615-626.e6.	2.5	7
1386	Clopidogrel therapy in ophthalmic procedures: a survey of subspecialty ophthalmologists and review of current guidelines. Canadian Journal of Ophthalmology, 2011, 46, 528-530.	0.7	2
1387	Le rapport b�n�fic�risque des nouveaux agents antiagr�gants plaquettaires. Archives Des Maladies Du C�ur Et Des Vaisseaux - Pratique, 2011, 2011, 27-31.	0.0	4
1388	L'uso della doppia terapia aspirina + clopidogrel: rischi in ambito odontoiatrico. Dental Cadmos, 2011, 79, 63-76.	0.1	0

#	ARTICLE	IF	CITATIONS
1389	Antiplatelet Therapy in Coronary Heart Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 71-85.	2.2	10
1390	High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 771-778.	2.8	77
1391	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 57, 672-684.	2.8	457
1392	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1190-1199.	2.8	61
1393	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non- α -ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). <i>Journal of the American College of Cardiology</i> , 2011, 57, 1920-1959.	2.8	332
1394	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- α -ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, e215-e367.	2.8	420
1395	High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2011, 58, 467-473.	2.8	196
1396	Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1592-1599.	2.8	107
1397	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2550-2583.	2.8	114
1398	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	2.8	2,027
1399	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2432-2446.	2.8	700
1400	Sirolimus-Eluting Coronary Stents in Octogenarians. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 982-991.	2.9	10
1401	Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1119-1128.	2.9	37
1402	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation? Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1129-1132.	2.9	15
1403	Adopting orphaned drugs: developing multidrug regimens using generic drugs. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2011, 8, 117-121.	0.5	2
1404	Non-adherence to aspirin in patients undergoing coronary stenting: Negative impact of comorbid conditions and implications for clinical management. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 306-312.	1.6	14
1405	Optical multichannel (optimum) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. <i>Platelets</i> , 2011, 22, 485-494.	2.3	47
1406	Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1285-1295.	1.8	42

#	ARTICLE	IF	CITATIONS
1407	Antiplatelet agents and anticoagulants for hypertension. The Cochrane Library, 2011, , CD003186.	2.8	29
1408	Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics, 2011, 66, 9-15.	1.5	81
1410	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. The Cochrane Library, 2011, , CD005158.	2.8	20
1411	Genetic variability in response to clopidogrel therapy and its clinical implications. Thrombosis and Haemostasis, 2011, 105, S55-S59.	3.4	22
1412	Unveiling the Mysteries of Clopidogrel Metabolism and Efficacy. Clinical Pharmacology and Therapeutics, 2011, 90, 774-776.	4.7	5
1413	Managing adverse effects and drug-drug interactions of antiplatelet agents. Nature Reviews Cardiology, 2011, 8, 592-600.	13.7	19
1414	Clopidogrel Response Variability and Its Correlation with Early Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention. Pharmacology, 2011, 87, 321-330.	2.2	3
1415	Ticagrelor: from concept to clinical evaluation. Biomarkers in Medicine, 2011, 5, 53-62.	1.4	8
1416	The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology, 2011, 8, 547-559.	13.7	84
1417	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
1418	The Influence of Low Platelet Count on Whole Blood Aggregometry Assessed by Multiplate. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E211-E217.	1.7	91
1419	Cost-effectiveness of oral antiplatelet agents-current and future perspectives. Nature Reviews Cardiology, 2011, 8, 580-591.	13.7	8
1420	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	2.3	48
1421	Review: Antiplatelet Therapy in Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 24-42.	2.0	9
1424	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	27.0	918
1425	Nursing clinical practice guidelines to improve care for people undergoing percutaneous coronary interventions. Australian Critical Care, 2011, 24, 18-38.	1.3	19
1426	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal, 2011, 161, 650-656.e1.	2.7	23
1427	Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. American Heart Journal, 2011, 161, 404-410.	2.7	22

#	ARTICLE	IF	CITATIONS
1428	Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. American Heart Journal, 2011, 161, 450-461.	2.7	30
1429	Early clopidogrel use in non-“ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. American Heart Journal, 2011, 161, 832-841.	2.7	16
1430	Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial. American Heart Journal, 2011, 162, 870-874.	2.7	15
1431	Treatment with Adenosine Diphosphate Receptor Inhibitors-“Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal, 2011, 162, 844-851.	2.7	51
1432	Upstream treatment of acute coronary syndrome in the ED. American Journal of Emergency Medicine, 2011, 29, 446-456.	1.6	0
1433	ED to catheterization laboratory: a roundtable integrating trials with practice. American Journal of Emergency Medicine, 2011, 29, 1203-1216.	1.6	0
1434	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. Canadian Journal of Cardiology, 2011, 27, 74-90.	1.7	273
1435	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2011, 27, S1-S59.	1.7	106
1436	Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. Canadian Journal of Cardiology, 2011, 27, 222-231.	1.7	2
1437	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology, 2011, 27, 208-221.	1.7	50
1438	Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. European Journal of Internal Medicine, 2011, 22, 471-477.	2.2	15
1439	Clopidogrel pretreatment in PCI: Absolute requirement or obsolete myth?. International Journal of Cardiology, 2011, 146, 305-310.	1.7	3
1440	Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention. International Journal of Cardiology, 2011, 153, 262-266.	1.7	3
1441	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2999-3054.	2.2	2,995
1442	The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thrombosis Research, 2011, 127, 23-28.	1.7	54
1443	Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thrombosis Research, 2011, 128, e130-e136.	1.7	29
1444	Evaluation and Management of Shock States. Journal of Pharmacy Practice, 2011, 24, 44-60.	1.0	28
1445	Safety and Efficacy of Clopidogrel before Surgery. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S2334.	0.4	2

#	ARTICLE	IF	CITATIONS
1447	Both peak and late aggregation are capable of identifying patients at risk for atherothrombotic events. <i>Thrombosis and Haemostasis</i> , 2011, 105, 197-199.	3.4	8
1448	Clopidogrel withdrawal: Is there a "rebound" phenomenon?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 211-220.	3.4	55
1449	Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. <i>Vascular Health and Risk Management</i> , 2011, 7, 445.	2.3	15
1450	Does Anticoagulant or Antiplatelet Therapy Need to Be Discontinued for Transrectal Ultrasound-Guided Prostate Biopsies? A Systematic Literature Review. <i>Current Urology</i> , 2011, 5, 121-124.	0.6	2
1451	Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. <i>Thrombosis and Haemostasis</i> , 2011, 106, 230-239.	3.4	41
1452	Emerging Therapies for Acute Coronary Syndromes. <i>Frontiers in Pharmacology</i> , 2011, 2, 61.	3.5	2
1453	Critical appraisal of ticagrelor in the management of acute coronary syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 473.	2.0	19
1454	Antiplatelet combinations for prevention of atherothrombotic events. <i>Vascular Health and Risk Management</i> , 2011, 7, 23.	2.3	6
1455	Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e20759.	2.5	4
1456	The genetic basis of platelet responsiveness to clopidogrel. <i>Thrombosis and Haemostasis</i> , 2011, 106, 203-210.	3.4	13
1457	Adjunctive pharmacologic therapy in percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2011, 22, 100-112.	0.7	0
1458	Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. <i>Critical Care Medicine</i> , 2011, 39, 2346-2353.	0.9	18
1459	Direct Vasoactive Properties of Thienopyridine-Derived Nitrosothiols. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 550-558.	1.9	9
1460	Light Transmittance Aggregometry Induced by Different Concentrations of Adenosine Diphosphate to Monitor Clopidogrel Therapy: A Methodological Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 94-98.	2.0	16
1461	The Perils of Combination Antithrombotic Therapy and Potential Resolutions. <i>Stroke</i> , 2011, 42, 278-281.	2.0	7
1462	Delayed Thrombosis or Stenosis Following Enterprise-Assisted Stent-Coiling: Is It Safe? Midterm Results of the Interstate Collaboration of Enterprise Stent Coiling. <i>Neurosurgery</i> , 2011, 69, 908-914.	1.1	117
1463	Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. <i>Coronary Artery Disease</i> , 2011, 22, 199-205.	0.7	35
1464	Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of Cardiovascular Nursing</i> , 2011, 26, 239-249.	1.1	2

#	ARTICLE	IF	CITATIONS
1465	Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y ₁₂ Inhibition and Thrombin Receptor Antagonists. <i>Current Drug Targets</i> , 2011, 12, 1805-1812.	2.1	4
1466	Antiplatelet therapy in elderly patients. <i>Aging Health</i> , 2011, 7, 311-320.	0.3	2
1467	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>Yearbook of Critical Care Medicine</i> , 2011, 2011, 57-60.	0.2	0
1468	The platelet P2Y ₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. <i>Blood</i> , 2011, 117, 2102-2112.	1.4	162
1469	Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 431-442.	2.0	46
1470	Acute Subdural Hematoma in Patients With Medication Associated With Risk of Hemorrhage. <i>Neurologia Medico-Chirurgica</i> , 2011, 51, 825-828.	2.2	11
1471	Cessation of Clopidogrel Before Major Abdominal Procedures. <i>Archives of Surgery</i> , 2011, 146, 334.	2.2	37
1472	Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 697-706.	2.4	43
1473	In the presence of strong P2Y ₁₂ receptor blockade, aspirin provides little additional inhibition of platelet aggregation. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 552-561.	3.8	157
1474	Contribution of the P2Y ₁₂ receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 810-819.	3.8	32
1475	Aspirin has little additional antiplatelet effect in healthy volunteers receiving prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2050-2056.	3.8	32
1476	Combined influence of proton pump inhibitors, calcium channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1892-1901.	3.8	39
1477	Influence of Antiplatelet Medications on Bleeding Events in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 454-459.	0.9	10
1478	Anti-inflammatory therapeutics for the treatment of atherosclerosis. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 365-376.	46.4	246
1479	Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. <i>Journal of Cardiology</i> , 2011, 57, 172-180.	1.9	17
1480	The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. <i>Journal of Cardiology</i> , 2011, 57, 283-289.	1.9	10
1481	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. , 2011, 129, 267-289.		52
1482	Chapter III: Management of Cardiovascular Risk Factors and Medical Therapy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2011, 42, S33-S42.	1.5	27

#	ARTICLE	IF	CITATIONS
1483	Direct formation of thienopyridine-derived nitrosothiols â€” Just add nitrite!. European Journal of Pharmacology, 2011, 670, 534-540.	3.5	9
1484	Safety and Efficacy of Clopidogrel Reloading in Patients on Chronic Clopidogrel Therapy Who Present With an Acute Coronary Syndrome and Undergo Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 1779-1782.	1.6	8
1485	Effect of Clopidogrel Pretreatment on Ischemic Complications of Percutaneous Coronary Intervention Among Bivalirudin-Treated Patients (from the EVENT Registry). American Journal of Cardiology, 2011, 107, 1751-1756.	1.6	6
1486	Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients â‰¥75 Years of Age (from the FAST-MI Registry). American Journal of Cardiology, 2011, 108, 755-759.	1.6	5
1487	Predictors of Low Clopidogrel Adherence Following Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 108, 822-827.	1.6	30
1488	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 760-765.	1.6	40
1489	Comparison of Platelet Reactivity and Clopidogrel Response in Patients â‰¥75 Years Versus <75 Years Undergoing Percutaneous Coronary Intervention for Nonâ€”ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 1411-1416.	1.6	18
1490	Prolonged clopidogrel application reduces tissue factor expression after percutaneous coronary intervention in the porcine model. Cardiovascular Revascularization Medicine, 2011, 12, 47-55.	0.8	4
1491	Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovascular Revascularization Medicine, 2011, 12, 94-98.	0.8	7
1492	Clopidogrel in acute coronary syndromes: Where are we now?. Thrombosis and Haemostasis, 2011, 105, 766-773.	3.4	6
1493	Modifying Clopidogrel Maintenance Doses According to Vasodilatorâ€”Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance. Clinical Cardiology, 2011, 34, 332-338.	1.8	47
1495	Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics, 2011, 12, 1269-1280.	1.3	46
1496	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	1.7	97
1497	Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. BMJ: British Medical Journal, 2011, 343, d4264-d4264.	2.3	9
1498	Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. Netherlands Heart Journal, 2011, 19, 279-284.	0.8	22
1499	Effect of gender difference on platelet reactivity. Netherlands Heart Journal, 2011, 19, 451-457.	0.8	67
1500	Personalized vascular medicine: Individualizing drug therapy. Vascular Medicine, 2011, 16, 391-404.	1.5	16
1501	Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600Âµg clopidogrel. Journal of Thrombosis and Thrombolysis, 2011, 32, 64-71.	2.1	33

#	ARTICLE	IF	CITATIONS
1502	Genetic determinants of platelet response to clopidogrel. Journal of Thrombosis and Thrombolysis, 2011, 32, 459-466.	2.1	69
1503	Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2281-2287.	2.4	16
1504	Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. Clinical Research in Cardiology, 2011, 100, 29-36.	3.3	25
1507	Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary) Tj ETQq1 1 0.784314 rgBT /Over 2.9 107 Interventions, 2011, 4, 14-23.	2.9	107
1508	How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 46-56.	0.9	1
1509	Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports, 2011, 5, 86-95.	2.0	0
1510	Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 *2/*2 genotype. Cardiovascular Intervention and Therapeutics, 2011, 26, 79-82.	2.3	2
1511	Antiplatelet Agents for Stroke Prevention. Neurotherapeutics, 2011, 8, 475-487.	4.4	23
1512	Personalized Antiplatelet Therapy: Review of the Latest Clinical Evidence. Current Cardiology Reports, 2011, 13, 296-302.	2.9	15
1513	Current Status of Antiplatelet Agents to Prevent Stroke. Current Neurology and Neuroscience Reports, 2011, 11, 6-14.	4.2	9
1514	The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thrombosis Journal, 2011, 9, 4.	2.1	28
1515	Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 206-215.	6.6	7
1516	Triple therapy in hospitalized patients: Facts and controversies. Journal of Hospital Medicine, 2011, 6, 537-545.	1.4	1
1517	Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: Rationale and safety. Catheterization and Cardiovascular Interventions, 2011, 77, 193-200.	1.7	2
1518	Emerging Genomic Applications in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2011, 4, 473-482.	2.9	35
1519	The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2011, 12, 1075-1086.	1.8	0
1520	Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence. Clinical Investigation, 2011, 1, 1315-1328.	0.0	0
1521	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine, 2011, 5, 9-30.	1.4	3

#	ARTICLE	IF	CITATIONS
1522	Secondary Stroke Prevention in Women. <i>Women's Health</i> , 2011, 7, 391-397.	1.5	2
1526	Unravelling the benefit against the risk of long-term dual antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2011, 26, S22-S30.	1.8	4
1527	High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. <i>Heart</i> , 2011, 97, 983-990.	2.9	71
1528	Results of a Survey Assessing Provider Beliefs of Adherence Barriers to Antiplatelet Medications. <i>Critical Pathways in Cardiology</i> , 2011, 10, 134-141.	0.5	7
1529	Preoperative Evaluation of the Adult Outpatient. <i>Refresher Courses in Anesthesiology</i> , 2011, 39, 57-64.	0.1	0
1530	Dual antiplatelet therapy duration. <i>Current Opinion in Cardiology</i> , 2011, 26, S4-S14.	1.8	5
1531	Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2011, 26, S1-S3.	1.8	0
1532	Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 603-609.	2.2	5
1533	Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures. <i>British Journal of Anaesthesia</i> , 2011, 107, 911-915.	3.4	36
1534	Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 371-380.	1.7	10
1535	Review: Antiplatelet Drugs: What Comes Next?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 9-26.	1.7	19
1536	Variability of clopidogrel response in patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 245-253.	2.0	28
1537	Is Timing Really Everything in Patients Receiving Antiplatelet Therapy?. <i>Archives of Surgery</i> , 2011, 146, 339.	2.2	1
1538	Thienopyridines, but Not Elinogrel, Result in Off-Target Effects at the Vessel Wall That Contribute to Bleeding. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 22-30.	2.5	27
1539	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Nonâ€“ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). <i>Circulation</i> , 2011, 123, 2022-2060.	1.6	321
1540	Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. <i>Journal of NeuroInterventional Surgery</i> , 2011, 3, 177-181.	3.3	31
1541	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
1542	Gastrointestinal Bleeding after Percutaneous Coronary Intervention. <i>Digestion</i> , 2011, 83, 153-160.	2.3	17

#	ARTICLE	IF	CITATIONS
1543	P2Y ₁₂ Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1151-1156.	1.9	9
1544	Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome. <i>Circulation</i> , 2011, 123, 722-730.	1.6	39
1545	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. <i>BMJ: British Medical Journal</i> , 2011, 342, d3527-d3527.	2.3	246
1546	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. <i>Heart</i> , 2011, 97, 626-631.	2.9	13
1547	A Clopidogrel-Insensitive Inducible Pool of P2Y ₁₂ Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y ₁₂ Antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 54-61.	2.5	28
1548	The Effect of Early Mobilisation for Patient Undergoing Coronary Angiography; A Pilot Study with Focus on Vascular Complications and Back Pain. <i>European Journal of Cardiovascular Nursing</i> , 2011, 10, 130-136.	0.9	30
1549	Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 95-103.	3.9	13
1550	The Perils of Combination Antithrombotic Therapy and Potential Resolutions. <i>Circulation</i> , 2011, 123, 232-235.	1.6	10
1551	Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. <i>European Heart Journal</i> , 2011, 32, 2358-2364.	2.2	17
1552	Percutaneous coronary intervention in the elderly. <i>Nature Reviews Cardiology</i> , 2011, 8, 79-90.	13.7	72
1553	Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. <i>Gut</i> , 2011, 60, 1170-1177.	12.1	158
1554	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- ∞ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
1555	Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US. <i>Current Medical Research and Opinion</i> , 2011, 27, 1079-1087.	1.9	10
1556	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
1557	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	3.9	19
1558	Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. <i>Circulation</i> , 2011, 123, 798-813.	1.6	272
1559	Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: Results from two distinct patient populations. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1015-1024.	1.0	10
1560	Impact of Dual Antiplatelet Therapy with Proton Pump Inhibitors on the Outcome of Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation. <i>ISRN Cardiology</i> , 2012, 2012, 1-8.	1.6	10

#	ARTICLE	IF	CITATIONS
1561	Comparison of Bolus Only With Bolus Plus Infusion of Bivalirudin in Patients Undergoing Elective Percutaneous Coronary Intervention: A Retrospective Observational Study. Journal of Pharmacy Practice, 2012, 25, 537-540.	1.0	2
1562	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) Tj ETQq11d.784314rgBT /O	1.0	2
1563	No One-Size-Fits-All. Circulation, 2012, 125, 471-473.	1.6	8
1564	Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin. Advances in Cardiology, 2012, 47, 20-30.	2.7	2
1565	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice, 2012, 2012, 1-18.	1.1	26
1566	Antiplatelet Therapy for Carotid Artery Stenting. Interventional Neurology, 2012, 1, 151-163.	1.8	21
1567	Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. Future Cardiology, 2012, 8, 555-562.	1.2	5
1568	Recommendations for Management of Antiplatelet Therapy in Patients Undergoing Elective Noncardiac Surgery After Coronary Stent Implantation. Critical Pathways in Cardiology, 2012, 11, 177-185.	0.5	19
1569	A brief review of the past and future of platelet P2Y12 antagonist. Coronary Artery Disease, 2012, 23, 368-374.	0.7	12
1570	Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. Coronary Artery Disease, 2012, 23, 523-527.	0.7	7
1571	Clopidogrel and Genetic Testing. Cardiology in Review, 2012, 20, 96-100.	1.4	11
1572	Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy. Blood Coagulation and Fibrinolysis, 2012, 23, 723-728.	1.0	22
1573	Platelet Function Profile Post-Clopidogrel Therapy in Patients With Type 2 Diabetes Undergoing Coronary Stent Implantation. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 249-257.	1.7	2
1574	Treatment algorithm in patients with NSTEMI and unstable angina. , 2012, , 331-346.		0
1575	Effect of <i>PON1</i> Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. Circulation: Cardiovascular Genetics, 2012, 5, 250-256.	5.1	25
1576	Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome â€. European Journal of Cardio-thoracic Surgery, 2012, 41, 550-555.	1.4	55
1578	Clinical Use of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5224-5239.	1.9	28
1579	Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease. Current Pharmaceutical Design, 2012, 18, 5362-5378.	1.9	8

#	ARTICLE	IF	CITATIONS
1580	Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?. Current Pharmaceutical Design, 2012, 18, 5392-5401.	1.9	2
1581	High Platelet Reactivity and Antiplatelet Therapy Resistance. Seminars in Thrombosis and Hemostasis, 2012, 38, 200-212.	2.7	49
1582	Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis. Current Pharmaceutical Design, 2012, 18, 4311-4325.	1.9	17
1583	The Role of Platelets in Athero-Thrombotic Events. Current Pharmaceutical Design, 2012, 18, 5197-5214.	1.9	57
1584	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
1585	The Pattern of Platelet Response to Clopidogrel in Iranian Patients After Percutaneous Coronary Intervention. Journal of Clinical Pharmacology, 2012, 52, 1098-1105.	2.0	3
1586	Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non-“ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment. Circulation: Cardiovascular Interventions, 2012, 5, 705-712.	3.9	29
1587	Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 318-325.	1.2	5
1588	Development of a cardiologist delivered service leads to improved outcomes following admission with acute coronary syndromes in a large district general hospital. Acute Cardiac Care, 2012, 14, 1-4.	0.2	2
1589	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640
1590	Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y ₁₂ blockade and influence of anticoagulant. Platelets, 2012, 23, 106-115.	2.3	32
1591	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. Expert Review of Cardiovascular Therapy, 2012, 10, 1273-1285.	1.5	6
1592	Cost-effectiveness of prasugrel in a US managed care population. Journal of Medical Economics, 2012, 15, 166-174.	2.1	15
1593	Antiplatelet therapy in ENT surgery: a review. Journal of Laryngology and Otology, 2012, 126, 331-336.	0.8	10
1594	Current Oral Antiplatelets: Focus Update on Prasugrel. Journal of the American Board of Family Medicine, 2012, 25, 343-349.	1.5	15
1595	Cervical Hematoma Following Carotid Endarterectomy is Morbid and Preventable. Vascular and Endovascular Surgery, 2012, 46, 610-616.	0.7	16
1596	The case for more intensive use of statins. Therapeutic Advances in Chronic Disease, 2012, 3, 201-210.	2.5	3
1597	Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vascular Health and Risk Management, 2012, 8, 77.	2.3	35

#	ARTICLE	IF	CITATIONS
1598	Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Hospital Practice (1995), 2012, 40, 104-117.	1.0	1
1599	Acute myocardial infarction in the obstetric patient. Obstetric Medicine, 2012, 5, 50-57.	1.1	4
1600	Newer agents in antiplatelet therapy: a review. Journal of Blood Medicine, 2012, 3, 33.	1.7	42
1601	Chronicle of an Unforetold Death. Archives of Internal Medicine, 2012, 172, 1174-7.	3.8	2
1602	Development and Clinical use of Prasugrel and Ticagrelor. Current Pharmaceutical Design, 2012, 18, 5240-5260.	1.9	27
1603	Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome, Transient Ischemic Attack, and Noncardioembolic Stroke in an Era of Cost Containment. Journal of Investigative Medicine, 2012, 60, 792-800.	1.6	3
1605	Appropriate Anti-Thrombotic/Anti-Thrombin Therapy for Thrombotic Lesions. Current Cardiology Reviews, 2012, 8, 181-191.	1.5	2
1606	Treatment of acute coronary syndrome. Critical Care Medicine, 2012, 40, 1939-1945.	0.9	12
1607	Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents. Current Pharmaceutical Design, 2012, 18, 850-860.	1.9	3
1608	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	1.9	35
1609	Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. Current Pharmaceutical Design, 2012, 18, 5273-5293.	1.9	19
1610	In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?. Current Vascular Pharmacology, 2012, 10, 476-478.	1.7	1
1611	Pharmacogenetics of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5309-5327.	1.9	16
1612	Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review. Current Cardiology Reviews, 2012, 8, 239-249.	1.5	16
1613	Long-term Results of Enterprise Stent-Assisted Coiling of Cerebral Aneurysms. Neurosurgery, 2012, 71, 239-244.	1.1	139
1614	A Randomized Crossover Study Comparing the Antiplatelet Effect of Plavix Versus Generic Clopidogrel. Journal of Cardiovascular Pharmacology, 2012, 60, 495-501.	1.9	10
1615	The effect of the CYP 2C19*2 polymorphism on stroke care. Acta Physiologica Hungarica, 2012, 99, 33-39.	0.9	4
1616	Primary and Secondary Prevention of Cardiovascular Disease. Chest, 2012, 141, e637S-e668S.	0.8	435

#	ARTICLE	IF	CITATIONS
1617	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial. Yearbook of Critical Care Medicine, 2012, 2012, 36-39.	0.2	0
1618	Invasive management of the acute coronary syndromes. Interventional Cardiology, 2012, 4, 279-285.	0.0	0
1619	Baseline Platelet Count and Clinical Outcome in Acute Coronary Syndrome. Circulation Journal, 2012, 76, 704-711.	1.6	21
1620	Association of CYP2C19 Genotype With Periprocedural Myocardial Infarction After Uneventful Stent Implantation in Chinese Patients Receiving Clopidogrel Pretreatment. Circulation Journal, 2012, 76, 2773-2778.	1.6	13
1621	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet, The, 2012, 379, 1705-1711.	13.7	341
1622	Perioperative Management of Antiplatelet Agents in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 680-686.	1.3	7
1623	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 2012, 33, 2143-2150.	2.2	86
1624	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of Thrombosis and Haemostasis, 2012, 10, 1999-2005.	3.8	112
1625	2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Annals of Thoracic Surgery, 2012, 94, 1761-1781.	1.3	256
1626	Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2012, 308, 2507.	7.4	175
1627	Genetic Considerations. Advances in Cardiology, 2012, 47, 100-113.	2.7	3
1628	Impact of Antiplatelet Therapy in Heart Disease. Advances in Cardiology, 2012, 47, 5-19.	2.7	4
1629	Prasugrel. Advances in Cardiology, 2012, 47, 39-63.	2.7	3
1630	Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial. European Radiology, 2012, 22, 1998-2006.	4.5	144
1631	Biomarkers in acute coronary artery disease. Wiener Medizinische Wochenschrift, 2012, 162, 489-498.	1.1	9
1632	Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor—a long continuing journey. Indian Heart Journal, 2012, 64, 54-59.	0.5	1
1633	Quelles indications pour le prasugrel et le ticagrelor dans les syndromes coronariens aigus? Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2012, 2012, 31-35.	0.0	0
1634	Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor. Journal of Cardiology, 2012, 60, 7-11.	1.9	3

#	ARTICLE	IF	CITATIONS
1635	Description of 3 Cases in Vietnam of Aspirin Desensitization in Patients With Coronary Artery Disease and Coexisting Aspirin Hypersensitivity. <i>World Allergy Organization Journal</i> , 2012, 5, 170-173.	3.5	5
1636	Pharmacogenetics of Clopidogrel: Comparison Between a Standard and a Rapid Genetic Testing. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 500-503.	0.7	17
1637	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 27-42.	1.8	4
1638	Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. <i>European Heart Journal</i> , 2012, 33, 2527-2534.	2.2	16
1639	Critique of "Stenting Versus Aggressive Medical Therapy for Intracranial Arterial Stenosis" by Chimowitz et al in the <i>New England Journal of Medicine</i> . <i>Stroke</i> , 2012, 43, 616-620.	2.0	70
1640	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. <i>Revista Española De Cardiología</i> , 2012, 65, 173.e1-173.e55.	1.2	31
1641	ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis. <i>Thrombosis Research</i> , 2012, 129, 754-759.	1.7	39
1642	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. <i>Thrombosis Research</i> , 2012, 130, 70-74.	1.7	12
1643	Acute Coronary Syndrome in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 1176-1178.	1.6	3
1644	A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: A magnetic resonance imaging study. <i>American Heart Journal</i> , 2012, 163, 500-507.	2.7	26
1645	Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2012, 163, 1011-1018.	2.7	4
1646	Outcomes of patients receiving clopidogrel prior to cardiac surgery. <i>International Journal of Cardiology</i> , 2012, 156, 34-40.	1.7	14
1647	Role of ASA in the primary and secondary prevention of cardiovascular events. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 113-123.	2.4	14
1648	Management and Outcome of Acute Coronary Syndrome Patients in Relation to Prior History of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 443-449.	1.7	20
1649	Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. <i>European Journal of Internal Medicine</i> , 2012, 23, 48-53.	2.2	13
1650	Newer Pharmaceutical Agents for STEMI Interventions. <i>Interventional Cardiology Clinics</i> , 2012, 1, 429-440.	0.4	0
1651	Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 406-407.	1.7	0
1652	Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 48.	1.6	17

#	ARTICLE	IF	CITATIONS
1653	Clopidogrel in Coronary Artery Disease: Update 2012. <i>Advances in Cardiology</i> , 2012, 47, 31-38.	2.7	4
1654	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2452-2461.	3.8	34
1655	Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2012, 51, 429-442.	3.5	66
1658	Anti-agrégants plaquettaires et syndromes coronaires aigus : État des lieux et limites actuelles. <i>Archives of Cardiovascular Diseases Supplements</i> , 2012, 4, 232-235.	0.0	0
1659	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. <i>American Heart Journal</i> , 2012, 164, 327-333.	2.7	8
1660	Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. <i>American Heart Journal</i> , 2012, 164, 817-824.e13.	2.7	20
1661	CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful?. <i>Indian Heart Journal</i> , 2012, 64, 341-352.	0.5	24
1662	Mortality Benefit With Prasugrel in the TRITON-TIMI 38 Coronary Artery Bypass Grafting Cohort. <i>Journal of the American College of Cardiology</i> , 2012, 60, 388-396.	2.8	169
1663	Platelet Reactivity and Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 60, 378-380.	2.8	0
1664	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) Tj ETQq1 1.0.7843144gBT /Dv	1.0	7843144
1665	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1280-1287.	2.9	92
1666	Acute Coronary Syndrome in Patients with Diabetes Mellitus: Perspectives of an Interventional Cardiologist. <i>American Journal of Cardiology</i> , 2012, 110, 13B-23B.	1.6	15
1667	Re-Visiting Consent for Clinical Research on Acute Myocardial Infarction and Other Emergent Conditions. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 251-257.	3.1	13
1668	Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. <i>Primary Care Diabetes</i> , 2012, 6, 167-177.	1.8	10
1669	Antiplatelet Agents in Ischemic Heart Disease. <i>Handbook of Experimental Pharmacology</i> , 2012, , 495-518.	1.8	1
1670	New anti-platelet agents: The end of resistance?. <i>Thrombosis Research</i> , 2012, 130, S53-S55.	1.7	7
1671	Safety profile and bleeding risk of ticagrelor compared with clopidogrel. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 959-967.	2.4	8
1672	Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?. <i>Platelets</i> , 2012, 23, 167-176.	2.3	6

#	ARTICLE	IF	CITATIONS
1673	Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 680-688.	2.2	198
1674	Antiplatelet Therapy for Prevention of Thromboembolic Complications Associated with Coil Embolization of Unruptured Cerebral Aneurysms. <i>Drugs in R and D</i> , 2012, 12, 1-7.	2.2	26
1675	Clopidogrel versus Aspirin in Patients with Atherothrombosis. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 331-342.	2.1	11
1676	Acute Coronary Syndromes. <i>Cardiology Clinics</i> , 2012, 30, 617-627.	2.2	2
1677	The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes. <i>Pharmacoeconomics</i> , 2012, 30, 1067-1084.	3.3	35
1679	InforMatrix: ADP antagonists in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 357-385.	1.8	0
1680	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2012, 33, 3078-3087.	2.2	115
1681	A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 99, 87-95.	1.9	12
1683	Discontinuation of Anticoagulant or Antiplatelet Therapy for Transrectal Ultrasound-Guided Prostate Biopsies: A Single-Center Experience. <i>Korean Journal of Urology</i> , 2012, 53, 234.	1.2	19
1684	Prediction of Clopidogrel Low Responders by a Rapid CYP2C19 Activity Test. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 186-193.	2.0	13
1685	Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter?. <i>Thrombosis and Haemostasis</i> , 2012, 107, 538-544.	3.4	17
1686	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 338-345.	3.4	29
1687	A Comparison of Two Brands of Clopidogrel in Patients With Drug-Eluting Stent Implantation. <i>Korean Circulation Journal</i> , 2012, 42, 458.	1.9	5
1688	Effects of PPIs and an H2 blocker on the Antiplatelet Function of Clopidogrel in Japanese Patients under Dual Antiplatelet Therapy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 559-569.	2.0	26
1689	Effects of 600 mg versus 300 mg Loading Dose of Clopidogrel in Asian Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Long-Term Follow-Up Study. <i>Yonsei Medical Journal</i> , 2012, 53, 906.	2.2	3
1690	Importance of potent P2Y12receptor blockade in acute myocardial infarction: focus on prasugrel. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1771-1796.	1.8	9
1691	New Treatments for Infrapopliteal Disease: Devices, Techniques, and Outcomes So Far. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 715-724.	2.0	14
1692	A comprehensive comparative review of adenosine diphosphate receptor antagonists. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 175-191.	1.8	11

#	ARTICLE	IF	CITATIONS
1693	Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 395-405.	1.7	11
1694	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 453-495.	1.7	157
1695	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. <i>European Heart Journal</i> , 2012, 33, 2856-2864.	2.2	64
1696	Recent advances in the pharmacogenetics of clopidogrel. <i>Human Genetics</i> , 2012, 131, 653-664.	3.8	26
1697	Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 20-30.	2.1	2
1698	Platelet Function and Inhibition in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2012, 14, 457-467.	2.9	15
1699	Diabetes Mellitus and Acute Coronary Syndrome: Lessons From Randomized Clinical Trials. <i>Current Diabetes Reports</i> , 2012, 12, 294-304.	4.2	33
1700	Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study. <i>Wiener Medizinische Wochenschrift</i> , 2012, 162, 67-73.	1.1	7
1701	Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 3-8.	1.9	12
1702	The Management of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation: A Survey among Interventional Cardiologists from Eight European Countries. <i>Journal of Interventional Cardiology</i> , 2012, 25, 163-169.	1.2	14
1703	Comparison of Three-Year Clinical Outcomes with Nonextended Versus Extended Dual Antiplatelet Therapy Between First- and Second-Generation Drug-Eluting Stent Implantation in Patients with Acute Myocardial Infarction: Data from the Infarct Prognosis Study Registry. <i>Journal of Interventional Cardiology</i> , 2012, 25, 245-252.	1.2	0
1704	Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2012, 34, 1209-1220.	2.5	21
1705	Modern Management of Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2012, 37, 237-310.	2.4	14
1707	The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. <i>Biochemical Pharmacology</i> , 2012, 83, 903-908.	4.4	31
1708	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. <i>Journal of Internal Medicine</i> , 2012, 271, 521-536.	6.0	18
1709	Improving Long-Term ACS Management: Is There a Role for the New Antiplatelets?. <i>Journal of Interventional Cardiology</i> , 2012, 25, 425-432.	1.2	4
1710	Safety of Temporary and Permanent Suspension of Antiplatelet Therapy After Drug Eluting Stent Implantation in Contemporary "Real-World" Practice. <i>Journal of Interventional Cardiology</i> , 2012, 25, 482-492.	1.2	21
1711	The Pharmacogenomics of Clopidogrel. <i>World Neurosurgery</i> , 2012, 77, 406-407.	1.3	4

#	ARTICLE	IF	CITATIONS
1712	Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCELâ€”TRIPLE (Accelerated) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 Journal of Clinical Pharmacology, 2012, 73, 629-640.	2.4	13
1713	Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2012, 79, 181-197.	1.7	7
1714	Promises of PAR-1 Inhibition in Acute Coronary Syndrome. Current Cardiology Reports, 2012, 14, 32-39.	2.9	13
1715	Clopidogrel and PPI Interaction: Clinically Relevant or Not?. Current Cardiology Reports, 2012, 14, 49-58.	2.9	12
1716	Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 57-68.	0.9	3
1717	Stent Thrombosis: Understanding and Managing a Critical Problem. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 91-107.	0.9	8
1718	Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 24-38.	0.9	10
1719	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research, 2012, 5, 41-51.	2.4	4
1720	Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. Journal of Thrombosis and Thrombolysis, 2012, 33, 137-142.	2.1	55
1721	Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials, 2013, 14, 56.	1.6	13
1722	CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. International Journal of Clinical Pharmacy, 2013, 35, 621-628.	2.1	19
1723	Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. Cardiovascular Diabetology, 2013, 12, 87.	6.8	11
1724	ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly. Journal of Cardiothoracic and Vascular Anesthesia, 2013, 27, 779-795.	1.3	12
1725	Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2013, 132, e15-e18.	1.7	28
1726	New oral anticoagulants after acute coronary syndrome. Best Practice and Research in Clinical Haematology, 2013, 26, 141-150.	1.7	2
1727	Clinical Implications of Plateletâ€”Vessel Interaction. Journal of Cardiovascular Translational Research, 2013, 6, 310-315.	2.4	16
1728	Platelet Function Testing and Tailored Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2013, 6, 316-328.	2.4	34
1729	Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research, 2013, 6, 329-345.	2.4	46

#	ARTICLE	IF	CITATIONS
1730	Clinical Impact of Genetically Determined Platelet Reactivity. Journal of Cardiovascular Translational Research, 2013, 6, 398-403.	2.4	6
1731	CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. Journal of Cardiovascular Translational Research, 2013, 6, 404-410.	2.4	6
1732	Comparison of Clinical Efficacy and Safety of Clopidogrel Resinate With Clopidogrel Bisulfate in Patients Undergoing Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 2013, 27, 441-449.	2.6	2
1733	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2013, 36, 1-6.	2.1	5
1734	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, The, 2013, 382, 1981-1992.	13.7	286
1735	Cangrelor: a new CHAMPION for percutaneous coronary intervention. Lancet, The, 2013, 382, 1960-1962.	13.7	3
1736	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. JACC: Cardiovascular Interventions, 2013, 6, 854-863.	2.9	67
1737	Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. International Journal of Cardiology, 2013, 170, e21-e22.	1.7	24
1738	Time from adenosine di-phosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome: Meta-analysis and meta-regression. International Journal of Cardiology, 2013, 168, 1955-1964.	1.7	21
1739	Benefit of Long-Term Dual Anti-Platelet Therapy in Patients Treated With Drug-Eluting Stents: From the NHLBI Dynamic Registry. American Journal of Cardiology, 2013, 111, 486-492.	1.6	39
1740	Aspirin and aspirin resistance in coronary artery disease. Current Opinion in Pharmacology, 2013, 13, 242-250.	3.5	35
1741	The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease. Atherosclerosis, 2013, 227, 106-111.	0.8	12
1742	Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics, 2013, 2, 499-513.	0.4	1
1743	Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology, 2013, 163, 19-25.	1.7	3
1744	Clopidogrel resistance: Pre- vs post-receptor determinants. Vascular Pharmacology, 2013, 59, 152-161.	2.1	17
1745	Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study. European Journal of Cardio-thoracic Surgery, 2013, 44, e133-e140.	1.4	36
1746	Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA - Journal of the American Medical Association, 2013, 310, 2510-22.	7.4	513
1747	Updates in Antiplatelet Agents Used in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 514-524.	2.0	23

#	ARTICLE	IF	CITATIONS
1748	Coronary stents: historical development, current status and future directions. British Medical Bulletin, 2013, 106, 193-211.	6.9	234
1749	Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial. American Heart Journal, 2013, 166, 669-675.	2.7	19
1750	Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery. Circulation, 2013, 128, 2785-2798.	1.6	91
1752	Impact of initial clinical presentation on clopidogrel low response. Archives of Cardiovascular Diseases, 2013, 106, 593-600.	1.6	1
1753	Perioperative management of antiplatelet therapy. British Journal of Anaesthesia, 2013, 111, i3-i17.	3.4	81
1754	Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment. International Journal of Cardiology, 2013, 167, 1794-1797.	1.7	11
1755	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 280-291.	1.0	5
1756	Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial. International Journal of Cardiology, 2013, 168, 3736-3740.	1.7	102
1757	Cardiovascular Prophylaxis and Aspirin – Allergy – Immunology and Allergy Clinics of North America, 2013, 33, 263-274.	1.9	20
1758	Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. Journal of Neurology, 2013, 260, 2928-2937.	3.6	10
1759	Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes. Current Cardiology Reports, 2013, 15, 405.	2.9	5
1760	Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties. Journal of Orthopaedics and Traumatology, 2013, 14, 171-177.	2.3	28
1761	Gender Differences in Cardiovascular Therapy: Focus on Antithrombotic Therapy and Percutaneous Coronary Intervention. Drugs, 2013, 73, 1921-1933.	10.9	19
1762	Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations. Pharmacoeconomics, 2013, 31, 959-970.	3.3	9
1763	Pretreatment with Prasugrel in Non-“ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine, 2013, 369, 999-1010.	27.0	539
1764	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. Interventional Cardiology, 2013, 5, 179-201.	0.0	0
1765	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 T 792-798.	1.6	12
1766	Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. Scandinavian Cardiovascular Journal, 2013, 47, 230-235.	1.2	0

#	ARTICLE	IF	CITATIONS
1767	Platelet Antiaggregants in Stroke Prevention. <i>Neurologic Clinics</i> , 2013, 31, 633-657.	1.8	7
1768	Using Platelet Function Testing to Guide Antiplatelet Therapy. <i>Drug Development Research</i> , 2013, 74, 517-525.	2.9	4
1769	Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 320-325.	1.5	20
1770	Protection from Procedural Myocardial Injury by Omega-3 Polyunsaturated Fatty Acids (<scp>PUFA</scp>s): Is Related with Lower Levels of Creatine Kinase- (<scp>MB</scp> (<scp>CK</scp>- (<scp>MB</scp>)) and Troponin (<scp>I</scp>)? <i>Cardiovascular Therapeutics</i> , 2013, 31, 268-273.	2.5	17
1771	Assessing post-treatment platelet reactivity: a focus on patient selection and setting. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1557-1566.	1.5	1
1772	Novel Antiplatelet Therapies. , 2013, , 1185-1213.		4
1773	Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2013, 111, 841-845.	1.6	25
1774	Drug Resistance and Pseudoresistance. <i>Circulation</i> , 2013, 127, 377-385.	1.6	187
1775	Clopidogrel -Resistance- Where are We Now?. <i>Cardiovascular Therapeutics</i> , 2013, 31, 3-11.	2.5	28
1776	Mean Platelet Volume and Long-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2013, 111, 185-189.	1.6	43
1777	Non-ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177.		0
1778	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 200-208.	2.1	6
1779	Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. <i>International Journal of Cardiology</i> , 2013, 163, 5-18.	1.7	18
1780	Characterization of aspirin allergies in patients with coronary artery disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 92-95.	1.0	29
1781	Improved biological efficacy of prasugrel one month after an acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 167, 2329-2330.	1.7	0
1782	Individualisation du traitement antiplaquettaire : quel est l'intérêt du monitoring plaquettaire ?. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 35-41.	0.0	0
1783	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	2.8	370
1784	The nuances of new antiplatelet drugs in acute coronary syndrome. <i>Journal of Indian College of Cardiology</i> , 2013, 3, 16-23.	0.1	1

#	ARTICLE	IF	CITATIONS
1785	Comparison of Antiplatelet Efficacy and Tolerability of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients After Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized, Open-Label, Phase IV, Noninferiority Trial. <i>Clinical Therapeutics</i> , 2013, 35, 28-37.e4.	2.5	8
1786	Combination Antithrombotic Management for Non-“ST Segment Elevation Acute Coronary Syndromes. <i>Interventional Cardiology Clinics</i> , 2013, 2, 553-571.	0.4	0
1787	New antiplatelet agents for cardiovascular disease. <i>Cmaj</i> , 2013, 185, 1405-1411.	2.0	10
1788	Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good. <i>American Journal of Emergency Medicine</i> , 2013, 31, 1408-1409.	1.6	1
1789	Acute Coronary Syndromes: Much Progress, New Challenges. <i>Clinical Therapeutics</i> , 2013, 35, 1054-1057.	2.5	0
1790	Short-term Bleeding Events Observed with Clopidogrel Loading in Acute Ischemic Stroke Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 1184-1189.	1.6	11
1791	Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 2579-2587.	1.7	39
1792	TRILOGY ACS: prasugrel of benefit only after angiography?. <i>Lancet, The</i> , 2013, 382, 580-582.	13.7	5
1793	Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: Results of a pilot randomized trial. <i>International Journal of Cardiology</i> , 2013, 167, 2177-2181.	1.7	26
1794	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. <i>International Journal of Cardiology</i> , 2013, 168, 4244-4248.	1.7	14
1795	Prescribing Patterns of Antiplatelet Agents Are Highly Variable After Lower Extremity Endovascular Procedures. <i>Annals of Vascular Surgery</i> , 2013, 27, 62-67.	0.9	35
1797	Pharmacogenomics in Interventional Pharmacology. <i>Interventional Cardiology Clinics</i> , 2013, 2, 615-625.	0.4	2
1798	Antiplatelet Therapy in Endovascular Surgery: The RENDOVASC Study. <i>Annals of Vascular Surgery</i> , 2013, 27, 168-177.	0.9	10
1799	The Effect of Antiplatelet and Anticoagulant Therapy on the Clinical Outcome of Patients Undergoing Ureteroscopy. <i>Urology</i> , 2013, 82, 773-779.	1.0	13
1800	Antiagregaci3n oral en el intervencionismo coronario percut3neo: f3rmas disponibles y duraci3n de la terapia oral. <i>Revista Espanola De Cardiologia Suplementos</i> , 2013, 13, 16-23.	0.2	1
1801	Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1069-1075.	2.8	39
1802	Antiplatelet Therapy After Coronary Stenting. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 1-10.	0.9	15
1803	Medical therapy of coronary artery disease after percutaneous intervention. <i>Current Opinion in Pharmacology</i> , 2013, 13, 287-293.	3.5	11

#	ARTICLE	IF	CITATIONS
1804	Statements of the <scp>M</scp>alaysian <scp>S</scp>ociety of <scp>G</scp>astroenterology & <scp>H</scp>epatology and the <scp>N</scp>ational <scp>H</scp>eart <scp>A</scp>ssociation of <scp>M</scp>alaysia task force 2012 working party on the use of antiplatelet therapy and proton pump inhibitors in the prevention of gastrointestinal bleeding. Journal of Digestive Diseases, 2013, 14, 1-10.	1.5	2
1805	Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaisâ€associated ulcers complication. Digestive Endoscopy, 2013, 25, 25-31.	2.3	3
1806	Atherothrombosis and Coronary Artery Disease. , 2013, , 653-668.		0
1807	ADP Receptor Antagonists. , 2013, , 1117-1138.		5
1808	Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty. CardioVascular and Interventional Radiology, 2013, 36, 1493-1499.	2.0	24
1809	Stent thrombosis and platelet reactivity. Cor Et Vasa, 2013, 55, e151-e157.	0.1	0
1810	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Review of Cardiovascular Therapy, 2013, 11, 307-317.	1.5	6
1811	Pharmacotherapy for the reduction of stent thrombosis. Expert Review of Cardiovascular Therapy, 2013, 11, 567-576.	1.5	1
1812	The discovery and development of prasugrel. Expert Opinion on Drug Discovery, 2013, 8, 897-905.	5.0	7
1813	Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Review. Current Cardiology Reports, 2013, 15, 378.	2.9	1
1814	Platelet Function Monitoring and Clopidogrel. Current Cardiology Reports, 2013, 15, 321.	2.9	9
1815	Stable Angina. , 2013, , 419-438.		0
1816	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. Canadian Journal of Cardiology, 2013, 29, S60-S70.	1.7	11
1817	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. International Journal of Cardiology, 2013, 167, 2140-2148.	1.7	113
1819	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. American Journal of Cardiovascular Drugs, 2013, 13, 233-250.	2.2	36
1820	The Duel between Dual Antiplatelet Therapies. New England Journal of Medicine, 2013, 368, 1356-1357.	27.0	13
1821	Acute Coronary Syndromes: Advances in Antithrombotics. Current Atherosclerosis Reports, 2013, 15, 318.	4.8	3
1822	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. American Journal of Cardiology, 2013, 111, 985-990.	1.6	59

#	ARTICLE	IF	CITATIONS
1823	Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. Platelets, 2013, 24, 352-361.	2.3	35
1824	Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 694-699.	2.2	14
1825	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. , 2013, , CD002130.		34
1826	Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. European Heart Journal, 2013, 34, 872-874.	2.2	2
1827	Adherence to dual antiplatelet therapy: can we do better?. Expert Review of Cardiovascular Therapy, 2013, 11, 1417-1424.	1.5	3
1828	Prehospital treatment of ST-segment elevated myocardial infarction patients. Future Cardiology, 2013, 9, 229-241.	1.2	4
1829	Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. Postgraduate Medicine, 2013, 125, 51-58.	2.0	2
1830	Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of Medical Economics, 2013, 16, 510-521.	2.1	15
1831	Cost-effectiveness of ticagrelor in acute coronary syndromes. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 9-18.	1.4	3
1832	P2Y12 Inhibition in Patients with NSTEMI " Can Later Be Better?. New England Journal of Medicine, 2013, 369, 1056-1057.	27.0	2
1833	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Circulation, 2013, 127, e663-828.	1.6	219
1834	Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation. BioMed Research International, 2013, 2013, 1-3.	1.9	14
1835	Aspirin resistance: Where are we now?. Anatolian Journal of Cardiology, 2013, 13, 370-3.	0.4	6
1836	Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy. ISRN Cardiology, 2013, 2013, 1-8.	1.6	18
1838	Long-Term Clinical Outcome of the Symmetry Aortic Connector System in Off-Pump Coronary Artery Bypass Grafting. Thoracic and Cardiovascular Surgeon, 2013, 61, 669-675.	1.0	2
1839	Historical Lessons in Translational Medicine. Circulation Research, 2013, 112, 174-194.	4.5	38
1840	Rivaroxaban and risk of myocardial infarction. Coronary Artery Disease, 2013, 24, 628-635.	0.7	44
1841	Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention. Coronary Artery Disease, 2013, 24, 312-320.	0.7	8

#	ARTICLE	IF	CITATIONS
1842	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2013, 24, 321-327.	0.7	3
1843	Twelve-Month Results of a Randomized Trial Comparing Mono With Dual Antiplatelet Therapy in Endovascularly Treated Patients With Peripheral Artery Disease. <i>Journal of Endovascular Therapy</i> , 2013, 20, 699-706.	1.5	84
1844	Thrombosis. , 2013, , 133-137.		0
1845	Novel Direct-Acting Anticoagulants for Risk Reduction in ACS. <i>Journal of Pharmacy Practice</i> , 2013, 26, 358-366.	1.0	3
1846	Characteristics of new P2Y12 inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S22-S30.	1.5	4
1847	Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 593-598.	1.0	11
1848	Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. <i>Journal of NeuroInterventional Surgery</i> , 2013, 5, 337-343.	3.3	97
1849	Kounis Syndrome Due To Clopidogrel: A Rare Case Report. <i>Journal of Turgut Ozal Medical Center</i> , 2013, 20, 182-184.	0.0	0
1850	Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India. <i>Journal of Pharmacogenomics & Pharmacoproteomics</i> , 2013, 05, .	0.2	2
1851	Carotid Artery Stenting in Patients With Acute Coronary Syndrome: A Possible Primary Therapy for Symptomatic Carotid Stenosis. <i>Journal of Endovascular Therapy</i> , 2013, 20, 546-551.	1.5	8
1852	Spontaneous and Procedural Plaque Embolisation in Native Coronary Arteries: Pathophysiology, Diagnosis, and Prevention. <i>Scientifica</i> , 2013, 2013, 1-15.	1.7	14
1853	Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease. <i>ISRN Cardiology</i> , 2013, 2013, 1-7.	1.6	4
1854	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
1855	Impact and Diagnosis of Antiplatelet Therapy Resistance in Patients Undergoing Cardiac Surgery. <i>Drug Development Research</i> , 2013, 74, 492-504.	2.9	1
1856	A Pilot Study of Prasugrel Followed by Postâ€Procedural Maintenance with Clopidogrel in Patients Receiving Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2013, 26, 38-42.	1.2	3
1857	Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 533-543.	2.0	8
1858	The Assessment of Risk for Gastrointestinal Injury with Anticoagulant and Antiplatelet Drugs: The Possible Beneficial Effect of Eicosapentaenoic Acid for the Risk of Gastrointestinal Injury. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 222-227.	1.4	4
1859	Tailoring Antiplatelet Therapy. <i>Circulation Journal</i> , 2013, 77, 1150-1151.	1.6	0

#	ARTICLE	IF	CITATIONS
1860	Clinical importance of antiplatelet drugs in cardiovascular diseases. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 81-96.	1.7	24
1861	Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013, 19, 1581-1586.	1.9	1
1862	Anterior Chamber Bleeding After Laser Peripheral Iridotomy. <i>JAMA Ophthalmology</i> , 2013, 131, 626.	2.5	21
1863	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. , 2013, , CD002130.		12
1864	Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents. <i>Current Clinical Pharmacology</i> , 2013, 8, 59-66.	0.6	0
1865	A Multicenter Study of Stent-Assisted Coiling of Cerebral Aneurysms With a Y Configuration. <i>Neurosurgery</i> , 2013, 73, 466-472.	1.1	118
1866	Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. <i>Journal of Trauma and Acute Care Surgery</i> , 2013, 74, 1419-1424.	2.1	9
1867	Oral antiplatelet therapy after drug-eluting stent implantation. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 81-90.	1.5	8
1868	Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?. <i>Postępy W Kardiologii Interwencyjnej</i> , 2013, 3, 234-240.	0.2	8
1870	Efficacy and Safety of Platelet Inhibitors. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 1.	2.1	10
1871	Platelet function testing and prediction of procedural bleeding risk. <i>Thrombosis and Haemostasis</i> , 2013, 109, 817-824.	3.4	30
1872	Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy. <i>PLoS ONE</i> , 2013, 8, e82562.	2.5	198
1873	Coronary Artery Disease and Myocardial Infarction. , 2013, , 516-529.		0
1874	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
1876	TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 301-305.	0.8	1
1877	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1141-1152.	3.4	26
1878	Impact of CYP2C19 Polymorphism on Platelet Function Tests and Coagulation and Inflammatory Biomarkers in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 64-76.	2.0	17
1879	Transfusion Strategy: Impact of Haemodynamics and the Challenge of Haemodilution. <i>Journal of Blood Transfusion</i> , 2014, 2014, 1-12.	3.3	9

#	ARTICLE	IF	CITATIONS
1880	Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis. Scientific World Journal, The, 2014, 2014, 1-16.	2.1	10
1881	Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2014, 12, 14-20.	1.0	0
1882	Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients. Medical Journal of Australia, 2014, 201, S91-6.	1.7	1
1883	Dual Antiplatelet Therapy after Noncardioembolic Ischemic Stroke or Transient Ischemic Attack: Pros		

#	ARTICLE	IF	CITATIONS
1898	Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. <i>Anatolian Journal of Cardiology</i> , 2014, 14, 134-139.	0.4	11
1899	Aspirin Allergy Desensitization in Cerebrovascular Disease. <i>Interventional Neuroradiology</i> , 2014, 20, 5-11.	1.1	2
1900	A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. <i>Interventional Cardiology</i> , 2014, 6, 453-462.	0.0	0
1901	Tailoring anti-platelet therapy “one size will not fit all. <i>Current Medical Research and Opinion</i> , 2014, 30, 2191-2192.	1.9	0
1904	Cost-effectiveness assessment of cardiac interventions: determining a socially acceptable cost threshold. <i>Interventional Cardiology</i> , 2014, 6, 45-55.	0.0	6
1905	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. <i>BMJ, The</i> , 2014, 347, g6269-g6269.	6.0	75
1906	Prasugrel in NSTEMI. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2572-2574.	2.8	1
1907	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2563-2571.	2.8	64
1908	Dual Antiplatelet Therapy Over 6 Months Increases the Risk of Bleeding after Biodegradable Polymer-Coated Sirolimus Eluting Stents Implantation: Insights from the CREATE Study. <i>Journal of Interventional Cardiology</i> , 2014, 27, 119-126.	1.2	9
1909	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Nature Reviews Cardiology</i> , 2014, 11, 597-606.	13.7	267
1910	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 963-976.	1.5	0
1911	Nationwide trends in development of heart failure and mortality after first-time myocardial infarction 1997-2010: A Danish cohort study. <i>European Journal of Internal Medicine</i> , 2014, 25, 731-738.	2.2	33
1912	Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies. <i>Pharmacogenomics</i> , 2014, 15, 643-653.	1.3	18
1913	A rare complication of arterio-venous fistula following coronary intervention using radial approach. <i>Journal of Indian College of Cardiology</i> , 2014, 4, 266-268.	0.1	0
1914	Point-of-care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic and Branded Clopidogrel Bisulfate. <i>Clinical Therapeutics</i> , 2014, 36, 1588-1594.	2.5	6
1915	Cangrelor: A Novel Intravenous Antiplatelet Agent with a Questionable Future. <i>Pharmacotherapy</i> , 2014, 34, 1061-1076.	2.6	16
1916	Pretreatment with P2Y ₁₂ Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36
1917	Pretreatment With P2Y ₁₂ Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Is Clinically Justified. <i>Circulation</i> , 2014, 130, 1891-1903.	1.6	39

#	ARTICLE	IF	CITATIONS
1918	Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 812-818.	1.9	8
1919	Duración del tratamiento antiagregante en el síndrome coronario agudo. <i>Revista Española De Cardiología Suplementos</i> , 2014, 14, 32-37.	0.2	1
1920	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
1921	Hypercoagulation Assessed by Thromboelastography is Neither Related to Infarct Size nor to Clinical Outcome After Primary Percutaneous Coronary Intervention. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 825-831.	1.7	2
1922	Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?. <i>Current Opinion in Cardiology</i> , 2014, 29, 301-306.	1.8	1
1923	Dual antiplatelet therapy after drug-eluting stents. <i>Coronary Artery Disease</i> , 2014, 25, 83-89.	0.7	8
1924	Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 41-46.	1.9	8
1925	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
1927	Variability of on-treatment platelet reactivity in patients on clopidogrel. <i>Platelets</i> , 2014, 25, 328-336.	2.3	18
1928	Effects of hormones on platelet aggregation. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2014, 18, 27-36.	0.7	9
1929	Assessing Uncertainties Surrounding Combined Endpoints for Use in Economic Models. <i>Medical Decision Making</i> , 2014, 34, 300-310.	2.4	2
1930	Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results. <i>Medical Devices: Evidence and Research</i> , 2014, 7, 35.	0.8	9
1931	Timing and nature of in-house postoperative events following uncomplicated elective endovascular aneurysm treatment. <i>Journal of Neurosurgery</i> , 2014, 121, 1063-1070.	1.6	13
1932	Aspirin Reload Before Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 577-584.	3.9	17
1933	Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 577-584.	1.0	5
1934	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. <i>Platelets</i> , 2014, 25, 348-356.	2.3	17
1935	PPAR β activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. <i>Experimental Neurology</i> , 2014, 253, 16-27.	4.1	56
1936	Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 872-877.	2.8	247

#	ARTICLE	IF	CITATIONS
1937	Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin. Cardiovascular Revascularization Medicine, 2014, 15, 308-310.	0.8	5
1938	Acute Coronary Syndrome. , 2014, , 49-66.		3
1939	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 76-89.	1.5	1
1940	Primary PCI in dabigatran-treated patient: is transradial approach and bivalirudin infusion a safe and effective therapeutic option?. Internal and Emergency Medicine, 2014, 9, 695-698.	2.0	0
1941	High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation, 2014, 85, 649-656.	3.0	105
1942	Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2014, 7, 112-125.	2.4	0
1943	Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation. Journal of Cardiovascular Translational Research, 2014, 7, 64-71.	2.4	2
1944	Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside. Journal of Cardiovascular Translational Research, 2014, 7, 82-90.	2.4	5
1945	Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Netherlands Heart Journal, 2014, 22, 55-61.	0.8	9
1946	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimenâ€”Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. American Heart Journal. 2014. 167. 459-465.e1.	2.7	19
1947	Combined Cardioprotectant and Antithrombotic Actions of Platelet P2Y12 Receptor Antagonists in Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 179-190.	2.0	48
1948	Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents. Current Medical Research and Opinion, 2014, 30, 51-54.	1.9	0
1949	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. American Journal of Cardiology, 2014, 113, 54-59.	1.6	35
1950	Neurologic complications of myocardial infarction. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 93-110.	1.8	1
1951	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. International Journal of Cardiology, 2014, 170, 413-418.	1.7	64
1952	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2014, 371, 2155-2166.	27.0	1,645
1953	Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: A systematic review of the literature. International Journal of Cardiology, 2014, 177, 461-466.	1.7	9
1955	Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity. Annals of Pharmacotherapy, 2014, 48, 1230-1233.	1.9	10

#	ARTICLE	IF	CITATIONS
1956	Acute Coronary Syndrome. Hospital Medicine Clinics, 2014, 3, 471-478.	0.2	1
1957	Managing Antithrombotic Therapy in Patients With Both Atrial Fibrillation and Coronary Heart Disease. Clinical Therapeutics, 2014, 36, 1176-1181.	2.5	8
1960	A new mechanism of action of thienopyridine antiplatelet drugs – A role for gastric nitrosthio metabolism?. Atherosclerosis, 2014, 237, 369-373.	0.8	7
1961	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes: Executive Summary. Journal of the American College of Cardiology, 2014, 64, 2645-2687.	2.8	424
1963	Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. Pharmacotherapy, 2014, 34, 1077-1090.	2.6	161
1964	Effectiveness of switching –low responders™ to prasugrel to ticagrelor after acute coronary syndrome. International Journal of Cardiology, 2014, 176, 1184-1185.	1.7	10
1965	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
1966	Antiplatelet therapy for secondary prevention of coronary artery disease. Heart, 2014, 100, 1750-1756.	2.9	33
1967	Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome. Pharmacoeconomics, 2014, 32, 1063-1078.	3.3	1
1968	Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovascular Disorders, 2014, 14, 100.	1.7	27
1971	Lessons from primary PCI practice for the next decade. Heart, 2014, 100, 1667-1672.	2.9	5
1972	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 64, e139-e228.	2.8	2,746
1973	Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. European Journal of Clinical Pharmacology, 2014, 70, 1041-1047.	1.9	23
1974	High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy. Thrombosis Research, 2014, 133, 257-264.	1.7	10
1975	Sex differences in stroke: The contribution of coagulation. Experimental Neurology, 2014, 259, 16-27.	4.1	97
1976	Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX). Current Cardiology Reports, 2014, 16, 493.	2.9	11
1977	Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. International Journal of Hematology, 2014, 99, 263-271.	1.6	14
1978	Temporary Adjunctive Cilostazol vs Clopidogrel Loading for ST-segment Elevation Acute Myocardial Infarction. American Journal of Cardiovascular Drugs, 2014, 14, 131-136.	2.2	3

#	ARTICLE	IF	CITATIONS
1979	The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome. BMC Genomics, 2014, 15, .	2.8	0
1980	Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome. BMC Cardiovascular Disorders, 2014, 14, 21.	1.7	2
1982	Impact of Early Versus Late Clopidogrel Discontinuation on Stent Thrombosis Following Percutaneous Coronary Intervention With First- and Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2014, 113, 1968-1976.	1.6	19
1983	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. International Journal of Cardiology Heart & Vessels, 2014, 4, 188-192.	0.5	4
1984	Clinical outcomes with 6 months dual antiplatelet therapy after implantation of Biolimus-A9 drug eluting coronary stents. International Journal of Cardiology, 2014, 172, 185-189.	1.7	5
1985	Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Non-â€œST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 2249-2257.	2.8	27
1986	Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. International Journal of Cardiology, 2014, 173, 120-121.	1.7	38
1987	Stent thrombosis: An increased adverse event after angioplasty following resuscitated cardiac arrest. Resuscitation, 2014, 85, 769-773.	3.0	71
1988	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 2014, 114, 1929-1943.	4.5	79
1989	Pharmacogenetics of Antiplatelet Therapy. Current Atherosclerosis Reports, 2014, 16, 411.	4.8	2
1990	RÃ©sistance aux antiagrÃ©gants plaquettaires : oÃ¹ en est-on en pratique ?. Archives Des Maladies Du Cœur Et Des Vaisseaux - Pratique, 2014, 2014, 34-37.	0.0	0
1991	Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. Thrombosis and Haemostasis, 2014, 112, 273-278.	3.4	60
1992	Will cangrelor become the favored agent for acute coronary syndrome treatment?. Interventional Cardiology, 2014, 6, 537-545.	0.0	0
1993	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Thrombosis and Haemostasis, 2014, 111, 1041-1049.	3.4	16
1994	Acetylsalicylic acid desensitization in the new era of percutaneous coronary intervention. Medicina Clínica (English Edition), 2015, 145, 253-257.	0.2	0
1995	Circulating primers enhance platelet function and induce resistance to antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2015, 13, 1479-1493.	3.8	21
1996	Outcomes of Percutaneous Coronary Intervention Performed With or Without Preprocedural Dual Antiplatelet Therapy. Circulation Journal, 2015, 79, 2598-2607.	1.6	9
1997	Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study. Cardiology Research and Practice, 2015, 2015, 1-10.	1.1	3

#	ARTICLE	IF	CITATIONS
1998	Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept. <i>EJVES Short Reports</i> , 2015, 29, 11-17.	0.7	2
2000	EJH â€“ Cardiovascular Pharmacotherapy: a warm welcome to the new member of the ESC journal family. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 2-6.	3.0	1
2001	The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy. <i>Thrombosis Journal</i> , 2015, 13, 28.	2.1	3
2002	Preâ€treatment with dual antiplatelet therapy in patients with nonâ€ST</scp>â€segment elevation acute coronary syndromes undergoing percutaneous coronary intervention. <i>Internal Medicine Journal</i> , 2015, 45, 1032-1037.	0.8	2
2003	Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model. <i>CMAJ Open</i> , 2015, 3, E438-E446.	2.4	7
2004	Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. <i>Thrombosis and Haemostasis</i> , 2015, 114, 498-518.	3.4	60
2005	Platelet function testing in acute cardiac care â€“ is there a role for prediction or prevention of stent thrombosis and bleeding?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 221-230.	3.4	33
2006	The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. <i>Current Opinion in Cardiology</i> , 2015, 30, 525-535.	1.8	7
2007	Aspirin desensitization for cardiovascular disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 314-322.	2.3	18
2008	Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 870-876.	3.9	11
2009	Nonâ€antiplatelet effect of clopidogrel: improving endothelial function in <scp>C</scp>hinese healthy subjects with different <i><scp>CYP</scp>2C19</i> genotype. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 22-26.	1.9	10
2010	Platelet Activation Markers (Î²-thromboglobulin and platelet factor 4) and Clopidogrel Drug Response in Patients with Myocardial Infarction. <i>Laboratory Medicine Online</i> , 2015, 5, 137.	0.2	0
2011	ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 9-10.	3.4	0
2012	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 95.	4.7	40
2013	Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. <i>World Journal of Critical Care Medicine</i> , 2015, 4, 40.	1.8	30
2014	Use of medicines recommended for secondary prevention of acute coronary syndrome. <i>Revista De Saude Publica</i> , 2015, 49, .	1.7	4
2015	Prevention of stent thrombosis: challenges and solutions. <i>Vascular Health and Risk Management</i> , 2015, 11, 93.	2.3	41
2016	Recent advances in the diagnosis and treatment of acute myocardial infarction. <i>World Journal of Cardiology</i> , 2015, 7, 243.	1.5	138

#	ARTICLE	IF	CITATIONS
2017	Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. PLoS ONE, 2015, 10, e0135915.	2.5	12
2018	Coronary artery bypass grafting versus percutaneous intervention in coronary revascularization: a historical perspective and review. Research Reports in Clinical Cardiology, 0, , 57.	0.2	0
2019	Comparing of Light Transmittance Aggregometry and Modified Thrombelastograph in Predicting Clinical Outcomes in Chinese Patients Undergoing Coronary Stenting with Clopidogrel. Chinese Medical Journal, 2015, 128, 774-779.	2.3	12
2020	Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention. Interventional Cardiology Review, 2015, 10, 26.	1.6	1
2021	Risks and benefits of antiplatelet therapies. British Journal of Cardiac Nursing, 2015, 10, 236-240.	0.1	1
2022	Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease. Journal of Vascular Surgery, 2015, 61, 1479-1488.	1.1	30
2023	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. Circulation, 2015, 132, 174-181.	1.6	45
2024	A novel biosensor-based microarray assay for the visualized detection of CYP2C19 \hat{a}^{-2} , \hat{a}^{-3} , \hat{a}^{-4} and \hat{a}^{-5} polymorphisms. Clinical Chemistry and Laboratory Medicine, 2015, 53, 217-23.	2.3	0
2025	Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. American Journal of Cardiology, 2015, 116, 660-668.	1.6	7
2026	Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. American Journal of Cardiovascular Drugs, 2015, 15, 415-427.	2.2	10
2027	Medical Treatment of Stable Angina. Cardiovascular Medicine, 2015, , 421-459.	0.0	0
2028	Comparison of Dual-Antiplatelet Therapy Durations after Endovascular Revascularization of Infrainguinal Arteries. Annals of Vascular Surgery, 2015, 29, 1235-1244.	0.9	9
2029	Length of hospital stay after hip fracture and short term risk of death after discharge: a total cohort study in Sweden. BMJ, The, 2015, 350, h696-h696.	6.0	136
2030	Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?. Circulation, 2015, 131, 2010-2019.	1.6	5
2031	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart, 2015, 101, 1219-1224.	2.9	15
2032	Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?. Medicine (United Tj ETQq1 1 0.784314 4gBT /Over	1.0	0
2033	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. Interventional Cardiology, 2015, 7, 283-293.	0.0	0
2034	Smoke Signals. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	0

#	ARTICLE	IF	CITATIONS
2035	Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia. Journal of Cataract and Refractive Surgery, 2015, 41, 2092-2101.	1.5	17
2036	Coronary Revascularization in the Current Era. Progress in Cardiovascular Diseases, 2015, 58, 227-229.	3.1	1
2038	Pneumonitis and pulmonary haemorrhage after acute myocardial infarction. Clinical Medicine, 2015, 15, 591-593.	1.9	4
2039	Which Should Be the Control Arm in Trials of Antiplatelet Therapies?. American Journal of Cardiology, 2015, 116, 493-494.	1.6	0
2040	Brachial-ankle pulse wave velocity and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes in Korea: A comparable and additive study. Platelets, 2015, 26, 665-671.	2.3	8
2041	PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets, 2015, 26, 236-242.	2.3	21
2042	Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. Vascular Pharmacology, 2015, 65-66, 17-22.	2.1	6
2043	Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. American Heart Journal, 2015, 169, 222-233.e5.	2.7	34
2045	Data collection as a barrier to personalized medicine. Trends in Pharmacological Sciences, 2015, 36, 68-71.	8.7	36
2046	Antiplatelet therapy after drug-eluting stent implantation. Journal of Cardiology, 2015, 65, 98-104.	1.9	7
2047	Neuroimaging Pharmacopoeia. , 2015, , .		2
2048	Prognostic Impact of Clopidogrel Pretreatment in Patients With Acute Coronary Syndrome Managed Invasively. American Journal of Cardiology, 2015, 115, 1019-1026.	1.6	17
2049	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. American Heart Journal, 2015, 169, 266-273.	2.7	14
2050	Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene, 2015, 558, 200-207.	2.2	48
2051	Vorapaxar in Atherosclerotic Disease Management. Annals of Pharmacotherapy, 2015, 49, 599-606.	1.9	3
2052	Clopidogrel Response Variability: Etiology and Clinical Relevance. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	1
2053	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. Circulation: Cardiovascular Interventions, 2015, 8, e002301.	3.9	58
2054	Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. Current Atherosclerosis Reports, 2015, 17, 501.	4.8	3

#	ARTICLE	IF	CITATIONS
2055	Use of Novel Antiplatelet Agents in Acute Coronary Syndromes. Current Atherosclerosis Reports, 2015, 17, 483.	4.8	1
2056	High On-Treatment Platelet Reactivity Associated With Prasugrel. Journal of Pharmacy Technology, 2015, 31, 38-42.	1.0	1
2057	Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. Revista Espanola De Cardiologia (English Ed), 2015, 68, 838-845.	0.6	4
2058	Oral dual antiplatelet therapy: what have we learnt from recent trials?. European Heart Journal, 2015, 37, ehv377.	2.2	15
2059	A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. Thrombosis Research, 2015, 136, 613-619.	1.7	4
2060	The pharmacogenetic control of antiplatelet response: candidate genes and <i>CYP2C19</i> . Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1599-1617.	3.3	22
2061	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2015, , 953-973.		0
2062	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
2063	Strategies for managing aortoiliac occlusions: access, treatment and outcomes. Expert Review of Cardiovascular Therapy, 2015, 13, 551-563.	1.5	50
2064	The Transradial Approach and Antithrombotic Therapy. Interventional Cardiology Clinics, 2015, 4, 213-223.	0.4	0
2065	Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Korean Volunteers. Clinical Therapeutics, 2015, 37, 563-573.	2.5	16
2066	Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry. International Journal of Cardiology, 2015, 187, 354-360.	1.7	9
2067	Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 977-993.	3.3	1
2068	Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. American Journal of Cardiology, 2015, 116, 339-343.	1.6	30
2069	Bleeding Avoidance Strategies During Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2015, 65, 2225-2238.	2.8	41
2070	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. Postgraduate Medical Journal, 2015, 91, 284-290.	1.8	1
2071	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2015, 131, 1047-1053.	1.6	73
2072	Dual Antiplatelet Therapy Duration After the Placement of a Drug-Eluting Stent: What Are the Data?. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 367.	0.9	2

#	ARTICLE	IF	CITATIONS
2073	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. American Journal of Cardiology, 2015, 115, 716-723.	1.6	30
2074	Initial Experience With the Absorb Bioresorbable Vascular Scaffold Below the Knee. Journal of Endovascular Therapy, 2015, 22, 226-232.	1.5	29
2076	Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 625-637.	3.3	7
2077	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	13.7	59
2078	Adherence to antiplatelet therapy after percutaneous coronary intervention. Journal of Cardiovascular Medicine, 2015, 16, 230-237.	1.5	5
2079	Evaluating the bioequivalence of clopidogrel generic formulations. Current Medical Research and Opinion, 2015, 31, 861-864.	1.9	2
2080	Association of Spontaneous Bleeding and Myocardial Infarction With Long-Term Mortality After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 65, 1411-1420.	2.8	101
2081	Overcoming Aspirin Resistance with Loading Clopidogrel Earlier in Elective Percutaneous Coronary Intervention. International Journal of Angiology, 2015, 24, 19-24.	0.6	2
2082	A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. Cardiology and Therapy, 2015, 4, 95-116.	2.6	13
2083	Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. Current Medical Research and Opinion, 2015, 31, 2313-2323.	1.9	20
2085	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. Current Cardiology Reports, 2015, 17, 64.	2.9	1
2086	Optimal Duration of Dual Antiplatelet Therapy After Coronary Stent Implantation. American Journal of Cardiology, 2015, 116, 1631-1636.	1.6	1
2087	Antiplatelet therapy and exodontia. Journal of the American Dental Association, 2015, 146, 851-856.	1.5	14
2088	Duration of Dual Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology, 2015, 66, 832-847.	2.8	105
2089	Dual antiplatelet therapy: optimal timing, management, and duration. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 198-204.	3.0	32
2090	Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial. Current Medical Research and Opinion, 2015, 31, 449-457.	1.9	2
2091	Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism. Clinica Chimica Acta, 2015, 451, 240-246.	1.1	22
2092	Interventional Cardiology in the Elderly. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
2093	Controversies in Cardiology. , 2015, , .		0
2094	Duration of Dual Anti-Platelet Therapy Post-Percutaneous Intervention: Is There A Correct Amount of Time?. Progress in Cardiovascular Diseases, 2015, 58, 285-298.	3.1	6
2096	Effect of traditional Uyghur medicine abnormal Savda Munziq extract on rabbit platelet aggregation in vitro and rat arteriovenous shunt thrombosis in vivo. Journal of Ethnopharmacology, 2015, 159, 184-188.	4.1	14
2097	Clopidogrel: A multifaceted affair. Journal of Clinical Pharmacology, 2015, 55, 1-9.	2.0	7
2098	Long term outcomes in octogenarians undergoing percutaneous coronary intervention: Comparison of bare metal versus drug eluting stent. International Journal of Cardiology, 2015, 179, 385-389.	1.7	10
2099	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. Journal of the American College of Cardiology, 2015, 65, 777-786.	2.8	322
2100	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2015, 39, 23-34.	2.1	25
2101	Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective percutaneous coronary intervention. Heart and Vessels, 2015, 30, 572-579.	1.2	1
2103	Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. Vascular Health and Risk Management, 2016, 12, 263.	2.3	8
2104	An Overview of Antiplatelets for Acute Coronary Syndromes. Journal of General Practice (Los Tj ETQq1 1 0.784314 rgBT /Overlock 10 TH	0.1	0
2105	The Role of Genetics in Acute Coronary Syndrome. , 2016, , 25-55.		0
2106	When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?. Arquivos Brasileiros De Cardiologia, 2016, 106, 236-46.	0.8	4
2107	Identification of clinically significant drug-drug interactions in cardiac intensive care units of two tertiary care hospitals in Peshawar, Pakistan. Tropical Journal of Pharmaceutical Research, 2016, 15, 2289.	0.3	3
2108	P2Y12-ADP receptor antagonists: Days of future and past. World Journal of Cardiology, 2016, 8, 327.	1.5	19
2109	Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism. Case Reports in Medicine, 2016, 2016, 1-4.	0.7	2
2110	P2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model. Journal of Clinical Medicine, 2016, 5, 72.	2.4	1
2112	Decision making on timing of surgery for hip fracture patients on clopidogrel. Annals of the Royal College of Surgeons of England, 2016, 98, 91-95.	0.6	14
2113	Comprehensive, Population-Based Sensitivity Analysis of a Two-Mass Vocal Fold Model. PLoS ONE, 2016, 11, e0148309.	2.5	9

#	ARTICLE	IF	CITATIONS
2114	Lumbar puncture in patients using anticoagulants and antiplatelet agents. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 679-686.	0.8	13
2115	Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome. <i>Drug Metabolism Letters</i> , 2016, 10, 65-70.	0.8	7
2116	High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 70-76.	1.0	19
2117	Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2016, 27, 580-585.	0.7	0
2118	Impact of anticoagulation regimen prior to revascularization in patients with nonâ€œST</scp>â€œsegment elevation acute coronary syndromes: The <scp>ACUITY</scp> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 174-181.	1.7	4
2119	Safety and efficacy of policosanol in patients with high onâ€œtreatment platelet reactivity after drugâ€œeluting stent implantation: twoâ€œyear followâ€œup results. <i>Cardiovascular Therapeutics</i> , 2016, 34, 337-342.	2.5	11
2120	Exome sequencing of extreme clopidogrel response phenotypes identifies <i>B4GALT2</i> as a determinant of onâ€œtreatment platelet reactivity. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 287-294.	4.7	22
2124	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
2125	Systematic review and meta-analysis of optimal P2Y₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. <i>Open Heart</i> , 2016, 3, e000296.	2.3	13
2126	Managing acute coronary syndromes: troponin and DAPT in the real world. <i>European Heart Journal</i> , 2016, 37, 3303-3306.	2.2	0
2127	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw051.	4.0	5
2128	The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients. <i>Medicine (United States)</i> , 2016, 95, e5306.	1.0	13
2129	Outcomes of â€œ6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation. <i>Medicine (United States)</i> , 2016, 95, e5819.	1.0	10
2130	2016 ACC/AHA Guideline FocusedÂ€Update on Duration of DualÂ€Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	2.8	1,232
2131	Direct oral anticoagulant use and stent thrombosis following an acute coronary syndrome: A potential new pharmacological option?. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 359-369.	1.6	1
2132	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2016, 134, e156-78.	1.6	105
2133	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With CoronaryÂ€Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1116-1139.	2.8	154
2134	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19

#	ARTICLE	IF	CITATIONS
2135	Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. <i>American Heart Journal</i> , 2016, 178, 37-44.	2.7	20
2136	Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016, 216, 190-193.	1.7	6
2137	One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 337-347.	1.6	7
2138	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	1.7	9
2139	Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. <i>Current Atherosclerosis Reports</i> , 2016, 18, 35.	4.8	12
2140	Ticagrelor for patients with acute coronary syndromes: PLATonic affair or lasting SWEDEHEART?. <i>European Heart Journal</i> , 2016, 37, 3343-3346.	2.2	10
2141	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1170-1185.	1.7	243
2142	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 319-321.	0.2	0
2143	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1243-1275.	0.8	249
2144	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1413-1447.	3.0	10
2145	Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1491-1502.	3.3	8
2146	Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team's safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. <i>American Heart Journal</i> , 2016, 182, 1-8.	2.7	7
2147	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1084-1093.	3.0	6
2148	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	2.9	21
2149	Structure-activity relationship studies for multitarget antithrombotic drugs. <i>Future Medicinal Chemistry</i> , 2016, 8, 2305-2355.	2.3	8
2150	Effect of Smoking Status on Clinical Outcome and Efficacy of Clopidogrel in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2016, 80, 1590-1599.	1.6	14
2151	Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	42
2152	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	2.9	38

#	ARTICLE	IF	CITATIONS
2153	Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. <i>Journal of Psychosomatic Research</i> , 2016, 90, 10-32.	2.6	64
2154	Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1125-1129.	1.8	6
2155	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. <i>American Heart Journal</i> , 2016, 179, 10-18.	2.7	14
2156	Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 521-530.	1.4	38
2157	The generic modeling fallacy: Average biomechanical models often produce non-average results!. <i>Journal of Biomechanics</i> , 2016, 49, 3609-3615.	2.1	24
2159	Perioperative management of dual anti-platelet therapy. <i>Hospital Practice (1995)</i> , 2016, 44, 237-241.	1.0	2
2160	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , 2016, 6, 33054.	3.3	14
2161	Protective Effects of Ticagrelor on Myocardial Injury After Infarction. <i>Circulation</i> , 2016, 134, 1708-1719.	1.6	101
2163	Genotype Frequencies of CYP2C19, P2Y ₁₂ and GPIIb Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. <i>International Heart Journal</i> , 2016, 57, 586-592.	1.0	19
2164	Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting. <i>Medicine (United States)</i> , 2016, 95, e3663.	1.0	6
2165	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016, 134, e123-55.	1.6	1,069
2166	Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a <i>Leaders Free ACS</i> sub-study. <i>European Heart Journal</i> , 2017, 38, ehw203.	2.2	57
2167	Dual antiplatelet therapy after coronary stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1775-1787.	1.8	11
2168	Why we need intravenous antiplatelet agents. <i>Future Cardiology</i> , 2016, 12, 553-561.	1.2	4
2169	Acute coronary syndromes in women and men. <i>Nature Reviews Cardiology</i> , 2016, 13, 471-480.	13.7	90
2170	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 319-321.	0.5	1
2171	Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 518-524.	1.8	18
2172	Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes. <i>Journal of Pharmacy Practice</i> , 2016, 29, 239-249.	1.0	10

#	ARTICLE	IF	CITATIONS
2173	Reperfusion Therapy for Acute Myocardial Infarction. , 0, , .		0
2175	The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. International Journal of Cardiology, 2016, 207, 128-131.	1.7	7
2176	The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents. Current Cardiology Reports, 2016, 18, 8.	2.9	4
2177	Medication Adherence Following Acute Coronary Syndrome: Does One Size Fit All?. American Journal of Cardiovascular Drugs, 2016, 16, 9-17.	2.2	1
2178	Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence. Clinical Therapeutics, 2016, 38, 961-973.	2.5	1
2179	Antiplatelet Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 221-237.	0.4	5
2180	Current status of data on cangrelor. , 2016, 159, 102-109.		39
2181	P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology, 2016, 97, 101-106.	2.2	15
2182	Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Thrombosis Research, 2016, 139, 114-120.	1.7	11
2183	Pivotal Bioequivalence Study of ClopacinÂ®, a Generic Formulation of Clopidogrel 75Âmg Film-Coated Tablets. Advances in Therapy, 2016, 33, 186-198.	2.9	5
2184	Reviewing the controversy surrounding pre-treatment with P2Y12inhibitors in acute coronary syndrome patients. Expert Review of Cardiovascular Therapy, 2016, 14, 811-820.	1.5	13
2185	Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial. American Heart Journal, 2016, 173, 134-142.	2.7	17
2186	Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genetics in Medicine, 2016, 18, 833-841.	2.4	14
2187	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2016, 117, 192-200.	1.6	16
2188	Pre-treatment with P2Y₁₂inhibitors in ACS patients: who, when, why, and which agent?. European Heart Journal, 2016, 37, 1284-1295.	2.2	52
2189	In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 271-276.	1.0	1
2190	Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes. Herz, 2016, 41, 246-249.	1.1	8
2191	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	2.2	5,890

#	ARTICLE	IF	CITATIONS
2192	Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 282-288.	1.0	3
2193	A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. <i>Pharmacogenomics Journal</i> , 2016, 16, 71-78.	2.0	35
2194	Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Heart and Vessels</i> , 2016, 31, 269-274.	1.2	9
2195	Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting. <i>Journal of Cardiology</i> , 2017, 69, 156-161.	1.9	12
2196	Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: An optical coherence tomography study. <i>Journal of Cardiology</i> , 2017, 69, 436-441.	1.9	10
2197	Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E99-E103.	1.7	10
2198	Oral Antiplatelet Therapy in Coronary Disease. <i>American Journal of Therapeutics</i> , 2017, 24, e744-e750.	0.9	2
2199	Antiplatelet therapies in patients with an indication for anticoagulation. <i>Clinical Hemorheology and Microcirculation</i> , 2017, 64, 273-278.	1.7	4
2200	Oral antiplatelet agents for the management of acute coronary syndromes. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 104-115.	0.9	2
2201	Editor's Choice "Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2017, 53, 403-410.	1.5	20
2203	Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment. <i>Pharmacological Research</i> , 2017, 119, 36-47.	7.1	48
2204	Outcome After Surgery for Acute Aortic Dissection: Influence of Preoperative Antiplatelet Therapy on Prognosis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 569-574.	1.3	17
2205	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 949-956.	2.4	59
2206	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". <i>American Heart Journal</i> , 2017, 188, 11-17.	2.7	13
2207	Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. <i>Platelets</i> , 2017, 28, 786-793.	2.3	24
2208	Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. <i>Heart</i> , 2017, 103, 871-884.	2.9	4
2209	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	13.7	35
2210	Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. <i>International Journal of Cardiology</i> , 2017, 235, 61-66.	1.7	22

#	ARTICLE	IF	CITATIONS
2211	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
2212	Sex differences in cardiovascular disease – Impact on care and outcomes. <i>Frontiers in Neuroendocrinology</i> , 2017, 46, 46-70.	5.2	179
2214	Cangrelor. <i>Interventional Cardiology Clinics</i> , 2017, 6, 39-47.	0.4	5
2215	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 61-70.	1.8	20
2216	Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. <i>Netherlands Heart Journal</i> , 2017, 25, 409-415.	0.8	8
2217	Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2017, 28, 478-485.	0.7	3
2219	Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate. <i>Anesthesia and Analgesia</i> , 2017, 124, 1091-1098.	2.2	11
2220	Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. <i>Medicine (United States)</i> , 2017, 96, e6553.	1.0	18
2221	The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 561-572.	2.4	21
2222	The use of intravenous tPA for the treatment of severe frostbite. <i>Burns</i> , 2017, 43, 1088-1096.	1.9	28
2223	Re chronic stable angina guidelines. <i>Indian Heart Journal</i> , 2017, 69, 129-132.	0.5	0
2224	Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. <i>Interventional Cardiology Clinics</i> , 2017, 6, 141-149.	0.4	11
2225	Antiplatelet agents in hemodialysis. <i>Journal of Nephrology</i> , 2017, 30, 373-383.	2.0	9
2226	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. <i>Journal of Interventional Cardiology</i> , 2017, 30, 5-15.	1.2	8
2227	Dual antiplatelet therapy for secondary prevention of coronary artery disease. <i>Open Heart</i> , 2017, 4, e000651.	2.3	49
2228	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2048-2090.	2.8	146
2229	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1760-1776.	2.8	140
2230	Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 3207-3212.	1.8	1

#	ARTICLE	IF	CITATIONS
2231	Caesarean delivery during dual antiplatelet therapy after acute myocardial infarction and stenting. Case Reports in Perinatal Medicine, 2017, 6, .	0.1	1
2232	To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question. Journal of the American Heart Association, 2017, 6, .	3.7	1
2233	The prescription of antiplatelet medication in a very elderly population: An observational study in 15141 ambulatory subjects. International Journal of Clinical Practice, 2017, 71, e13020.	1.7	3
2234	Precatheterization Use of P2Y ₁₂ Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry. Journal of the American Heart Association, 2017, 6, .	3.7	9
2235	Effects With and Without Clopidogrel Loading Treatment for Acute Ischemic Cerebrovascular Disease Patients: A Retrospective Cohort Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2901-2908.	1.6	5
2236	Many shades of grey: seeking the optimal medical therapy of acute coronary syndrome in older people. Journal of Pharmacy Practice and Research, 2017, 47, 403-410.	0.8	0
2237	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	71
2238	Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. Journal of Thrombosis and Thrombolysis, 2017, 44, 303-315.	2.1	5
2239	Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. Expert Review of Cardiovascular Therapy, 2017, 15, 681-693.	1.5	4
2240	Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Journal of Interventional Cardiology, 2017, 30, 457-464.	1.2	8
2242	A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. Scientific Reports, 2017, 7, 16021.	3.3	6
2243	Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 323-331.	2.1	12
2244	Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Current Atherosclerosis Reports, 2017, 19, 56.	4.8	16
2245	The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Research in Cardiology, 2017, 112, 64.	5.9	42
2246	Antiplatelet Therapy for Percutaneous Coronary Intervention: Something Old and Something New. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	0
2247	P2Y12 receptor inhibitor resistance and coronary artery disease. Current Opinion in Cardiology, 2017, 32, 617-626.	1.8	1
2249	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. International Journal of Cardiology, 2017, 229, 82-89.	1.7	12
2250	Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. Catheterization and Cardiovascular Interventions, 2017, 89, 1176-1184.	1.7	5

#	ARTICLE	IF	CITATIONS
2251	A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovascular Revascularization Medicine, 2017, 18, 79-85.	0.8	28
2252	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 133-141.	2.0	2
2253	Pharmacodynamic effects of a new fixed-dose clopidogrel+aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Platelets, 2017, 28, 187-193.	2.3	4
2254	Optimizing the Use of Cangrelor in the Real World. American Journal of Cardiovascular Drugs, 2017, 17, 5-16.	2.2	7
2255	Percutaneous Treatment of Cardiovascular Diseases in Women. , 2017, , .		0
2256	Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, 13-24.	0.4	6
2257	Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, 25-37.	0.4	8
2258	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. The Cochrane Library, 2017, 2017, CD005158.	2.8	50
2259	Antithrombotic therapy for acute coronary syndrome: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1240-1248.	3.4	41
2260	One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper. Acta Cardiologica, 2017, 72, 19-27.	0.9	3
2261	The dawn of neurosurgery in pre-conquest Mesoamerican territories. Child's Nervous System, 2017, 33, 1621-1629.	1.1	3
2262	A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. Thrombosis and Haemostasis, 2017, 117, 303-310.	3.4	25
2263	On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. Thrombosis and Haemostasis, 2017, 117, 1644-1650.	3.4	6
2264	Impact of Double Loading Regimen of Clopidogrel on Final Angiographic Results, Incidence of Upper Gastrointestinal Bleeding and Clinical Outcomes in Patients with STEMI Undergoing Primary Coronary Intervention. International Heart Journal, 2017, 58, 686-694.	1.0	1
2265	Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial. Trials, 2017, 18, 529.	1.6	5
2266	Platelet turnover predicts outcome after coronary intervention. Thrombosis and Haemostasis, 2017, 117, 923-933.	3.4	37
2267	Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients. Brazilian Journal of Medical and Biological Research, 2017, 50, e5660.	1.5	13
2268	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures. European Heart Journal Supplements, 2017, 19, D151-D162.	0.1	1

#	ARTICLE	IF	CITATIONS
2269	Regional anesthesia and antithrombotic agents: instructions for use. Minerva Anestesiologica, 2017, 83, 321 - 335.	1.0	4
2270	CYP2C19<math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:msup><mml:mrow>/></mml:mrow><mml:mo>âŽ</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math>2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls. BioMed Research International, 2017, 2017, 1-6.	1.9	5
2271	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetology and Metabolic Syndrome, 2017, 9, 53.	2.7	34
2272	The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovascular Drugs and Therapy, 2017, 31, 433-444.	2.6	4
2274	Advances in Antiplatelet Agents. , 2017, , 556-599.		1
2275	Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. Thrombosis Research, 2018, 164, 17-23.	1.7	9
2276	Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 17.	0.9	1
2278	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation, 2018, 137, 2435-2445.	1.6	116
2279	Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy â€œReal Worldâ€œExperience. Progress in Cardiovascular Diseases, 2018, 60, 531-536.	3.1	7
2280	Evidence and prospective of plant derived flavonoids as antiplatelet agents: Strong candidates to be drugs of future. Food and Chemical Toxicology, 2018, 119, 355-367.	3.6	66
2281	The evolution of coronary stents. Expert Review of Cardiovascular Therapy, 2018, 16, 219-228.	1.5	47
2282	Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity. Circulation, 2018, 137, 2231-2245.	1.6	68
2283	The Timing of P2Y 12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?. Progress in Cardiovascular Diseases, 2018, 60, 471-477.	3.1	6
2284	Early versus delayed invasive strategy for intermediateâ€œand highâ€œrisk acute coronary syndromes managed without P2Y₁₂ receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial. Clinical Cardiology, 2018, 41, 5-12.	1.8	6
2285	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. , 2018, , 119-172.		0
2286	The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist. Mayo Clinic Proceedings, 2018, 93, 199-216.	3.0	1
2287	Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opinion on Pharmacotherapy, 2018, 19, 103-112.	1.8	25
2288	Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS. Herz, 2018, 43, 11-19.	1.1	2

#	ARTICLE	IF	CITATIONS
2289	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	1.7	181
2290	PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 448-456.	2.4	79
2291	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490.	3.1	61
2292	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 36-45.	3.0	14
2293	Optimal treatment of patients with NSTEMI-ACS in the Dutch health care system. <i>Netherlands Heart Journal</i> , 2018, 26, 289-295.	0.8	1
2294	Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 234-239.	1.5	2
2295	Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004194.	2.2	18
2296	First 24h in the management of non-ST segment elevation myocardial infarction. <i>European Heart Journal Supplements</i> , 2018, 20, B29-B38.	0.1	1
2297	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. <i>International Journal of Cardiology</i> , 2018, 259, 20-25.	1.7	18
2298	Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. <i>European Heart Journal Supplements</i> , 2018, 20, B21-B28.	0.1	2
2299	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2018, 13, 1019-1028.	2.0	2
2300	Incidence and predictors of bleeding among Egyptian patients presenting with acute coronary syndrome: Using CRUSADE risk score. <i>Egyptian Heart Journal</i> , 2018, 70, 135-142.	1.2	0
2301	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018, 69, 795-802.	1.8	35
2302	6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 1274-1284.	13.7	261
2303	Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 135-145.	2.3	24
2304	Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 452-461.	1.7	1
2305	Ticagrelor for Neuroendovascular Procedures: A Case Series. <i>Journal of Pharmacy Practice</i> , 2018, 31, 115-119.	1.0	12
2306	Personalizing antiplatelet therapies: What have we learned from recent trials?. <i>Platelets</i> , 2018, 29, 131-139.	2.3	8

#	ARTICLE	IF	CITATIONS
2307	Clinical outcomes of patients with acute coronary syndrome and moderate or severe chronic anaemia undergoing coronary angiography or intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 646-651.	1.0	5
2308	Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1072-1080.	1.3	8
2309	Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review. <i>Journal of Pharmacy Practice</i> , 2018, 31, 335-341.	1.0	1
2310	Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?. <i>Platelets</i> , 2018, 29, 228-237.	2.3	3
2311	The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 242-250.	1.7	4
2312	Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	1.7	5
2313	Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Pharmacokinetics</i> , 2018, 57, 817-829.	3.5	12
2314	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018, 197, 133-141.	2.7	17
2315	Non-ST-Segment Acute Coronary Syndromes. <i>Cardiology Clinics</i> , 2018, 36, 37-52.	2.2	39
2316	DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF ASPIRIN, ROSUVASTATIN, CLOPIDOGREL IN BULK AND PHARMACEUTICAL DOSAGE FORM. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 10, 50.	0.3	6
2317	Diabetes and antiplatelet therapy: from bench to bedside. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 594-609.	1.7	45
2318	Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 72, 296-302.	1.9	12
2319	Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. <i>TH Open</i> , 2018, 02, e357-e368.	1.4	3
2320	Antiplatelet agents in uncertain clinical scenarios – a bleeding nightmare. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 647-662.	1.7	7
2321	Monitoring platelet function: what have we learned from randomized clinical trials?. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 621-629.	1.7	5
2322	Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 217.	1.7	33
2323	ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2915-2931.	2.8	273
2324	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1041-1052.	2.4	20

#	ARTICLE	IF	CITATIONS
2325	Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. <i>BMJ</i> : British Medical Journal, 2018, 363, k3793.	2.3	125
2326	Parameter Estimation of Platelets Deposition: Approximate Bayesian Computation With High Performance Computing. <i>Frontiers in Physiology</i> , 2018, 9, 1128.	2.8	5
2327	Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 735-748.	1.5	8
2328	Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2341-2346.	3.8	11
2329	Real-world incidence of patient-reported dyspnoea with ticagrelor. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 577-584.	2.4	10
2330	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. <i>Cardiovascular Innovations and Applications</i> , 2018, 3, .	0.3	0
2331	MWCNT/CdSe quantum dot modified glassy carbon electrode for the determination of clopidogrel bisulfate in tablet dosage form and serum samples. <i>Journal of Electroanalytical Chemistry</i> , 2018, 827, 51-57.	3.8	13
2332	Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarctionâ€• The CALDERA-GENE Study â€•. <i>Circulation Journal</i> , 2018, 82, 1517-1525.	1.6	9
2333	The Incidence of Myocardial Injury after Loading Doses of Clopidogrel versus Prasugrel in the Candidates for Percutaneous Coronary Intervention: A Randomized Controlled Trial. <i>Critical Pathways in Cardiology</i> , 2018, 17, 69-72.	0.5	3
2334	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. <i>Critical Pathways in Cardiology</i> , 2018, 17, 53-68.	0.5	2
2335	Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials. <i>International Journal of Cardiology</i> , 2018, 264, 30-38.	1.7	20
2336	Clinical safety profile of ticagrelor compared to clopidogrel in 1208 patients: Real world evidence. <i>Egyptian Heart Journal</i> , 2018, 70, 375-378.	1.2	5
2337	Non-ST-Elevation Myocardial Infarction: Management. , 2018, , 522-530.		0
2338	Acute myocardial infarction occurring while on chronic clopidogrel therapy (â€~clopidogrel failureâ€™™) is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. <i>PLoS ONE</i> , 2018, 13, e0195504.	2.5	2
2339	Thromboelastography evaluation of low response to clopidogrel in patients with acute coronary syndrome. <i>International Journal of Gerontology</i> , 2018, 12, 43-47.	0.6	1
2340	Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice. <i>American Heart Journal</i> , 2018, 203, 74-81.	2.7	2
2341	Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. <i>Journal of Clinical Medicine</i> , 2018, 7, 74.	2.4	5
2342	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 766-790.	1.7	44

#	ARTICLE	IF	CITATIONS
2344	Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI. , 2018, , 99-108.		0
2345	Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. BMC Geriatrics, 2018, 18, 86.	2.7	3
2346	Strategies in Acute Coronary Syndrome. , 2018, , 921-938.		2
2347	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.1	25
2348	Polyphenols: Anti-Platelet Nutraceutical?. Current Pharmaceutical Design, 2018, 24, 146-157.	1.9	14
2349	Antiplatelet and anticoagulation therapy during percutaneous coronary interventions: A review for the interventionalist. Journal of Interventional Cardiology, 2018, 31, 693-704.	1.2	2
2350	Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction. Hellenic Journal of Cardiology, 2019, 60, 296-302.	1.0	8
2351	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
2352	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	1.4	402
2353	The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. Journal of NeuroInterventional Surgery, 2019, 11, 352-356.	3.3	19
2354	Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2019, 72, 215-223.	0.6	4
2355	Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 509-520.	2.0	40
2356	Non-ST Elevation Myocardial Infarction: Diagnosis and Management. , 0, , .		3
2357	Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic. , 2019, 203, 107393.		20
2358	â€œTicagrelor or Prasugrel, Doctor?â€•The Basis for Decision in Clinical Practice. Canadian Journal of Cardiology, 2019, 35, 1283-1285.	1.7	2
2359	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety, 2019, 18, 1171-1189.	2.4	23
2361	Fifty years of research on antithrombotic therapy: Achievements and disappointments. European Journal of Internal Medicine, 2019, 70, 1-7.	2.2	17
2363	Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel. Turkish Journal of Medical Sciences, 2019, 49, 1358-1365.	0.9	1

#	ARTICLE	IF	CITATIONS
2364	Oxidative pathways of arachidonic acid as targets for regulation of platelet activation. Prostaglandins and Other Lipid Mediators, 2019, 145, 106382.	1.9	24
2365	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	13.7	155
2366	16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. European Heart Journal, 2020, 41, 847-854.	2.2	39
2367	Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. Atherosclerosis, 2019, 289, 118-125.	0.8	6
2368	Risk of Gastrointestinal Bleed and Endoscopic Procedures on Antiplatelet and Antithrombotic Agents. Journal of Digestive Endoscopy, 2019, 10, 011-020.	0.2	0
2369	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation Research, 2019, 124, 416-425.	4.5	29
2370	Effects of Catheterization on Artery Function and Health: When Should Patients Start Exercising Following Their Coronary Intervention?. Sports Medicine, 2019, 49, 397-416.	6.5	5
2371	Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery, 2019, 69, 3S-125S.e40.	1.1	841
2372	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S1-S109.e33.	1.5	741
2373	Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Vascular Pharmacology, 2019, 120, 106564.	2.1	12
2374	Changing Paradigms of Periprocedural Antithrombotic Therapy in Neuroendovascular Therapy: Analysis of JR-NET 3. Neurologia Medico-Chirurgica, 2019, 59, 247-256.	2.2	9
2375	Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. Thrombosis Research, 2019, 179, 87-94.	1.7	8
2377	Refining Antithrombotic Therapy for Atrial Fibrillation and Acute Coronary Syndromes or PCI. New England Journal of Medicine, 2019, 380, 1580-1581.	27.0	14
2378	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine, 2019, 380, 1825-1833.	27.0	96
2379	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y ₁₂ Inhibitor Pretreatment. Circulation: Cardiovascular Interventions, 2019, 12, e007445.	3.9	0
2380	Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials. Atherosclerosis, 2019, 284, 136-147.	0.8	11
2381	Pre-treatment with a P2Y ₁₂ antagonist before PCI in STEMI: why should we wait?. European Heart Journal, 2019, 40, 1211-1213.	2.2	14
2382	Pretreatment with P2Y ₁₂ receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. European Heart Journal, 2019, 40, 1202-1210.	2.2	34

#	ARTICLE	IF	CITATIONS
2383	Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy. American Journal of Cardiology, 2019, 123, 1878-1883.	1.6	4
2384	P2Y12 Antagonists. , 2019, , 937-956.		1
2385	Novel Antiplatelet Therapies. , 2019, , 991-1015.		1
2386	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
2387	Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. Thrombosis and Haemostasis, 2019, 119, 1000-1020.	3.4	15
2388	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology, 2019, 42, 498-505.	1.8	24
2389	Interval From Initiation of Prasugrel toÂCoronary Angiography in PatientsÂWith NonÂ€ST-Segment ElevationÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2019, 73, 906-914.	2.8	14
2390	Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation. Journal of the American College of Cardiology, 2019, 73, 915-918.	2.8	11
2391	Clinical trials in long-term antiplatelet therapies. Current Opinion in Cardiology, 2019, 34, 315-322.	1.8	2
2392	Antithrombotic Management After Intracranial Hemorrhage. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 88.	0.9	2
2393	Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. Irish Journal of Medical Science, 2019, 188, 453-467.	1.5	4
2394	Clopidogrel Hypersensitivity: Overview of the Problem. Current Vascular Pharmacology, 2019, 17, 108-109.	1.7	0
2395	Antiplatelet Therapy. , 2019, , 379-393.e4.		1
2396	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	1.6	9
2397	Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention. Platelets, 2019, 30, 1030-1035.	2.3	4
2398	Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety. Annals of Pharmacotherapy, 2019, 53, 726-737.	1.9	17
2399	Effectiveness and Safety of Clopidogrel Co-administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. Clinical Pharmacology and Therapeutics, 2019, 106, 182-194.	4.7	4
2400	â€œNo Such Thing as a Free Lunchâ€ Personalized P2Y ₁₂ Inhibition to Optimize Patient Outcomes. Journal of the American Heart Association, 2019, 8, e011660.	3.7	2

#	ARTICLE	IF	CITATIONS
2401	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. International Journal of Cardiology, 2019, 275, 39-45.	1.7	12
2402	Unstable Angina and Non-ST Elevation Myocardial Infarction. Contemporary Cardiology, 2019, , 233-259.	0.1	0
2403	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
2404	Modern Management of ST-Segment Elevation Myocardial Infarction. Current Problems in Cardiology, 2020, 45, 100393.	2.4	26
2405	Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?. Cardiovascular Revascularization Medicine, 2020, 21, 182-188.	0.8	0
2406	Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends in Cardiovascular Medicine, 2020, 30, 198-202.	4.9	4
2407	Evaluation of an in vitro coronary stent thrombosis model for preclinical assessment. Platelets, 2020, 31, 167-173.	2.3	2
2408	Dual antiplatelet therapy beyond 12 months versus for 12 months after drug-eluting stents for acute myocardial infarction. Journal of Cardiology, 2020, 75, 66-73.	1.9	9
2409	Study on the characteristic of intestinal flora in patients with dual antiplatelet therapy. Journal of Drug Targeting, 2020, 28, 500-507.	4.4	4
2410	Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Internal Medicine, 2020, 59, 311-321.	0.7	25
2411	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 57-68.	3.0	13
2412	Carotid artery stenting is safe and effective for symptomatic patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2020, 96, 129-135.	1.7	1
2413	Effect on 30-Day Readmissions after Early Versus Delayed Discharge after Uncomplicated Transcatheter Aortic Valve Implantation (from the Nationwide Readmissions Database). American Journal of Cardiology, 2020, 125, 100-106.	1.6	4
2414	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Diabetes, Obesity and Metabolism, 2020, 22, 30-38.	4.4	4
2415	Antiplatelet agents: past, present and future. ISBT Science Series, 2020, 15, 131-141.	1.1	9
2416	Benefits of short-term or prolonged as compared to standard 1-year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. Journal of Thrombosis and Thrombolysis, 2020, 50, 337-354.	2.1	7
2417	Multistage release matrices for potential antiplatelet therapy: Assessing the impact of polymers and Sorb-Cel MA® on floating, swelling, and release behavior. Journal of Drug Delivery Science and Technology, 2020, 55, 101387.	3.0	5
2418	Assessment of platelet function after discontinuation of ticagrelor. Acta Anaesthesiologica Scandinavica, 2020, 64, 526-531.	1.6	3

#	ARTICLE	IF	CITATIONS
2419	Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. Cardiovascular Intervention and Therapeutics, 2020, 35, 19-29.	2.3	37
2420	Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 76, 2450-2459.	2.8	64
2421	Effect of CYP3A4*22 and PPAR-Î± Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes, 2020, 11, 1068.	2.4	2
2422	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
2423	Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin. Scientific Reports, 2020, 10, 16723.	3.3	6
2424	Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes With Outcomes. JAMA Network Open, 2020, 3, e2018735.	5.9	48
2425	Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiology Clinics, 2020, 38, 551-561.	2.2	2
2426	Acute coronary syndromes with high thrombotic burden: therapeutic innovations. European Heart Journal Supplements, 2020, 22, L97-L100.	0.1	0
2427	Comparison of QT dispersion in patients with ST elevation acute myocardial infarction (STEMI) before and after treatment by streptokinase versus primary percutaneous coronary intervention (PCI). BMC Cardiovascular Disorders, 2020, 20, 493.	1.7	7
2428	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation, 2020, 142, 2172-2188.	1.6	26
2429	Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study. BMJ Open, 2020, 10, e042229.	1.9	4
2430	Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. Handbook of Experimental Pharmacology, 2020, , 1.	1.8	10
2431	Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs. Pharmaceutics, 2020, 12, 685.	4.5	20
2432	<i>CYP2C19</i> genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics, 2020, 21, 889-897.	1.3	13
2433	Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 2578.	2.4	1
2434	Factors Influencing Provider and Patient Choice of P2Y12 Inhibitor Therapy. Journal of Pharmacy Practice, 2020, , 089719002096617.	1.0	0
2435	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 56-64.	3.0	17
2436	Pre-Treatment With Oral P2Y12 Inhibitors in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2020, 13, 918-920.	2.9	2

#	ARTICLE	IF	CITATIONS
2437	Synthesis and antithrombotic activity of 1-benzyl-N-2-benzylidenepiperidine-3-carbohydrazide derivatives. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 179-185.	1.0	1
2438	Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. <i>Drug Metabolism and Disposition</i> , 2020, 48, 230-244.	3.3	62
2439	Aspirin-free strategy versus standard term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e25-e28.	1.8	0
2440	Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1613-1618.	0.8	4
2441	P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2020, 9, 1657.	2.4	7
2442	JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2020, 84, 831-865.	1.6	197
2443	One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. <i>PLoS ONE</i> , 2020, 15, e0227612.	2.5	2
2444	New Antithrombotic Drugs in Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2059.	2.4	10
2445	Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine learning decision tree approaches. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1076-1086.	1.5	9
2446	Cangrelor in clinical use. <i>Future Cardiology</i> , 2020, 16, 89-102.	1.2	5
2447	Smoking status and mortality outcomes following percutaneous coronary intervention. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1222-1228.	1.8	10
2448	Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 117-129.	2.3	30
2449	Nonvariceal upper GI hemorrhage after percutaneous coronary intervention for acute myocardial infarction: a national analysis over 11 months. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 65-74.e2.	1.0	12
2450	Ticagrelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing Percutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. <i>American Heart Journal</i> , 2020, 225, 19-26.	2.7	14
2452	Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-12.	2.5	5
2453	Management of STEMI in Low- and Middle-Income Countries. <i>Global Heart</i> , 2020, 9, 469.	2.3	5
2454	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. <i>Global Heart</i> , 2020, 9, 457.	2.3	34
2455	Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 193-204.	2.2	1

#	ARTICLE	IF	CITATIONS
2456	Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 218-224.	3.0	12
2457	Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 140-148.	0.6	5
2458	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 86-93.	3.0	34
2459	Efficacy and safety of short-term 1â€“3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. <i>Platelets</i> , 2021, 32, 582-590.	2.3	3
2460	Pharmacology before, during and after percutaneous coronary intervention. <i>Heart</i> , 2021, 107, 585-592.	2.9	4
2461	Multiplex allele-specific detection of clinically important CYP2C19 variants associated with clopidogrel metabolism in a Bangladeshi population sample. <i>Meta Gene</i> , 2021, 27, 100830.	0.6	1
2462	Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. <i>Journal of Palliative Medicine</i> , 2021, 24, 273-284.	1.1	5
2463	Bare Metal Stents Are Obsolete and No Longer Have a Role in PCI. Stop Using Them!. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 50-51.	0.8	0
2464	Shortâ€“term vs longâ€“term dual antiplatelet therapy after drugâ€“eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and metaâ€“analysis. <i>International Journal of Clinical Practice</i> , 2021, 75, e13938.	1.7	1
2465	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	2.2	3,048
2466	Efficacy and safety outcomes of short duration antiplatelet therapy with early cessation of aspirin post percutaneous coronary intervention: a systematic review and meta-analysis. <i>Current Cardiology Reviews</i> , 2021, 17, .	1.5	1
2467	Cardiovascular Medications. , 2021, , 597-642.		1
2468	Acute coronary syndromes and percutaneous coronary interventionâ€“current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data?. , 2021, , 57-77.		0
2469	Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockadeâ€“why it could be a novel paradigm?. , 2021, , 167-191.		0
2470	Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. <i>Thrombosis and Haemostasis</i> , 2021, 121, 854-866.	3.4	8
2472	Clinical risk scores: a tool to understand bleeding and thrombotic risk. , 2021, , 145-166.		0
2473	Endovascular drug-delivery and drug-elution systems. , 2021, , 595-631.		7
2474	Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk. <i>Heart International</i> , 2021, 15, 26.	1.4	2

#	ARTICLE	IF	CITATIONS
2475	Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00738.	2.4	6
2476	Tratamiento antiagregante de muy corta duración tras la ICP y nuevos SLF: metanálisis de 5 estudios aleatorizados. <i>Revista Española De Cardiología</i> , 2021, 74, 140-148.	1.2	14
2477	Pretreatment with antiplatelet drugs improves the cardiac function after myocardial infarction without reperfusion in a mouse model. <i>Cardiology Journal</i> , 2021, 28, 118-128.	1.2	6
2478	Appropriateness of oral clopidogrel for prehospital STEMI management. <i>International Paramedic Practice</i> , 2021, 11, 4-14.	0.1	0
2479	Antithrombotic strategies in elderly patients with acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 232-245.	1.6	2
2480	Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 144.	1.7	3
2481	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <i>Journal of Clinical Medicine</i> , 2021, 10, 1923.	2.4	3
2482	Oral Antiplatelet Therapy After Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1545.	7.4	62
2483	Gender differences with short-term vs 12-months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 797-807.	2.1	6
2484	Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT "like" patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	1.7	3
2485	An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: The OPTIMA-2 randomized controlled trial. <i>American Heart Journal</i> , 2021, 234, 42-50.	2.7	6
2486	De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes. <i>CJC Open</i> , 2021, 3, 1091-1099.	1.5	1
2488	Antiplatelet Therapy And Percutaneous Coronary Interventions. <i>Current Cardiology Reviews</i> , 2021, 17, 232-243.	1.5	0
2489	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <i>Russian Journal of Cardiology</i> , 2021, 26, 4449.	1.4	63
2490	Effects of Prolonged Dual Antiplatelet Therapy in ST-Segment Elevation vs. Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation Journal</i> , 2021, 85, 817-825.	1.6	1
2491	Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. <i>PLoS ONE</i> , 2021, 16, e0251109.	2.5	0
2492	Reperfusion Strategies in Acute Myocardial Infarction: State of the Art. <i>International Journal of Cardiovascular Sciences</i> , 2021, , .	0.1	0
2493	Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction. <i>Basic Research in Cardiology</i> , 2021, 116, 36.	5.9	16

#	ARTICLE	IF	CITATIONS
2495	Prehospital clopidogrel use and STEMI management: a review. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2021, 13, 1-10.	0.1	0
2496	Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2021, 78, 384-407.	2.8	16
2497	De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials. The Cochrane Library, 2021, 2021, .	2.8	0
2498	What antithrombotic treatment is required in a patient after TAVI in the year 2021?. Intervencni A Akutni Kardiologie, 2021, 20, 111-115.	0.0	0
2499	Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis. Atherothrombosis, 2021, , 89-105.	0.3	1
2500	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 181-264.	0.8	45
2501	Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy. Journal of Clinical Medicine, 2021, 10, 2968.	2.4	15
2502	Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. Frontiers in Endocrinology, 2021, 12, 713849.	3.5	2
2503	Association of Parenteral Anticoagulation Therapy With Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Without Invasive Therapy: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project. Clinical Pharmacology and Therapeutics, 2021, 110, 1119-1126.	4.7	0
2504	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 492-502.	3.0	22
2505	Efficacy and Safety of Very Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 2021, 8, 660360.	2.4	3
2506	Antiplatelet Therapy After Percutaneous Coronary Intervention – Past, Current and Future Perspectives –. Circulation Journal, 2021, , .	1.6	1
2507	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 2569-2591.	1.3	56
2508	Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives. Microorganisms, 2021, 9, 2041.	3.6	206
2509	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Annals of Thoracic Surgery, 2021, 112, 981-1004.	1.3	88
2511	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0, , 397-425.		2
2513	Antiplatelet Agents. , 2005, , 335-367.		1
2514	Resistance to Antiplatelet Drugs. , 2010, , 449-464.		1

2516	Antiplatelet Therapy in Elderly Patients. , 2015, , 135-143.		1
2517	Pharmacology of Platelet Adhesion and Aggregation. Handbook of Experimental Pharmacology, 2004, , 437-471.	1.8	5
2518	Antikoagulantien und Thrombozytenaggregationshemmer. , 2009, , 381-395.		1
2521	Antithrombotika und AntihÄmorrhagika. , 2012, , 425-445.		2
2522	Antithrombotika und AntihÄmorrhagika. , 2013, , 413-433.		1
2523	Coronary Atherosclerosis: Acute Coronary Syndromes. , 2002, , 746-779.		1
2524	Antithrombotika und AntihÄmorrhagika. , 2015, , 477-500.		1
2525	Antithrombotika und AntihÄmorrhagika. , 2016, , 351-368.		2
2526	Antithrombotika und AntihÄmorrhagika. , 2017, , 353-372.		1
2527	Antithrombotika und AntihÄmorrhagika. , 2018, , 401-421.		3
2528	Antithrombotika und AntihÄmorrhagika. , 2019, , 531-555.		8
2529	Haemostasis and thrombosis. , 2007, , 331-346.		2
2530	Î±IIbÎ²3 (GPIIb-IIIa) Antagonists. , 2007, , 1145-1163.		7
2531	ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Nonâ€“ST-Segment Elevation Myocardial Infarctionâ€“A Summary Article. , 2011, , 385-404.		2
2532	Unstable Angina and Nonâ€“ST Elevation Myocardial Infarction. , 2012, , 1178-1209.		5
2533	Platelet Inhibitor Agents. , 2012, , 97-112.		2
2534	Utilidad de la puntuaciÃ³n PARIS para evaluar el equilibrio isquÃ©mico-hemorrÃ¡gico con ticagrelor y prasugrel tras un sÃndrome coronario agudo. Revista Espanola De Cardiologia, 2019, 72, 215-223.	1.2	6

#	ARTICLE	IF	CITATIONS
2535	Acute coronary syndromes: diagnosis and management, part I. Mayo Clinic Proceedings, 2009, 84, 917-38.	3.0	147
2536	Una historia resumida. Impacto de los avances en cardiopatía isquémica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 2-6.	0.2	1
2537	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	2.2	57
2538	Role of Antiplatelet Agents in the Primary and Secondary Prevention of Atherothrombotic Events in High Risk-Patients. Southern Medical Journal, 2008, 101, 273-283.	0.7	5
2539	Bench to Bedside: Pathophysiology of Acute Coronary Syndromes and Implications for Therapy. Academic Emergency Medicine, 2002, 9, 1029-1044.	1.8	8
2540	Clopidogrel in acute coronary syndromes. BMJ: British Medical Journal, 2009, 338, b1180-b1180.	2.3	13
2541	Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis. JCI Insight, 2018, 3, .	5.0	23
2542	P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. Journal of Clinical Investigation, 2003, 112, 398-406.	8.2	296
2543	Early Antiplatelet Therapy in Coronary Artery Bypass Grafting a Calculated Benefit. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2010, 5, 317-325.	0.9	1
2544	CVD prevention in diabetes. Independent Nurse, 2007, 2007, .	0.1	1
2545	Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy. PLoS ONE, 2016, 11, e0157812.	2.5	6
2546	Angiographic and Clinical Outcome Following Paclitaxel-Eluting Stent (Taxus) Implantation. International Heart Journal, 2006, 47, 1-12.	1.0	6
2547	A Case Report of Very Late Thrombosis of Coronary Bare-Metal Stent 10 Years After Stenting. International Heart Journal, 2007, 48, 547-552.	1.0	3
2548	Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy. European Cardiology Review, 2020, 15, 1-8.	2.2	9
2549	Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice. Interventional Cardiology Review, 2014, 9, 164.	1.6	1
2550	Twelve Months Dual Antiplatelet Therapy after Drug-eluting Stents â€“ Too Long, too Short or Just Right?. Interventional Cardiology Review, 2015, 10, 136.	1.6	2
2551	Platelet function monitoring in patients on clopidogrel. Interventional Medicine & Applied Science, 2011, 3, 32-38.	0.2	1
2552	Brain Injury Secondary to Carotid Intervention. Journal of Endovascular Therapy, 2007, 14, 219-231.	1.5	8

#	ARTICLE	IF	CITATIONS
2554	Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. Aging, 2020, 12, 12930-12942.	3.1	1
2555	Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?. Vascular Health and Risk Management, 2006, 2, 39-48.	2.3	4
2556	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vascular Health and Risk Management, 2006, 2, 379-387.	2.3	3
2557	Clopidogrel. American Journal of Cardiovascular Drugs, 2012, 12, 361-374.	2.2	7
2558	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Current Pharmaceutical Design, 2019, 25, 4063-4084.	1.9	200
2559	Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention. Current Pharmaceutical Design, 2020, 26, 2780-2788.	1.9	14
2560	Whatâ€™s Age Got to do with it? A Review of Contemporary Revascularization in the Elderly. Current Cardiology Reviews, 2015, 11, 199-208.	1.5	11
2561	Corrected and republished from: Regional anesthesia and antithrombotic agents: instructions for use. Minerva Anesthesiologica, 2020, 86, 341-353.	1.0	2
2562	Stent thrombosis after Cypher and Taxus stent implantation. , 2005, , 187-198.		1
2563	Pharmacology and Clot. , 2008, , 103-122.		1
2564	Diabetes Mellitus and Cardiovascular Disease in the Elderly. Fundamental and Clinical Cardiology, 2008, , 179-214.	0.0	4
2565	Anti-Platelet Drug Resistance in the Prediction of Thromboembolic Complications after Neurointervention. Journal of Korean Neurosurgical Society, 2010, 48, 319.	1.2	30
2566	The Impact of Generic Clopidogrel Bisulfate on Platelet Inhibition in Patients with Coronary Artery Stents: Results of the ACCEL-GENERIC Study. Korean Journal of Internal Medicine, 2010, 25, 154.	1.7	22
2567	Dual antiplatelet therapy for acute coronary syndromes: How long to continue?. Cleveland Clinic Journal of Medicine, 2016, 83, 675-688.	1.3	2
2568	Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region. World Journal of Cardiovascular Diseases, 2013, 03, 4-10.	0.2	7
2569	Mean Platelet Volume and Prognosis of Unstable Angina. World Journal of Cardiovascular Diseases, 2015, 05, 32-41.	0.2	3
2570	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. EuroIntervention, 2009, 5, 325-329.	3.2	123
2571	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation â€“ past, present and future perspectives. EuroIntervention, 2017, 13, 717-733.	3.2	37

#	ARTICLE	IF	CITATIONS
2572	Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention, 2019, 15, e990-e998.	3.2	122
2573	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention, 2015, 11, 68-74.	3.2	48
2574	Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice?. EuroIntervention, 2018, 14, 19-23.	3.2	2
2575	A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. EuroIntervention, 2007, 3, 228-234.	3.2	7
2576	Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention, 2007, 3, 371-380.	3.2	23
2577	Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. EuroIntervention, 2009, 4, 593-599.	3.2	3
2578	A novel strategy for managing clopidogrel-induced adverse skin reactions. EuroIntervention, 2009, 5, 470-474.	3.2	4
2579	Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. EuroIntervention, 2010, 5, 953-961.	3.2	9
2580	Coronary angioscopic findings eight months after sirolimus-eluting stent implantation: a comparison between ST-elevation myocardial infarction and stable angina pectoris. EuroIntervention, 2010, 6, 251-256.	3.2	10
2581	Patent coronary artery and myocardial infarction in the era of primary angioplasty: assessment of an old problem in a new setting with data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention, 2010, 6, 590-595.	3.2	3
2582	Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. EuroIntervention, 2011, 6, 1046-1052.	3.2	22
2583	Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. EuroIntervention, 2012, 7, 1413-1419.	3.2	23
2584	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention, 2013, 8, 1033-1039.	3.2	25
2585	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	3.2	251
2586	2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2019, 14, 1435-1534.	3.2	367
2587	Knowledge, attitude and perception of antiplatelet therapy among dentists in Central Eastern Turkey. World Journal of Cardiology, 2012, 4, 226.	1.5	7
2588	ORAL ANTIPLATELET THERAPY IN STROKE PREVENTION. MINIREVIEW. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2010, 154, 203-210.	0.6	11
2589	Pharmacodynamic effects of loading of antiplatelets in acute stroke patients. Journal of Neuroendovascular Therapy, 2014, 8, 251-258.	0.1	3

#	ARTICLE	IF	CITATIONS
2590	P2Y ₁₂ Platelet Receptors: Importance in Percutaneous Coronary Intervention. Arquivos Brasileiros De Cardiologia, 2013, 101, 277-82.	0.8	6
2591	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 111-134.	0.8	4
2592	An Idiosyncratic Reaction to Clopidogrel. , 2015, 19, 74-76.		5
2593	Evaluation of Clopidogrel Safety in Geriatric Patients with Hip Fracture: A Retrospective Study. Orthopaedic Surgery, 2021, 13, 1912-1921.	1.8	2
2595	Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion. JACC: Cardiovascular Interventions, 2021, 14, 2353-2364.	2.9	43
2596	Formation of a Rectus Sheath Hematoma Secondary to COPD Exacerbation While Taking Dual Antiplatelet Therapy. Cureus, 2021, 13, e18821.	0.5	0
2598	Koronarinsuffizienz und Herzinfarkt. , 2003, , 3-29.		0
2599	Instabile Angina pectoris. , 2004, , 549-556.		0
2600	Aggregationshemmertherapie bei Koronarerkrankungen. , 2004, , 897-910.		1
2601	Antikoagulantien und Thrombozytenaggregationshemmer. , 2004, , 356-368.		0
2602	Klinik der koronaren Herzerkrankung II: Akute Koronarsyndrome. , 2004, , 497-529.		0
2603	Verordnungsprofil der Internisten. , 2004, , 1013-1041.		0
2604	Verordnungsprofil der NervenÄrzte. , 2004, , 1060-1071.		0
2605	Early and Late Angiographic and Clinical Outcome Following Helistent Stent Implantation. International Heart Journal, 2004, 45, 1-10.	0.6	0
2606	Verordnungsprofil der Chirurgen. , 2004, , 957-977.		0
2607	Antikoagulantien und Thrombozytenaggregationshemmer. , 2004, , 265-278.		0
2608	Inflammatory Markers in Acute Coronary Syndromes. , 2004, , 339-364.		0
2611	Treatment of Vulnerable Plaques. , 2004, , 164-202.		0

#	ARTICLE	IF	CITATIONS
2612	Early versus Late Complications. , 2005, , 92-112.		0
2613	Antithrombotic therapy for ischemic stroke. , 2005, , 241-262.		0
2614	Optimal antiplatelet and anticoagulation therapy for drug-eluting stents. , 2005, , 126-135.		0
2615	Anti-platelet treatment in reperfusion therapy for acute myocardial infarction. , 2006, , 77-96.		0
2616	Rescue percutaneous coronary intervention in acute myocardial infarction. , 2006, , 147-166.		0
2618	Antiplatelet therapy. Japanese Journal of Thrombosis and Hemostasis, 2006, 17, 649-663.	0.1	0
2619	Primary coronary intervention for acute myocardial infarction. , 2006, , 65-75.		0
2620	Anticoagulation and Antiplatelet Agents. Fundamental and Clinical Cardiology, 2006, , 501-524.	0.0	0
2621	Optimal antiplatelet and anticoagulation therapy, prevention and management of thrombotic complications. , 2006, , 39-52.		0
2622	Optimal patient preparation and selection to avoid complications. , 2006, , 17-37.		0
2623	Percutaneous Coronary Intervention for Unstable Coronary Artery Disease. , 2007, , 1005-1020.		0
2624	Mechanical Approaches to Percutaneous Coronary Intervention. , 2007, , 121-134.		0
2627	Coronary Artery Bypass Surgery and Percutaneous Coronary Revascularization: Impact on Morbidity and Mortality in Patients with Coronary Artery Disease. , 2007, , 1073-1111.		1
2630	Anti-platelet therapies. , 2008, , 35-44.		0
2631	Antikoagulantien und Thrombozytenaggregationshemmer. , 2008, , 379-393.		0
2632	Medicamenteuze preventie en behandeling van atherotrombose. , 2008, , 89-101.		0
2634	Diagnosis and Treatment of Unstable Angina. , 2008, , 73-85.		0
2635	Anti-platelet treatment for acute coronary syndrome in Japan. Japanese Journal of Thrombosis and Hemostasis, 2008, 19, 504-509.	0.1	0

#	ARTICLE	IF	CITATIONS
2637	Antiplatelet Agents. Fundamental and Clinical Cardiology, 2008, , 176-194.	0.0	0
2638	Comparison of Reperfusion Strategies for ST Elevation Acute Myocardial Infarction: Primary Coronary Intervention Versus Fibrinolysis. , 2009, , 9-25.		0
2639	Anti-platelet therapies. , 2009, , 37-48.		0
2640	ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007:Implications for Nursing Practice. Progress in Cardiovascular Nursing, 2008, 23, 53-56.	0.4	0
2641	Intensity of antiplatelet therapy and percutaneous coronary intervention. F1000 Medicine Reports, 2009, 1, .	2.9	0
2642	Case 24. Coronary Artery Disease. , 2009, , .		0
2643	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2009, , 87-105.		1
2644	Variability of the antiplatelet effect of clopidogrel in Japanese. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 589-593.	0.1	0
2645	Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 48-55.	0.1	0
2646	Antithrombotic therapy after acute myocardial infarction. Cor Et Vasa, 2009, 51, 112-117.	0.1	0
2647	Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. Fundamental and Clinical Cardiology, 2009, , 471-484.	0.0	0
2648	Markers of Platelet Function. Fundamental and Clinical Cardiology, 2009, , 409-428.	0.0	0
2649	Platelet Glycoprotein IIb/IIIa Inhibitors. , 2009, , 67-76.		0
2650	Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. , 2010, , 219-233.		0
2651	Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction. , 2010, , 145-163.		0
2652	Antithrombotic Therapy in Percutaneous Coronary Intervention. , 2010, , 261-282.		0
2653	Thrombosen und Gefäßverschlüsse trotz antithrombotischer Therapie. , 2010, , 681-688.		0
2656	Adjunctive Pharmacologic Therapies. , 2010, , 54-64.		0

#	ARTICLE	IF	CITATIONS
2658	Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2011, , 195-225.		0
2659	Vasopressors, vasodilators and antithrombotics in the catheterization laboratory. , 2010, , 53-66.		0
2660	Clopidogrel and Salicylates. , 2011, , 139-153.		0
2661	Oral antiplatelet therapy. , 2011, , 311-319.		0
2662	Kardiovaskuläre Erkrankungen. , 2011, , 1-186.		0
2664	Revascularization in Non-“ST-Segment Elevation Acute Coronary Syndrome” For Whom, When, and How?. , 2011, , 299-312.		0
2665	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2011, , 341-359.		0
2666	Management of the postcoronary patient. , 2011, , 650-659.		0
2667	Diabetes in the coronary care unit. , 2011, , 606-610.		0
2669	Antiplatelet Therapy. , 2011, , 201-221.		0
2670	Antithrombotic therapy in secondary prevention. Srce I Krvni Sudovi, 2011, 30, 224-233.	0.1	0
2671	1. Historical Perspective on the Pros and Cons of Coadministration of Proton Pump Inhibitors with Thienopyridine Antiplatelet Drugs (Clopidogrel and Prasugrel). Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 357-360.	0.1	0
2672	Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy. , 2011, , 313-321.		0
2673	3. Risk of Upper Gastrointestinal Bleeding during Clopidogrel Therapy with or without a PPI. Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 369-373.	0.1	0
2674	Can a rash cause stent thrombosis?. , 2011, , 15-32.		0
2675	Coronary Plaque Rupture in Patients with Acute. , 2011, , 49-67.		0
2683	Peripartum Management of Dual Antiplatelet Therapy and Neuraxial Labor Analgesia After Bare Metal Stent Insertion for Acute Myocardial Infarction. Anesthesia and Analgesia, 2012, 115, 613-615.	2.2	10
2687	Left main pci, still a main issue. Research in Cardiovascular Medicine, 2013, 2, 185.	0.1	0

#	ARTICLE	IF	CITATIONS
2688	Evaluation of percutaneous coronary intervention and stenting of left main coronary artery stenosis in tehran's rajaie and lavasani hospitals from 2010 to 2011. Research in Cardiovascular Medicine, 2013, 2, 181.	0.1	3
2689	Effects of Antiplatelet Drugs in Cardiovascular Prevention. Korean Journal of Medicine, 2013, 85, 15.	0.3	1
2690	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
2691	Myocardial revascularization in patients with acute coronary syndrome. Srce I Krvni Sudovi, 2013, 32, 298-303.	0.1	0
2692	Percutaneous Coronary Interventions in the Elderly. , 2014, , 243-252.		0
2694	Invasive Therapy for Women Presenting with Acute Coronary Syndromes. , 2014, , 113-138.		0
2695	Antithrombotic Issues in Women. , 2014, , 321-357.		0
2696	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2014, , 1-24.		0
2697	Percutaneous Coronary Interventional Treatment for Coronary Artery Disease and the Role of Antiplatelets Therapy: A Review of the Literature. International Journal of Clinical Medicine, 2014, 05, 275-283.	0.2	0
2698	Evaluation of Aggregometry Parameters and Efficacy of Plavix versus Clopidex in Patients Suffering from Ischemic Heart Disease: A Randomized Double Blind Clinical Trial. Iranian Red Crescent Medical Journal, 2014, 16, e15277.	0.5	0
2700	THE ROLE OF GENETIC TESTING FOR OPTIMAL ANTIPLATELET THERAPY SELECTION IN THE TREATMENT OF CORONARY ARTERY DISEASE PATIENTS. Cardiovascular Therapy and Prevention (Russian Federation), 2014, 13, 71-75.	1.4	1
2702	ST Elevation Related to the Site of Coronary Occlusion. , 2015, , 3-15.		0
2703	Koronare Herzkrankheit â€“ Allgemeine und interventionelle Therapie. , 2015, , 1-33.		0
2704	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. , 2015, , 255-269.		0
2705	Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting. Current Opinion in Cardiology, 2015, 30, 319-324.	1.8	0
2706	Peri- and Post-procedural Antithrombotic Therapy in Women. , 2017, , 73-100.		1
2707	Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy of Non-vitamin K Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. , 2017, , 169-182.		0
2708	Novedades en la evaluaci3n del riesgo hemorr3gico del paciente con cardiopatÃa isquÃ©mica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 16-23.	0.2	2

#	ARTICLE	IF	CITATIONS
2709	Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cyclooxygenase inhibition. World Journal of Hematology, 2017, 6, 32.	0.1	4
2711	Efectos cardioprotectores del ticagrelor. Revista Espanola De Cardiologia Suplementos, 2017, 17, 3-8.	0.2	0
2712	Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?. , 2018, , 73-89.		0
2713	OBSOLETE: Non-ST-Elevation Myocardial Infarction: Management. , 2018, , .		0
2714	Postoperative Bleeding Following Preoperative Clopidogrel Administration in Patients with Haemoglobin Level Above 110 g/L Undergoing Urgent CABG. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 59-63.	0.6	1
2715	EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?. Atherothrombosis, 2018, , 76-86.	0.3	0
2716	Intervenci3n coronaria en pacientes con fibrilaci3n auricular. Revista Espanola De Cardiologia Suplementos, 2019, 18, 15-20.	0.2	0
2717	Benefits of a combination of clopidogrel and aspirin in patients with high cardiovascular risk. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2019, 12, 504.	0.3	0
2718	Anticoagulation Options. , 2019, , 474-498.		0
2719	Comorbidity as a risk factor of postoperative complications in patients during coronary artery bypass grafting with cardiopulmonary bypass. Emergency Medicine, 2019, , .	0.2	0
2720	Antithrombotic therapy of coronary heart disease: time - tested essential principles. Terapevticheskii Arkhiv, 2019, 91, 19-24.	0.8	1
2721	Infarto del miocardio: diagnosi, gestione e complicate. EMC - AKOS - Trattato Di Medicina, 2019, 21, 1-14.	0.0	0
2722	Infarto de miocardio: diagn3stico, tratamiento y complicaciones. EMC - Tratado De Medicina, 2019, 23, 1-14.	0.0	0
2723	Method Hierarchies in Clinical Epidemiology. Scientonomy Journal for the Science of Science, 0, 3, 45-61.	0.0	1
2724	Management of acute coronary syndrome. , 2020, , 3626-3655.		0
2725	Antithrombotika und Antih3morrhagika. , 2020, , 395-420.		0
2726	Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Critical Pathways in Cardiology, 2020, 19, 166-172.	0.5	1
2727	TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention. US Cardiology Review, 0, 14, .	0.5	0

#	ARTICLE	IF	CITATIONS
2728	The role of clopidogrel in the current treatment of acute coronary syndrome. Atherothrombosis, 2020, , 72-81.	0.3	0
2729	Antiplatelet therapy after PCI in patients with high risk of bleeding. Pharmacia, 2020, 67, 135-143.	1.2	2
2730	Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet) Tj ETQq0 0 0 rgBT3/0verlocku140 Tf 50 6	0.0	0
2731	Antiplatelet Therapy. Contemporary Cardiology, 2021, , 249-288.	0.1	0
2733	Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor. Medicine (United States), 2020, 99, e18683.	1.0	0
2734	ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL. Juvenis Scientia, 2020, 6, 14-24.	0.2	0
2735	Does Extended Use of Clopidogrel-Based Dual Anti-Platelet Therapy Increase the Risk of Gastrointestinal Bleeding?. Gastroenterology Research, 2020, 13, 146-149.	1.3	1
2736	Anticoagulation Options. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 253-277.	0.3	0
2737	Heart Failure, Atrial Fibrillation, and Diabetes Mellitus. , 2007, , 77-88.		0
2738	Koronarinsuffizienz und Herzinfarkt. , 2005, , 3-33.		0
2739	Antikoagulantien und Thrombozytenaggregationshemmer. , 0, , 429-442.		0
2740	Neue Arzneimittel. , 0, , 37-107.		0
2741	Interventionelle Kardiologie. , 2005, , 272-295.		0
2742	Einsatz und Wirkung von Medikamenten. , 2006, , 47-61.		0
2743	Koronare Herzkrankheit â€” akute Verlaufsformen. , 2006, , 169-201.		0
2744	Instabile Angina pectoris und akuter Myokardinfarkt. , 2006, , 185-206.		1
2745	Diagnostik und interventionelle Therapie der koronaren Herzkrankheit. , 2006, , 230-249.		0
2746	Pharmacodynamics of GPIIb-IIIa Receptor Blockade. , 2005, , 247-266.		0

#	ARTICLE	IF	CITATIONS
2747	Platelet Function Studies. , 2005, , 201-222.		1
2748	Stable Angina. , 2005, , 451-470.		0
2749	Complications of Carotid Artery Stenting. , 2007, , 175-188.		0
2750	Management of Angina. , 2007, , 159-181.		0
2751	Management of Acute Myocardial Infarction. , 2007, , 183-210.		0
2752	Clopidogrel: an updated and comprehensive review. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 621-631.	3.3	7
2753	Platelets and new antiplatelet drugs. Therapy: Open Access in Clinical Medicine, 2005, 2, 465-502.	0.2	0
2756	Antikoagulantien und Thrombozytenaggregationshemmer. , 2008, , 387-401.		0
2758	Clopidogrel versus Aspirin in Patients with Atherothrombosis. Applied Health Economics and Health Policy, 2012, 10, 331-342.	2.1	0
2759	Antiplatelet Therapy for Prevention of Thromboembolic Complications Associated with Coil Embolization of Unruptured Cerebral Aneurysms. Drugs in R and D, 2012, 12, 1-7.	2.2	0
2760	Acute Coronary Syndrome. , 2021, , 59-80.		0
2761	Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?. Minerva Cardioangiologica, 2020, 68, 436-450.	1.2	3
2763	The NIVC working group guidelines for the management of patients with non-ST-elevation acute coronary syndromes. Netherlands Heart Journal, 2002, 10, 54-64.	0.8	0
2764	Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis. Netherlands Heart Journal, 2006, 14, 297-300.	0.8	1
2765	Cardiac complications in type 2 diabetic patients with mild anginal symptoms and documented reversible myocardial perfusion defects: Results of the MERIDIAN trial. Netherlands Heart Journal, 2006, 14, 409-416.	0.8	4
2766	Antiplatelet therapy in populations at high risk of atherothrombosis. Journal of the National Medical Association, 2006, 98, 711-21.	0.8	10
2767	Late stent thrombosis associated with heavy exercise. Texas Heart Institute Journal, 2009, 36, 154-7.	0.3	0
2768	Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. Western Journal of Emergency Medicine, 2009, 10, 163-75.	1.1	3

#	ARTICLE	IF	CITATIONS
2770	Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part) Tj ETQq0 0.0,rgBT /Ovcrlock 10	0.3	12
2771	Percutaneous coronary intervention in elderly patients: is it beneficial?. Texas Heart Institute Journal, 2011, 38, 398-403.	0.3	25
2772	The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. Journal of Research in Medical Sciences, 2011, 16, 640-50.	0.9	15
2773	Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. American Journal of Cardiovascular Disease, 2011, 1, 255-63.	0.5	1
2774	Restoration of microcirculatory patency after myocardial infarction: results of current coronary interventional strategies and techniques. Texas Heart Institute Journal, 2012, 39, 342-50.	0.3	5
2775	Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses. CADTH Technology Overviews, 2012, 2, e2103.	0.5	0
2776	Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proceedings in Intensive Care & Cardiovascular Anesthesia, 2012, 4, 153-67.	0.6	9
2777	Is the Combination of Aspirin and Clopidogrel always Better than Aspirin Alone? Or will it be too much of a good thing?. Malaysian Family Physician, 2008, 3, 94-5.	0.6	0
2778	Mean Platelet Volume as a Predictor of One-Year Major Adverse Cardiac Events following Elective Percutaneous Coronary Interventions. The Journal of Tehran Heart Center, 2014, 9, 64-9.	0.3	1
2779	Contemporary use of dual antiplatelet therapy for preventing cardiovascular events. American Journal of Managed Care, 2014, 20, 659-65.	1.1	1
2780	Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of Invasive Cardiology, 2017, 29, 340-351.	0.4	2
2781	Acute Subdural Hematoma Evacuation: Predictive Factors of Outcome. Journal of Innovative Optical Health Sciences, 2018, 13, 565-571.	1.0	4
2782	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Journal of Extra-Corporeal Technology, 2021, 53, 97-124.	0.4	3
2783	P2Y12 Inhibitors Exacerbate Low-dose Aspirin-induced Small Bowel Injury in Dual Antiplatelet Therapy. Internal Medicine, 2021, 60, 3517-3523.	0.7	1
2784	Efficacy and safety of short-term dual antiplatelet therapy in East Asians. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	0
2785	Dual Antiplatelet Therapy after PCI: When Could We Go Shorter?., 0, , .		0
2786	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). Eurasian Heart Journal, 2021, , 6-59.	0.8	4
2787	Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes. JAMA Network Open, 2021, 4, e2134322.	5.9	12

#	ARTICLE	IF	CITATIONS
2788	Antithrombotika und Antihämorrhagika. , 2021, , 299-326.		3
2789	The Evolution of Evidence-Based Medicine: When the Magic of the Randomized Clinical Trial Meets Real-World Data. Circulation, 2022, 145, 107-109.	1.6	5
2790	Periprocedural Myocardial Injury in High-Risk Patients With NSTEMI Pretreated With Ticagrelor for Less or More Than 6 Hours Before PCI. Journal of Clinical Pharmacology, 2021, , .	2.0	1
2791	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	2.8	561
2792	Acute subdural hematoma evacuation: Predictive factors of outcome. Journal of Innovative Optical Health Sciences, 2018, 13, 565-571.	1.0	12
2793	Acetylsalicylsäure: Heutiger Stellenwert in der antithrombotischen Therapie. , 0, , .		0
2794	Antithrombotic therapy in acute coronary syndromes setting: new clinical guidelines, controversial issues and the role of prehospital stage. Emergency Medical Care, 2022, 22, 4-11.	0.2	0
2795	Antiplatelet Therapy in Acute Coronary Syndrome. Sklifosovsky Journal Emergency Medical Care, 2022, 10, 769-777.	0.6	0
2797	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	2.9	6
2798	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
2799	Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. JACC Asia, 2022, 2, 1-18.	1.5	15
2800	Prevalence of High Bleeding Risk among Hospitalized Suspected NSTEMI Patients. Journal of Clinical Medicine, 2022, 11, 1324.	2.4	3
2801	Antiplatelet agents for chronic kidney disease. The Cochrane Library, 2022, 2022, CD008834.	2.8	6
2802	Evaluation of the duration of dual-antiplatelet therapy after percutaneous coronary intervention: a retrospective audit on the compliance with guidelines or cardiologist recommendation. Journal of Pharmacy Practice and Research, 2022, 52, 42-48.	0.8	0
2803	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. Canadian Journal of Cardiology, 2022, 38, S79-S88.	1.7	6
2805	Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. Cardiovascular Intervention and Therapeutics, 2022, 37, 255-263.	2.3	14
2806	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. Current Cardiology Reports, 2022, 24, 277-293.	2.9	3
2807	Ticagrelor monotherapy after percutaneous coronary intervention in comparison with dual-antiplatelet therapy. Intervencni A Akutni Kardiologie, 2022, 21, 35-40.	0.0	0

#	ARTICLE	IF	CITATIONS
2808	Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome. JAMA Cardiology, 2022, 7, 407.	6.1	121
2809	Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study. Clinical Interventions in Aging, 2022, Volume 17, 331-341.	2.9	1
2810	Cardioprotective effect of extracellular vesicles derived from ticagrelor-pretreated cardiomyocyte on hyperglycemic cardiomyocytes through alleviation of oxidative and endoplasmic reticulum stress. Scientific Reports, 2022, 12, 5651.	3.3	15
2811	The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women – Chapter 6: Sex- and Gender-Specific Diagnosis and Treatment. CJC Open, 2022, 4, 589-608.	1.5	13
2812	Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis. JAMA Network Open, 2022, 5, e227624.	5.9	8
2813	Use of Antiplatelet Drugs in Secondary Prevention in Patients With Atherothrombotic Disease. Comprehensive Therapy, 2006, 32, 182-188.	0.2	0
2814	Adjunctive Medical Therapy in Percutaneous Coronary Intervention. , 0, , 360-370.		0
2815	Carotid Endarterectomy Compared with Carotid Angioplasty and Stenting. , 0, , 575-586.		0
2816	Antithrombotic Therapy for Non ST-Elevation Acute Coronary Syndromes. , 0, , 79-92.		1
2822	Revascularization for Left Ventricular Dysfunction. , 0, , 99-110.		0
2823	Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0
2825	Acute coronary syndrome without persistent elevation of the ST segment: New recommendations. , 2022, 1, 105-110.		0
2826	Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2022, 15, 596.	3.8	2
2830	Drug-eluting stents and contemporary dual antiplatelet therapy in revascularized STEMI. The times they are a-changin'™?. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	0
2831	Part 5: Acute Coronary Syndromes. Circulation, 2005, 112, .	1.6	4
2832	ADEQUATE ANTITHROMBOTIC THERAPY: REDUCTION OF MORTALITY BY THE RESULTS OF INTERNATIONAL CLINICAL TRIALS (literature review). Problemy Zdorov'ia i Ākologii, 2013, , 22-29.	0.1	0
2833	Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases. Frontiers in Pharmacology, 0, 13, .	3.5	5
2834	Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective. Jundishapur Journal of Chronic Disease Care, 2022, In Press, .	0.3	1

#	ARTICLE	IF	CITATIONS
2835	Optimal cardiovascular medical therapy: current guidelines and new developments. Baylor University Medical Center Proceedings, 0, , 1-7.	0.5	3
2836	Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 960-972.	2.4	4
2837	Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel. Atherothrombosis, 2022, 12, 30-45.	0.3	0
2838	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. US Cardiology Review, 0, 16, .	0.5	0
2839	The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 0, , .	2.6	0
2840	Pre-treatment with P2Y12 inhibitors: Old habits die hard. Revista Portuguesa De Cardiologia, 2022, 41, 909-909.	0.5	0
2841	P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis. Medicine (United States), 2022, 101, e29824.	1.0	0
2842	Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. International Journal of Environmental Research and Public Health, 2022, 19, 8977.	2.6	7
2843	Antiplatelet agents and anticoagulants for hypertension. The Cochrane Library, 2022, 2022, .	2.8	9
2844	Safety of Transcarotid Revascularization in Patients with a Contraindication to Dual Antiplatelets. Vascular and Endovascular Surgery, 2022, 56, 746-753.	0.7	3
2845	Things We Do for No Reason: Routine pretreatment with a P2Y12 receptor inhibitor before invasive coronary angiography for patients with a nonST elevation acute coronary syndrome. Journal of Hospital Medicine, 2023, 18, 177-180.	1.4	0
2846	CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
2847	Platelet reactivity after clopidogrel loading in patients with acute ischemic stroke. Frontiers in Neurology, 0, 13, .	2.4	0
2848	Temporal trends in major cardiovascular events following first-time myocardial infarction in the reperfusion era – a Danish nationwide cohort study from 2000 to 2017. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 268-280.	4.0	5
2849	An Albumin-Enriched Nanocomplex Achieves Systemic Delivery of Clopidogrel Bisulfate to Ameliorate Renal Ischemia Reperfusion Injury in Rats. Molecular Pharmaceutics, 2022, 19, 3934-3947.	4.6	6
2850	Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment. Journal of Cardiovascular Development and Disease, 2022, 9, 397.	1.6	2
2852	Aspirin and Plavix/Clopidogrel. , 2022, , 297-303.		0
2853	Efficacy and safety of single versus dual antiplatelet therapy in carotid artery stenting. Journal of Vascular Surgery, 2023, 77, 1434-1446.e11.	1.1	4

#	ARTICLE	IF	CITATIONS
2854	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	2
2855	Management of Antiplatelet Therapy During Acute Percutaneous Coronary Intervention: New Strategies and Therapeutics. Annals of the Academy of Medicine, Singapore, 2010, 39, 221-229.	0.4	2
2856	Dissolvable polymeric microneedles loaded with aspirin for antiplatelet aggregation. Asian Journal of Pharmaceutical Sciences, 2023, 18, 100776.	9.1	5
2857	Switching Between Intravenous and Oral P2Y12 Inhibition. JACC: Cardiovascular Interventions, 2023, 16, 47-49.	2.9	0
2858	Acute Coronary Syndrome in the Older Adult Populations. Contemporary Cardiology, 2023, , 303-341.	0.1	0
2859	Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI. JACC: Cardiovascular Interventions, 2023, 16, 1-18.	2.9	21
2860	Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
2861	Acute Coronary Syndrome. , 2013, , 452-468.e1.		0
2862	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Expert Opinion on Pharmacotherapy, 2023, 24, 453-471.	1.8	5
2863	Antithrombotische Therapie. , 2022, , 233-263.		0
2864	Propensity-score-matched analysis of dual antiplatelet treatment and alternative antiplatelet regimens after transcatheter aortic valve replacement. Journal of Vascular Medicine and Biology, 2023, 35, 142-149.	1.1	0
2865	miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. European Journal of Medical Research, 2023, 28, .	2.2	0
2866	Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. , 2023, 2, 100607.		1
2867	Pretreatment with P2Y12 Receptor Inhibitors in Acute Coronary Syndromes "Is the Current Standpoint of ESC Experts Sufficiently Supported?. Journal of Clinical Medicine, 2023, 12, 2374.	2.4	0
2868	Acute coronary syndrome in very elderly patients "a real-world experience. Heart and Vessels, 2023, 38, 1019-1027.	1.2	2
2869	Percutaneous Myocardial Revascularization. , 2023, , 369-382.		0
2870	Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease. Platelets, 2023, 34, .	2.3	0
2871	The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman. Pharmacy (Basel, Switzerland), 2023, 11, 79.	1.6	0

#	ARTICLE	IF	CITATIONS
2872	Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 462-496.	3.0	13
2873	De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options. European Journal of Internal Medicine, 2023, 110, 16-18.	2.2	1
2874	Redefining the Roles of Aspirin Across the Spectrum of Cardiovascular Disease Prevention. Current Cardiology Reviews, 2023, 19, .	1.5	0
2875	Outcomes with P2Y12 inhibitor monotherapy after PCI according to bleeding risk: A Bayesian meta-analysis. Cardiovascular Revascularization Medicine, 2023, , .	0.8	1
2876	European practice patterns for antiplatelet management in NSTEMI-ACS patients: Results from the REal-world ADOption survey focus on Acute antiPlatelet Treatment (READAPT) survey. International Journal of Cardiology, 2023, 386, 8-16.	1.7	2
2877	Twenty Years of an Institutional Chest Pain Pathway: Whatâ€™s Come and Whatâ€™s Yet to Come. Critical Pathways in Cardiology, 2023, 22, 41-44.	0.5	0
2878	Advances in Cardiovascular Pharmacology in Atherosclerotic-Related Therapeutic Areas: Addressing Patientsâ€™ Clinical Needs. Journal of Clinical Medicine, 2023, 12, 3665.	2.4	0
2879	Optimal duration of dual antiplatelet therapy for stent-assisted coiling or flow diverter placement. Journal of NeuroInterventional Surgery, 0, , jnis-2023-020285.	3.3	2
2880	ANTIPLATELET DRUGS IN CARDIOVASCULAR DISEASES. International Journal of Clinical Practice, 2003, 57, 898-905.	1.7	2
2881	Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding. European Heart Journal Supplements, 2023, 25, E25-E32.	0.1	1
2882	Gas Chromatography-Mass Spectrometry Analysis, Phytochemical Screening, Antioxidant and Antibacterial Activity of Methanol Root Extract of Rhabdiostylis beninensis (Hook.f.) Planch. [family ICACINACEAE] against Uropathogens. Biomedical and Pharmacology Journal, 2023, 16, 1055-1079.	0.5	0
2883	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Journal of Extra-Corporeal Technology, 2021, 53, 97-124.	0.4	14
2885	Remnant cholesterol but not LDL cholesterol is associated with 5-year bleeding following percutaneous coronary intervention. IScience, 2023, 26, 107666.	4.1	0
2890	Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting: A Survey of UK Cardiac Surgeons. Journal of Cardiothoracic and Vascular Anesthesia, 2023, , .	1.3	0
2891	Antithrombotic Treatment in Coronary Artery Disease. Current Pharmaceutical Design, 2023, 29, .	1.9	1
2892	2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal, 2023, 44, 3720-3826.	2.2	288
2893	Effect of pretreatment with a P2Y12 inhibitor in patients with non-ST-elevation acute coronary syndrome: a systematic review and network meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
2894	A nightmare of clopidogrel resistance in a resource-limited setting: case report of subacute stent thrombosis. Egyptian Heart Journal, 2023, 75, .	1.2	0

#	ARTICLE	IF	CITATIONS
2895	Age, Frailty, and Antiplatelets: Age Is Only Relevant If You Make It So. American Journal of Cardiology, 2023, , .	1.6	0
2896	2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2024, 13, 55-161.	1.0	10
2897	Toward Optimizing Antiplatelet Therapy for Patients at High Bleeding Risk. American Journal of Cardiology, 2023, , .	1.6	0
2898	In Vitro Antibacterial Activity and Phytochemical Screening of Galoba (Hornstedtia alliacea) Seeds Extract. , 2023, 1, 81-89.		2
2899	Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review. Journal of Clinical Medicine, 2023, 12, 7144.	2.4	0
2900	Voltammetric Detection of Clopidogrel in Pharmaceuticals Utilizing Electropolymerized o-Aminophenol-MWCNTs Modified Electrode. Russian Journal of Electrochemistry, 2023, 59, 930-940.	0.9	0
2901	More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?. Mayo Clinic Proceedings, 2023, 98, 1590-1592.	3.0	0
2902	Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2024, 40, 160-181.	1.7	0
2903	Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review. Interventional Cardiology Review, 0, 18, .	1.6	0
2904	Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines. European Heart Journal: Acute Cardiovascular Care, 2024, 13, 173-180.	1.0	0
2905	Aspirin-free antiplatelet strategies after percutaneous coronary interventions. European Heart Journal, 2024, 45, 572-585.	2.2	1
2906	The Antimicrobial Potential of the Hop (Humulus lupulus L.) Extract against Staphylococcus aureus and Oral Streptococci. Pharmaceuticals, 2024, 17, 162.	3.8	0
2907	Prasugrel Only May Be Enough After Percutaneous Coronary Intervention for Chronic Coronary Syndrome Patients. JACC Asia, 2024, 4, 183-184.	1.5	0
2908	The Effects of Clopidogrel Duration on Carotid Artery In-Stent Restenosis. Annals of Vascular Surgery, 2024, 103, 68-73.	0.9	0
2909	A review on regulation of DNA methylation during post-myocardial infarction. Frontiers in Pharmacology, 0, 15, .	3.5	0
2910	Antithrombotische Therapie. , 2023, , 255-287.		0
2911	Clopidogrel and Percutaneous Coronary Interventionsâ€™Reply. JAMA - Journal of the American Medical Association, 2003, 289, 1926.	7.4	0
2912	Antibacteria Activity of <i>Peganum harmala</i> and <i>Haloxylon salicornicum</i> Leaves Extracts. Advances in Microbiology, 2024, 14, 122-136.	0.6	0

#	ARTICLE	IF	CITATIONS
2913	Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones. Biomolecules, 2024, 14, 305.	4.0	0
2914	Level of Adherence to Dual Anti-platelet Therapy at 6 and 12 Months after Coronary Stenting; The Impact on Post-angioplasty Cardiovascular Events. Multidisciplinary Cardiovascular Annals, 2024, 15, .	0.1	0